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Abstract	The	immune	system	plays	a	key	role	in	atherosclerosis,	and	to	date	several	immune	cells	 have	 been	 characterised	 as	 having	 pro-atherogenic	 or	 athero-protective	properties.	In	particular,	great	attention	has	been	paid	to	the	study	of	CD4+	T-cells	in	lesion	formation	and	progression.		In	recent	times,	the	role	of	a	new	T-cell	subset	termed	T-follicular	helper	(Tfh)	cells	has	 gained	 attention	 in	 atherosclerosis	 related	 autoimmune	 conditions.	 Involved	 in	aiding	germinal	centre	(GC)	B-cells	in	the	production	of	high	affinity,	isotype	switched	antibodies;	 Tfh	 cells	 comprise	 a	 fundamental	 proportion	 of	 both	 homeostatic	 and	pathologic	GCs.	Of	 importance,	 the	 role	of	 the	Tfh	 cell	 :	GC	B-cell	 axis	has	not	been	fully	elucidated	in	atherosclerosis.	Therefore,	as	part	of	this	thesis,	the	role	of	the	Tfh	cell	:	GC	B-cell	axis	in	experimental	models	of	atherosclerosis	was	dissected.		Apolipoprotein-E	 knock	 out	 (apoE-/-)	 mice	 fed	 chow	 or	 high	 fat	 diet	 (HFD)	 for	variable	lengths	of	time	(1,	2,	4,	8	and	12	weeks)	displayed	an	increasing	trend	in	Tfh	cell	number,	peaking	at	12	weeks	post-diet.	In	contrast,	GC	B-cell	populations	peaked	at	 4	weeks	 post-diet.	 Importantly,	 immunohistochemcal	 studies	 demonstrated	 that	apoE-/-	mice	fed	HFD	for	12	weeks	comprised	the	sole	group	to	express	the	Tfh	cell	transcription	factor	–	B-cell	lymphoma-6	(Bcl-6).	Therefore	indicating	hyperlipidemia	as	a	driver	in	bonafide	Tfh	cell	marker	expression.		Interleukin	 (IL)-21	 enhances	 Tfh	 cell	 and	 GC	 B-cell	 differentiation	 in	 vivo.	 In	 an	attempt	 to	 modulate	 the	 Tfh	 cell	 :	 GC	 B-cell	 axis,	 as	 part	 of	 chapter	 4,	 an	 IL-21	receptor	(IL-21R)	deficient	hyperlipidemic	chimeric	mouse	model	(IL-21R-/-	:	LDLR-/-)	was	generated.	Loss	of	 IL-21R	significantly	attenuated	both	Tfh	cell	 and	GC	B-cell	populations,	 alongside	 total	 and	 oxidised	 low-density	 lipoprotein	 specific	 antibody	titres.	Interestingly,	 loss	of	IL-21R	enhanced	lesion	formation	and	pro-inflammatory	cell	 infiltration.	Taken	 together,	 the	 results	described	 in	 chapter	4	demonstrate	 the	potential	athero-protective	role	of	Tfh	cell	and	GC	B-cells	in	atherosclerosis.			In	conclusion,	the	results	presented	in	this	thesis	provide	evidence	indicative	of	Tfh	and	GC	B-cells	cells	playing	an	important	role	in	atherosclerosis.	By	affecting	antibody	production	 in	 vivo,	 Tfh	 cells	 may	 regulate	 lesion	 formation	 and	 subsequent	
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pathological	 progression.	 As	 such,	 Tfh	 cells	 may	 form	 an	 attractive	 target	 in	 the	development	of	effective	therapeutics	for	atherosclerosis.																																		
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Chapter	1:	General	Introduction	
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 Cardiovascular	Disease	(CVD)	
Cardiovascular	 Disease	 (CVD)	 is	 now	 the	 leading	 cause	 of	 death	 worldwide.	Accounting	 for	 approximately	17.5	million	deaths	 in	2012	 [1],	 CVD	 can	manifest	 in	various	forms,	from	myocardial	infarction	(MI),	stroke	and	peripheral	artery	disease	(PAD).	Closer	to	home,	Scotland	has	the	highest	death	rate	from	CVD	than	any	other	British	nation	(347	per	100,0000)	[2].	In	combination	with	other	non-communicable	diseases,	 Glasgow	 is	 said	 to	 suffer	 from	 the	 phenomenon	 termed	 the	 “the	 Glasgow	effect”	[3],	where	diseases	with	significant	death	rates	affect	the	city’s	inhabitants.		Strikingly,	 CVD	 is	 fast	 becoming	 an	 epidemic	 in	 developing	 countries	 [4].	Traditionally	 viewed	 as	 regions	 with	 low	 CVD	 incidence,	 developing	 nations	 now	have	 extensive	 access	 to	 westernised,	 high	 fat	 diets	 [5].	 Helped	 by	 an	 increase	 in	disposable	 income,	 developing	 countries	 are	 now	 witnessing	 the	 beginning	 of	 a	cardiovascular	crisis	[5].	Unless	effective	therapeutics	are	developed	and	developing	nations	receive	appropriate	education	on	CVD,	such	nations	 face	a	 future	similar	 to	that	of	their	developed	counterpart’s.		Common	 to	 all	 branches	 of	 CVD	 is	 the	 arterial	 disease	 –	 atherosclerosis.	Atherosclerosis	is	a	chronic	immune	disease	of	small	and	medium	sized	arteries	[6].	Characterised	 by	 the	 gradual	 accumulation	 of	 low-density	 lipoprotein	 (LDL)	 in	 the	sub-endothelial	 space,	affected	arteries	house	dense	populations	of	both	 innate	and	adaptive	immune	cells	[6].	Proliferating	and	secreting	immune	mediators,	these	cells	orchestrate	the	pro-atherogenic	 immune	response	to	oxidised	forms	of	LDL,	as	well	as	other	 implicated	antigens.	As	a	result	of	sustained	inflammation,	 luminal	plaques	become	 increasingly	 complex,	 with	 additional	 immune	 cells	 being	 recruited.	Following	 a	 breach	 in	 the	 protective	 smooth	 muscle	 /	 collagenous	 cap	 that	encapsulates	 all	 plaques,	 plaques	 may	 rupture	 and	 release	 their	 pro-thrombic	contents	 into	 the	 luminal	 space.	 Affected	 arteries	 consequently	 lose	 their	 patency,	resulting	 in	 reduced	 blood	 flow	 to	 end	 organs.	 Individuals	 affected	 by	 such	 events	may	experience	a	stroke	or	MI,	resulting	in	organ	necrosis	and/or	death.			
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 Risk	Factors		
Factors	that	influence	atherosclerosis	may	comprise	both	physiological	and	life	style	components.	 Termed	 risk	 factors,	 risk	 factors	 comprise	 a	 range	 of	 traits,	 habits	 or	conditions	that	may	increase	ones	likelihood	of	developing	atherosclerosis.	The	term	risk	 factor	was	 first	 coined	at	 the	start	of	 the	1960’s,	when	 the	presence	of	 specific	factors	or	conditions	were	found	to	be	linked	to	an	individual’s	susceptibility	to	lesion	formation	[7].	Risk	factors	are	now	divided	into	either	traditional	and	non-tradition	risk	factors.			Traditional	risk	factors	comprise	a	comprehensive	list	including,	smoking,	diet,	race,	high	blood	pressure	 and	 genetics.	Although	 stand-alone,	 traditional	 risk	 factors	 are	insufficient	 in	 predicting	 lesion	 formation;	 their	 cumulative	 presence	 is	 associated	with	approximately	75	%	-	90	%	of	cardiovascular	events	[8].	In	testament	to	the	pro-atherogenic	 effects	 of	 traditional	 risk	 factors,	 cigarette	 smoking	 has	 been	 linked	 to	reduced	nitrous	oxide	(NO)	production,	enhanced	adhesion	molecule	expression	and	increased	lipid	peroxidation	[9-11].	Moreover,	genetic	abnormalities	-	such	as	familial	hyperlipidemia	–	result	in	increased	serum	LDL	levels,	leading	to	increased	retention	and	oxidation.	High	blood	pressure	can	significantly	enhance	endothelial	dysfunction	and	adhesion	molecule	expression	by	increasing	sheer	stress	on	endothelial	surfaces.	Table	1	below	outlines	 the	various	 traditional	 risk	 factors	 linked	 to	 atherosclerosis	formation.		Of	 those	 discussed	 above,	 diabetes	 has	 emerged	 as	 a	 major	 risk	 factor	 for	 the	development	of	CV	morbidities	[12].	Using	large	data	sets,	collected	over	a	period	of	two	decades,	researchers	have	identified	that	diabetes	doubles	and	triples	CV	risk	in	men	and	woman	 respectively	 [13].	Although	 rates	of	CVD	 in	patients	with	diabetes	have	 steadily	 decreased,	 the	 relative	 risk	 of	 CVD	 in	 diabetic	 cohorts	 remains	unchanged	[14].	As	a	result,	diabetes	has	now	become	an	 integral	component	of	CV	treatment	regimes,	with	a	strong	focus	on	prevention.								
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Table	1:	Traditional	Risk	Factors	involved	in	Atherosclerosis.	Although	 active	 inflammation	 plays	 an	 important	 role	 on	 atherosclerosis,	 several	lifestyle	and	hereditary	factors	may	influence	plaque	development.				
 Atherosclerosis	–	Accumulation	to	Inflammation	
Atherosclerosis	 was,	 for	 decades,	 considered	 to	 be	 a	 vapid	 disease	 of	 lipid	accumulation	 that	 resulted	 in	 lumen	occlusion	 and	 end	organ	necrosis.	 This	 notion	soon	 gave	 way	 to	 a	 new	 theory	 based	 heavily	 on	 the	 involvement	 of	 the	 immune	system	 [15].	 Using	 a	 combination	 of	 animal	 models	 and	 clinical	 observations,	scientists	 identified	 a	 fundamental	 association	 between	 the	 immune	 system	 and	atherosclerosis	 progression.	 Using	 genetically	 modified	 animal	 models	 of	atherosclerosis	(discussed	elsewhere);	researchers	now	understand	the	fundamental	role	 of	 immune	 cells	 such	 as,	 T-cells,	 B-cells,	 macrophages	 and	 dendritic	 cell	 in	atherosclerosis.		As	part	of	 this	 section,	 the	natural	progression	of	 atherosclerosis	will	be	discussed.	Particular	 focus	will	be	given	to	the	role	of	 immune	cells	 in	plaque	progression	and	the	pathological	processes	involved.			
Traditional*Risk*Factors*Diabetes(Smoking(High(Fat(Diet((Age((Sex((Race((Genetics((High(Blood(Pressure(
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 Structure	of	Arteries		
To	understand	the	pathological	processes	that	lead	to	the	formation	of	intra-arterial	plaques,	it	is	important	to	appreciate	the	structure	of	arteries.	Arteries	represent	the	body’s	network	of	vessels	 that	carry	oxygenated	blood	from	the	heart	 to	peripheral	organs.	Without	 their	 plentiful	 supply	 of	 blood	 to	 organs,	 organs	 -	 and	 subsequent	physiological	processes	 -	would	cease,	 resulting	 in	multi-organ	 failure	and	eventual	death.			Structurally,	 arteries	 are	 designed	 to	 withstand	 the	 force	 of	 blood	 moving	 at	 high	velocity.	All	arteries	are	composed	of	three	structurally	distinct	areas.	The	innermost	layer,	or	the	tunica	intima	is	composed	largely	of	connective	tissue	with	an	overlying	layer	of	endothelial	 cells	 [16].	This	 layer	 is	continuously	exposed	 to	blood	 flow	and	plays	 an	 important	 role	 in	 the	 initiation	 and	 progression	 of	 inflammatory	atherosclerosis.	 Separating	 the	 tunica	 intima	 from	 the	middle	 layer	 –	 or	 the	 tunica	media	–	is	a	thin	layer	of	elastic	tissue	called	the	elastic	lamina	[17]	[16].	The	tunica	media	comprises	a	large	component	of	arteries	and	consists	mainly	of	smooth	muscle	cells	and	underlying	elastic	tissue	[17].	The	outermost	layer,	or	the	tunica	externa	or	adventitia,	is	composed	of	collagen	and	another	layer	of	elastic	lamina	tissue.		Taken	 together,	 the	 components	 of	 each	 layer	 allow	arteries	 to	withstand	pressure	from	circulating	blood,	while	maintaining	a	plentiful	 supply	of	oxygen	rich	blood	 to	end	 organs.	 Due	 to	 the	 pathological	 nature	 of	 atherosclerosis,	 lesion	 formation	significantly	 alters	 the	 anatomy	 and	 function	 of	 these	 layers,	 with	 the	 intense	infiltration	of	immune	cells	and	structural	augmentation.								
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 Development	and	Progression	of	Atherosclerosis	
For	 decades,	 atherosclerosis	 was	 viewed	 as	 a	 physiological	 disease	 of	 aging.	 In	testament	 to	 this	 theory,	 nascent	 stages	 of	 atherosclerosis	 can	 be	 found	 in	 young	children	 [18].	 Whether	 these	 early	 stages	 develop	 into	 mature	 plaques	 is	 heavily	dependent	on	the	presence	of	risk	factors	including,	genetics,	smoking,	diet,	lifestyle	and	 co-morbidity	 (discussed	 elsewhere).	 In	 general	 terms,	 atherosclerosis	 is	 the	result	of	impaired	clearance	of	LDLs	coupled	with	a	chronic	inflammatory	response.	Although	other	factors	play	an	important	role	in	plaque	progression,	LDL’s	role	in	the	initiation	and	progression	of	atherosclerosis	is	fundamental.			LDL	are	homeostatic	transport	molecules	composed	of	triglycerides,	cholesterol	and	free	fatty	acids	[19].	As	such,	LDL’s	transport	components	of	energy	metabolism	and	cellular	 construction	 to	 their	 relevant	 locations	 throughout	 the	 body	 [19].	 Under	physiological	 conditions,	 LDL	 infiltrate	 artery	 walls,	 where	 they	 release	 their	components	and	are	transported	away	from	arteries	via	another	lipoprotein	pathway	[20].	 This	 pathway,	 or	 the	 reverse	 cholesterol	 transport	 pathway,	 is	 dependent	 on	another	class	of	plasma	lipoproteins	–	termed	high-density	 lipoproteins	(HDL)	[21].	HDL,	as	such	remove	excess	cholesterol	from	the	sub-endothelial	layer	of	arteries	and	transports	 it	 to	 the	 liver,	 from	where	 it	 is	 excreted	 in	bile	 [21].	 In	 cases	where	 the	homeostatic	balance	between	LDL	infiltration	and	removal	is	favoured	in	the	balance	of	the	former,	LDLs	accumulate	in	the	sub-endothelial	layer	and	initiate	the	formation	of	 nascent	 atherosclerotic	 plaques.	 Such	 cases	 can	 arise	 when	 individuals	 lead	sedentary	life	styles	coupled	with	fat	enriched	diets,	or	in	cases	of	genetic	disorders	such	as	familial	hyperlipidemia.		Once	in	the	sub-endothelial	layer,	LDL	particles	are	exposed	to	a	wealth	of	oxidising	agents	 that	 progressively	 modify	 native	 LDL	 (nLDL)	 into	 pathogenic	 oxidised-LDL	(Ox-LDL)	[22].	Due	to	the	progressive	oxidation	of	nLDL,	Ox-LDL	particles	are	more	“immune-obvious”	 than	 their	 native	 counterparts.	 In	 particular,	 tissue	 resident	macrophages	display	high	affinity	 for	 the	newly	 formed	molecules.	By	 their	nature,	phagocytising	macrophages	bind	and	uptake	Ox-LDL	via	a	range	of	 innate	receptors	called	 scavenger	 receptors	 (SR)s	 on	 their	 surface.	 SRs	 comprise	 a	 diverse	 group	 of	innate	 receptors	 involved	 in	 binding	 pattern	 molecules	 located	 on	 the	 surface	 of	pathogens,	apoptotic	cells	and	altered	physiological	molecules	[23].	To	date,	several	
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SRs	have	been	implicated	in	Ox-LDL	recognition	and	uptake	by	arterial	macrophages.	These	 include,	 CD36,	 scavenger	 receptor-A	 (SR-A)	 and	 lectin-like	 oxidised	 low-density	lipoprotein	receptor-1	(LOX-1)	[24-26].	Highlighting	the	importance	of	SRs	to	lesion	formation,	some	have	shown	that	loss	of	SR	function	significantly	ameliorates	lesion	 formation	 [27-29].	 Conversely,	 others	 have	 demonstrated	 that	 loss	 of	 SR	function	 in	 fact	enhances	 lesion	 formation	[30].	As	such,	 these	 findings	suggest	 that	several	Ox-LDL	uptake	mechanisms	may	exist	to	promote	lesion	formation.			As	arterial	macrophages	progressively	uptake	and	internalise	Ox-LDL	molecules,	they	become	overwhelmed	and	cease	functioning	as	local	phagocytes.	As	a	result,	arterial	macrophages	readily	transform	into	pathological	structures	termed	foam	cells.	Seen	under	 the	microscope,	 foam	 cells	 are	 characteristically	 yellow	 in	 colour,	 due	 to	 the	excessive	cholesterol	products	contained	in	their	cytoplasm.	As	such,	foam	cells	were	one	 of	 the	 first	 immune	 cells	 to	 be	 linked	 with	 atherosclerosis	 and	 form	 the	characteristic	signs	of	nascent	plaque	formation	[31,	32].	When	aggregated	together,	foam	cells	form	structures	called	fatty	streaks.	Found	at	early	stages	of	disease,	fatty	steaks	 can	 be	 found	 in	 stillborn	 babies	 as	 well	 as	 infants	 [33].	 Once	 completely	overwhelmed,	 foam	 cells	 release	 their	 toxic	 contents	 through	 apoptosis	 and	contribute	to	the	formation	of	a	necrotic	core	[34].			Diverging	 from	 the	 original	 descriptions	 of	 atherosclerosis	 as	 a	 simple	 disease	 of	accumulation,	the	past	few	decades	have	provided	evidence	indicating	the	important	role	 of	 Ox-LDL	 in	 initiating	 pro-inflammatory,	 atherogenic	 events.	 Importantly,	remnants	of	oxidation	have	been	implicated	in	the	up-regulation	of	various	leukocyte	adhesion	molecules	and	chemokines.	Specifically,	Ox-LDL	can	 induce	the	expression	of	 vascular	 cellular	 adhesion	 molecule-1	 (VCAM-1),	 intracellular	 cellular	 adhesion	molecule-1	 (ICAM-1),	 P-selectin	 and	 the	 chemokine	 (C-C	motif)	 ligand	 2	 (CCL2)	 or	also	referred	to	as	monocyte	chemotactic	protein	1	(MCP-1)	on	endothelial	cells	[35,	36].	 Facing	 the	 lumen,	 adhesion	 molecules	 bind	 circulating	 leukocytes	 via	 specific	receptors.	As	a	result,	bound	leukocytes	roll	along	the	endothelial	surface	and	migrate	towards	 the	 sub-endothelial	 space,	 where	 they	 contribute	 to	 the	 evolving	inflammatory	response.	Highlighting	the	importance	of	adhesion	molecules	and	their	receptors	 to	 lesion	 formation,	 loss	 of	 adhesion	molecule	 expression	 in	 apoE-/-	mice	significantly	attenuates	atherosclerosis	[37].			
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As	 well	 as	 affecting	 adhesion	 molecule	 expression,	 Ox-LDL	 activates	 arterial	macrophages,	resulting	in	the	secretion	of	pro-inflammatory	cytokines.	The	release	of	these	 cytokines	 induces	 a	 pro-inflammatory	 cascade	 in	 which	 further	 adhesion	molecule	 expression	 is	 induced,	 resulting	 in	 increased	 leukocyte	 migration	 [35].	Supporting	 this,	 Ox-LDL	 has	 been	 implicated	 in	 the	 up	 regulation	 of	 various	macrophage	associated	pro-inflammatory	genes.	This	continuous	cycle	of	activation	and	 infiltration	 contributes	 significantly	 to	plaque	progression	and	evolution	of	 the	local	 immune	 response.	 Highlighting	 the	 importance	 of	 Ox-LDL	 to	 macrophage	activation,	loss	of	human	SRs	has	been	shown	to	attenuate	pro-inflammatory	tumour	necrosis	 factor-alpha	 (TNF-α)	 and	 IL-1β	 production	 in	 a	 nuclear	 factor	 kappa-light	chain	enhancer	of	activated	B-cells	(NF-κβ)	dependent	manner	[38].		As	well	as	macrophages,	T-cells	are	well-characterised	components	of	atherosclerotic	plaques	 [39-41].	 Responding	 to	 a	 single	 antigen	 via	 T-cell	 receptor	 (TCR)	 –	 major	histocompatibility	 complex	 (MHC)-I/II	 interaction,	 T-cells	 secrete	 vast	 amounts	 of	pro-inflammatory	 cytokines	 [42]	 [43].	 These	 cytokines	 consequently	 influence	 the	pro-inflammatory	 processes	 involved	 in	 cell	 recruitment	 and	 plaque	 progression.	Moreover,	T-cells	can	help	B-cells	 in	 the	production	of	high	affinity	antibodies	 [44].	Several	 products	 required	 for	 this	 process	 have	 been	 identified	 in	 aortic	 tertiary	lymphoid	 organs	 (ATLO)s	 [45]	 –	 ectopic	 structures	 found	 in	 the	 adventitia	 of	 aged	atherosclerotic	mice.	Upon	engagement	of	antigen,	T-cells	home	to	affected	arteries	using	adhesion	molecules	such	as	VCAM-1	and	ICAM-1.	Binding	of	such	molecules	to	the	 endothelial	 expressed	 integrins,	 very-late	 antigen-4	 (VLA-4)	 and	 lymphocyte	function	 associated	 antigen-1	 (LFA-1)	 mediates	 this	 process	 [46]	 [47].	 Upon	migration	 to	 the	 sub-endothelial	 space,	 T-cells	 proceed	 to	 secrete	 toxic	 cytokines,	thereby	 increasing	 endothelial	 dysfunction,	 adhesion	 molecule	 expression	 and	migration	of	additional	leukocytes.			Collectively,	 debris	 from	 dying	 foam	 cells,	 cholesterol	 products	 and	 immune	 cells	form	 a	 structure	 termed	 the	 necrotic	 core.	 A	 hallmark	 of	 advanced	 disease,	 the	necrotic	 core	houses	a	 range	of	potential	neo-antigens	 for	 resident	 immune	cells	 to	recognise	 and	 react	 to.	 Driven	 by	 the	 secretion	 of	 inflammatory	 mediators,	 the	necrotic	core	continues	to	grow	in	size,	resulting	in	the	gradual	occlusion	of	the	artery	in	 question.	 Secreted	 products	 also	 enhance	 smooth	 muscle	 phenotypic	 transition	from	contractile	to	pathological	in	function.	Specifically,	smooth	muscle	cells	migrate	
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from	 the	 tunica	 media	 to	 the	 sub-endothelial	 space,	 where	 they	 accumulate	 and	deposit	 extra-cellular	matrix	 components	 into	 forming	 lesion	 cap.	Exposure	 to	pro-inflammatory	 stimuli	 and	persistent	 erosion	 of	 the	 smooth	muscle	 cap	may	 breach	plaque	integrity	and	allow	the	pro-thromic	contents	of	spill	into	the	luminal	space.	If	such	an	event	occurs,	it	is	most	likely	to	result	in	stroke	or	MI	by	inducing	thrombus	formation.																											
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 Antigen	Specificity	and	Molecular	Mimicry	
To	 date,	 various	 antigens	 have	 been	 implicated	 in	 the	 induction	 of	 atherosclerosis,	including,	 Ox-LDL,	 heat	 shock	 protein	 60	 (HSP-60)	 and	 various	 microbes.	 In	particular,	 Helicobacter	 pylori	 can	 be	 found	 in	 a	 significant	 proportion	 of	 human	lesions,	 with	 a	 strong	 correlation	 to	 adhesion	 molecule	 expression	 [48,	 49].	Chlamydia	Pneumoniae	 can	 also	 be	detected	 in	 atherosclerotic	 lesions	 [48,	 50,	 51].	Moreover,	inoculation	of	both	mice	and	rabbits	with	Chlamydia	Pneumoniae	has	been	shown	to	drive	lesion	formation	[52].		Interestingly,	 some	 have	 suggested	 that	 common	 motifs	 between	 different	pathological	 molecules	 may	 drive	 atherosclerosis.	 Termed,	 molecular	 mimicry,	several	 studies	 have	 studied	 the	 potential	 significance	 of	 this	 notion.	 Supporting	molecular	 mimicry,	 immunization	 of	 low-density	 lipoprotein	 receptor	 knock	 out	(LDLR-/-)	 mice	 with	 Streptococcus	 Pneumoniae	 induces	 Ox-LDL	 specific	 antibody	production	 [53].	 Importantly,	 these	 antibodies	 bind	 pneumococcal	 components	effectively	[53],	therefore	indicating	a	common	motif.			It	 is	 well	 documented	 that	 antigens	 play	 an	 important	 role	 in	 atherosclerosis.	 Of	importance	 to	 this	notion	however,	 the	 location	 in	which	a	T-cell	become	activated	and	 subsequently	 exerts	 their	 pro-atherogenic	 affects	 is	 contested.	 Conforming	 to	traditional	views,	T-cells	become	activated	in	secondary	lymphoid	organs	and	travel	to	 arteries,	 where	 they	 exert	 their	 pro-atherogenic	 effects.	 In	 contrast,	 some	 have	provided	data	suggesting	that	antigen	presentation	and	subsequent	T-cell	activation	may	in	fact	occur	locally	within	the	aorta	[54]								
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 Animal	Models	of	Atherosclerosis		
Due	to	the	location	of	plaques	and	the	importance	of	arteries	to	life,	researchers	are	restrained	 to	 studying	 human	 atherosclerosis	 post-mortem	 or	 by	 using	 surgical	biopsies.	As	such,	the	pathophysiological	processes	that	lead	to	plaque	development	may	only	be	studied	when	plaques	are	the	cause	of	death.	To	study	the	multifaceted	nature	 of	 atherosclerosis,	 and	 the	 role	 of	 various	 processes	 in	 plaque	 formation,	researchers	have	utilised	animal	models	throughout	the	decades.	In	testament	to	the	role	 of	 animal	 models	 in	 atherosclerosis	 research,	 much	 of	 what	 researchers	understand	about	plaque	formation	is	a	direct	result	of	animal	experimentation.			To	 date,	 several	 species	 have	 been	 used	 in	 the	 study	 of	 atherosclerosis,	 including,	mice,	pigs,	rabbits	and	non-human	primates.	Like	all	models	of	disease,	these	models	have	 advantages	 and	 limitations	 to	 their	 use.	 In	 recent	 times,	 mouse	models	 have	dominated	atherosclerosis	research.	However,	in	using	these	models,	 it	 is	important	to	 acknowledge	 the	 differences	 between	 mice	 and	 humans	 and	 their	 subsequent	effect	on	atherosclerosis.			Humans	 develop	 lesions	 mainly	 in	 the	 carotid,	 coronary	 and	 peripheral	 arteries,	whereas	 mice	 develop	 lesions	 more	 commonly	 in	 the	 aortic	 root	 and	 aortic	 arch.	Although	 plaque	 location	 may	 differ,	 many	 of	 the	 pathophysiological	 processes	required	 for	 lesion	 formation	 are	 common	 to	 both	 humans	 and	mice.	 This	 coupled	with	 the	 short	 time	needed	 for	plaque	 formation;	 low	cost	 and	high	 litter	numbers	has	resulted	in	mouse	models	dominating	atherosclerosis	research.		Although	 mouse	 models	 have	 dominated	 atherosclerosis	 research,	 larger	 animal	species	have	also	contributed	to	our	understanding	of	atherosclerosis	formation	and	progression.	 As	with	mouse	models,	 these	models	 represent	 their	 own	 advantages	and	 disadvantages	 as	 faithful	 models	 of	 atherosclerosis.	 Unlike	 mice,	 pigs	 develop	spontaneous	atherosclerosis	that	can	be	enhanced	with	the	use	of	atherogenic	diets	[55-57].	Moreover,	pigs	develop	lesions	at	sites	more	commonly	affected	in	humans	[58],	 display	 human-like	 lipoprotein	 profiles	 and	 are	 big	 enough	 for	 minimally-invasive	interventional	studies	[59].	As	such,	pigs	may	be	viewed	as	a	robust	model	of	atherosclerosis.	 However,	 pigs	 are	 expensive	 to	 maintain	 and	 display	 little	susceptibility	to	genetic	manipulation.	 In	contrast	to	this,	however,	pig	models	have	
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provided	valuable	data	with	regards	to	the	transcriptional	regulation	of	genes	at	sites	susceptible	and	resistant	to	atherosclerosis	[60].			Rabbits	 have	 been	 used	 extensively	 throughout	 the	 literature	 as	 another	model	 of	atherosclerosis.	 Rabbits	 are	 most	 sensitive	 to	 cholesterol	 burden	 [61],	 cheap	 to	maintain	and	share	some	of	the	characteristics	found	in	pigs.	Moreover,	rabbits	have	been	 instrumental	 in	 the	 study	 of	 lipoprotein	 fractions	 and	 genetic	 conditions	affecting	lipoprotein	metabolism	[62]	[63].			Perhaps	most	 controversially,	 non-human	primates	 have	 been	 used	 in	 the	 study	 of	atherosclerosis.	Non-human	primates	display	the	advantage	of	expressing	humanoid	lipoproteins	 and	 lipoprotein	 metabolism.	 Males	 are	 more	 susceptible	 to	 lesion	formation	 and	 plaques	 occur	 in	 areas	 more	 applicable	 to	 human	 disease	 [63].	Moreover,	 non-human	 primates	 display	 enhanced	 vasa	 vasorum	 density	 and	increased	intimal	thickening	[64]	-	a	feature	of	human	disease	not	commonly	found	in	lower	animal	models.	The	size,	maintenance	cost,	 lack	of	genetic	diversity	and	 time	taken	 for	 plaque	 development	 represent	 a	 limitation	 to	 the	 use	 of	 non-human	primates	in	atherosclerosis	research.		In	 comparison	 to	 large	 animals,	 the	 mouse	 has	 remained	 the	 animal	 of	 choice	 in	atherosclerosis	 research.	 In	 comparison	 to	 humans,	 wild	 type	 (WT)	 mice	 are	relatively	resistant	to	plaque	formation.	This	is	mainly	due	to	variations	in	rodent	and	human	 cholesterol	 metabolism.	 Mouse	 cholesterol	 is	 composed	 mainly	 of	 athero-protective	HDL	particles,	while	humans	display	a	more	pro-atherogenic	LDL	profile.	One	 reason	 for	 this	 difference	 can	 be	 found	 in	 the	 expression	 of	 cholesterol	 ester	transfer	 protein	 (CETP)	 in	 the	 mouse	 [65].	 Involved	 in	 the	 transport	 of	 LDL	constituents	 to	 HDL	 particles,	 CETP	 significantly	 reduces	 circulating	 levels	 of	atherogenic	 LDL	 in	 the	 mouse.	 Moreover,	 humans	 absorb	 approximately	 50%	 of	cholesterol	derived	from	dietary	sources,	while	the	mouse	does	not	absorb	significant	amounts	 [66].	 A	 combination	 of	 these	 two	 processes	 allows	 mice	 to	 express	 HDL	dominant	(athero-protective)	lipid	profiles.			To	 address	 these	 issues,	 early	 researchers	 used	 genetic	 approaches	 to	 ablate	components	of	cholesterol	transport.	In	doing	so,	scientists	were	able	to	skew	mouse	lipoprotein	 kinetics	 from	 athero-protective	 profiles	 to	 atherogenic	 ones.	 Although	
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these	 approaches	 yielded	 a	 variety	 of	 transgenic	 animals,	 two	 models	 have	predominated	and	are	in	common	use	today.	These	models	were	termed	the	apoE-/-	and	LDLR-/-	mouse	models.		As	part	of	this	section,	both	the	apoE-/-	and	LDLR-/-	mouse	models	will	be	discussed.	Particular	attention	will	be	given	to	their	advantages	 in	atherosclerosis	research,	as	well	as	their	disadvantages	as	a	model	of	human	disease.																											
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1.7.1 	ApoE-/-	Mouse	Model	of	Atherosclerosis	The	apoE-/-	mouse	model	lacks	the	34	kD	glycoprotein	apoE	and	is	perhaps	the	most	used	animal	model	of	atherosclerosis	[67].	Involved	in	chylomicron	remnant	and	LDL	metabolism,	apoE	displays	high	affinity	for	LDL	receptors	in	the	liver,	where	receptor	mediated	endocytosis	results	in	lipid	clearance	[67].	Lack	of	functional	apoE	in	apoE-/-	mice	 results	 in	 enhanced	 serum	 very	 low-density	 lipoprotein	 (VLDL),	 LDL,	intermediate	 density	 lipoprotein	 (IDL)	 levels	 with	 a	 concomitant	 decrease	 in	 HDL	levels.	 As	 such,	 apoE-/-	mice	 display	 lipoprotein	 levels	 that	 are	 favourable	 to	 lesion	development.	 In	 testament	 to	 this,	 apoE-/-	 mice	 develop	 lesions	 typical	 of	 a	 more	advanced	 stage	 of	 human	pre-atherosclerotic	 lesions	when	 fed	 standard	 laboratory	diet	 [68].	 When	 fed	 diets	 enriched	 with	 cholesterol	 and	 fat,	 apoE-/-	 mice	 develop	arterial	 lesions	 in	 an	 accelerated	manner	 [68].	 However,	 lesions	 induced	 in	 such	 a	manner,	display	reduced	cellularity	and	contain	primarily	lipid	laden	foam	cells	[69].	The	short	time	frame	in	which	apoE	mice	breed,	coupled	with	their	large	litters,	has	allowed	 scientists	 to	 employ	 several	 genetic	 approaches	 to	 study	 immune	 cell	involvement	in	atherosclerosis.	In	particular,	the	apoE-/-	mice	crossed	with	immuno-deficient	 recombinase	 activation	 gene	 (RAG)	 or	 severe	 combined	 immuno-deficient	(SCID)	mice	have	been	instrumental	in	our	understanding	of	the	role	of	T-cells	and	B-cells	in	atherosclerosis.			Although	 used	 throughout	 the	 literature	 as	 a	 reliable	model	 of	 atherosclerosis,	 the	apoE-/-	mouse	model	 has	 several	 disadvantages.	 In	 particular,	 atherogenesis	 in	 the	apoE-/-	 mouse	 is	 dependent	 on	 lipoprotein	 remnants,	 rather	 than	 the	 larger	 LDL	particles	 that	are	 causative	 in	humans.	Moreover,	 apoE	has	been	suggested	 to	have	important	roles	in	macrophage,	immune	and	adipose	tissue	biology	[70].	As	such,	loss	of	apoE	may	affect	these	processes	in	a	manner	independent	of	cholesterol	kinetics.	Irrespective	 of	 these	 disadvantages,	 the	 apoE	mouse	model	 has	 become	 one	 of	 the	gold	standard	models	of	experimental	atherogenesis.				
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1.7.2 	LDLR-/-	Mouse	Model	of	Atherosclerosis	Unlike	 apoE,	 loss	 of	 low-density	 lipoprotein	 receptor	 (LDLR)	 expression	 in	 LDLR-/-	solely	 affects	 lipoprotein	 uptake	 and	 clearance.	 Due	 to	 the	 lack	 of	 hepatic	 LDLRs,	LDLR-/-	are	unable	 to	remove	and	metabolise	atherogenic	 lipoprotein	molecules	via	apoE-LDLR	mediated	 endocytosis.	 As	 such,	 LDL	 predominates	 in	 the	 circulation	 of	animals,	 leading	 to	 vascular	 accumulation	 and	 atherosclerosis	 formation.	Interestingly,	 LDLR-/-	 mice	 do	 not	 develop	 spontaneous	 atherosclerosis	 and	 are	dependent	on	the	use	of	cholesterol	and	fat	enriched	HFDs	[71,	72].	When	fed	HFD	for	extended	 periods	 of	 time,	 LDLR-/-	 mice	 develop	 advanced	 lesions	 throughout	 the	aortic	 tree,	 aortic	 root	 and	 innominate	 arteries	 [73].	 Unfortunately,	 studies	 using	LDLR-/-	mice	use	a	variety	of	atherogenic	diets,	with	varying	cholesterol	content.	As	such,	 studies	 using	 the	 LDLR-/-	 model	 are	 often	 not	 standardised,	 making	comparisons	difficult.	A	major	advantage	of	the	LDLR-/-	model	is	that	these	mice	are	ideal	for	the	generation	of	chimeras.	Repopulation of irradiated apoE-/- mice with 
bone marrow cells from apoE+/+ donors ablated atherosclerosis. On	the	contrary,	
LDL receptor phenotype of the donor cells does not significantly impact 
atherosclerosis when used to repopulate LDLR-/- mice	[74].		Despite	 their	 limitations,	 the	 apoE-/-	 and	 LDLR-/-	models	 have	 proven	 invaluable	 in	our	understanding	of	the	complex	nature	of	atherosclerosis.	Both	models	have	been	used	in	this	thesis.											
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 T-cells	in	Atherosclerosis		
Although	found	in	healthy	arteries	[75],	T-cells	are	greatly	expanded	in	the	context	of	atherosclerosis,	 where	 they	 accumulate	 mainly	 within	 the	 adventitia	 of	 affected	arteries.	 The	 majority	 of	 T-cells	 found	 in	 atherosclerotic	 plaques	 are	 of	memory/effector	 phenotype,	 express	 the	 αβ-TCR	 [39,	 76]	 and	 are	 found	 in	 close	proximity	 to	 dendritic	 cells	 (DCs)	 in	 humans	 [77].	 As	 well	 as	 this,	 atherosclerotic	lesions	house	dense	populations	of	Ox-LDL	and	HSP	specific	T-cells,	 thus	 indicating	local	activation	and	proliferation	[78,	79].			The	importance	of	CD4+	T-cells	in	atherosclerosis	has	been	demonstrated	in	studies	using	 the	 immune-deficient	recombinase	activating	gene-1	(Rag-1)	and	SCID	mouse	strains	[80,	81].	Crossed	with	LDLR-/-	or	apoE-/-	mice,	these	mice	develop	attenuated	lesions,	 with	 one	 study	 reporting	 a	 54%	 reduction	 in	 lesion	 formation	 [82].	Consequently,	and	reinforcing	 the	 importance	of	T-cells	 in	atherosclerosis,	adoptive	transfer	 of	 T-cells	 into	 apoE-/-	 scid/scid	mice	 enhances	 lesion	 formation;	 with	 one	study	demonstrating	a	164%	increase	 [81].	Highlighting	 the	 importance	of	oxidised	forms	 of	 LDL,	 malondialdehyde	 modified	 LDL	 (MDA-Ox-LDL)	 specific	 T-cells	preferentially	enhance	lesion	formation	when	transferred	into	apoE-/-	scid/scid	mice	[83].													
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 T-helper	1	Cells	&	Atherosclerosis		
T-helper	 1	 cells	 (Th1)	 represent	 the	 most	 studied	 lymphocyte	 population	 in	atherosclerosis.	 In	 testament	 to	 this,	 atherosclerosis	 is	now	considered	 to	be	a	Th1	mediated	 disease.	 The	 prominence	 of	 Th1	 responses	may	 be	 explained	 by	 the	 Th1	skewed	 animal	 models	 used	 to	 study	 lesion	 development	 [84];	 therefore	 the	importance	of	other	immune	cells	should	not	be	ignored.		Using	apoE-/-	and	LDLR-/-	mice	scientists	have	been	able	to	study	the	involvement	of	Th1	mediated	pathways	in	disease	progression.	Research	into	the	role	of	Th1	cells	in	atherosclerosis	 has	 followed	 two	 directions	 –	 modulation	 of	 signature	 Th1	 cell	cytokines	 and	 the	modulation	 of	 CD4+	Th1	 cells	 in	vivo.	As	 result,	we	now	have	 an	extensive	understanding	of	the	role	Th1	cells	(and	their	signature	cytokines)	play	in	atherosclerosis.		In	this	section,	 the	role	of	Th1	associated	cytokines	and	Th1	cells	 in	atherosclerosis	will	be	discussed.																		
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1.9.1 IFN-γ		Interferon-gamma	 (IFN-γ)	 is	 perhaps	 the	 most	 noted	 and	 discussed	 cytokines	secreted	 by	 activated	 Th1	 cells.	 Interestingly,	 in	 situ	 and	 immunohistochemical	analysis	of	human	plaques	has	demonstrated	that	presence	of	IFN-γ	secreting	cells	in	human	plaques	(10,	11).			IFN-γ	 has	 been	 documented	 to	 have	 various	 pro-atherogenic	 effects.	 These	 effects	include,	 reduced	 collagen	 fibre	 production,	 enhanced	 major	 MHC-II	 expression,	elevated	 cytokine	 secretion	 and	 increased	 protease	 production	 [42,	 85].	 As	well	 as	this,	 IFN-γ	 contributes	 to	 the	 feedback	 loop	 between	 adaptive	 and	 innate	 immune	systems,	 by	 enhancing	 VCAM-1	 and	 ICAM-1	 expression	 on	 smooth	 muscle	 cells,	macrophages	and	endothelial	cells	[86-88].		Moreover,	 exogenous	 administration	 of	 IFN-γ	 increases	 lesion	 size,	 MHC-II	expression	and	CD4+	T-cell	expansion	in	apoE-/-	mice	in	vivo	[89].	Further	supporting	a	 pro-atherogenic	 role	 of	 IFN-γ,	 apoE-/-	or	 LDLR-/-	 mice	 deficient	 in	 IFN-γ	 receptor	develop	 reduced	 atherosclerosis	 [42,	 90].	 Exerting	 its	 effects	 throughout	atherosclerosis	 development,	 IFN-γ	 also	 enhances	 oxidised	 LDL	 uptake	 into	 THP-1	macrophages	 in	vitro	[91]	and	 induces	SR-1	expression	on	THP-1	macrophages	and	vascular	smooth	muscle	cells	(SMCs)	[91,	92].			It	is	important	to	consider	that	other	cell	types	secrete	IFN-γ,	including	macrophages	and	natural	killer	 (NK)	 cells.	The	effect	of	T-cell	 independent	 IFN-γ	 secretion	must,	therefore,	be	considered.	Indeed,	IFN-γ	can	enhance	atherosclerosis	formation	in	the	absence	of	T	and	B-cells	 in	vivo,	via	modulation	of	smooth	muscle	cells	 in	vivo	[93].	Irrespective	of	this,	IFN-γ	is	secreted	in	vast	amounts	by	activated	Th1	cells	–	a	source	that	contributes	significantly	to	pathology.		Taken	 together,	 the	studies	described	above	provide	evidence	 that	 implicates	 IFN-γ	as	an	important	cytokine	in	atherosclerosis	development.	They	also	indicate	that	IFN-γ	functions	to	exert	its	effects	throughout	atherosclerosis	development,	and	as	such	is	an	important	mediator	in	all	stages	of	the	pro-atherogenic	immune	response.		
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1.9.2 IL-18	IL-18,	along	with	IL-12,	is	an	important	cytokine	in	the	formation	of	effector	Th1	cells	[39].	The	importance	of	IL-18	to	Th1	cell	function	is	demonstrated	by	the	finding	that	IL-18	deficient	mice	develop	significantly	reduced	Th1	responses	in	vivo	[94].	IL-18	is	believed	 to	 exert	 its	 pro-atherogenic	 effects	 via	 enhanced	 IFN-γ	 production	 [95].		Using	 IL-18-/-/apoE-/-	 mice,	 researchers	 have	 demonstrated	 that	 IL-18	 ablation	reduces	I-Ab	and	IFN-	γ	expression,	as	well	as	reducing	lesion	formation	in	an	IFN-γ	dependent	manner	[96].			Interestingly,	IL-18-/-	apoE-/-	mice	display	elevated	serum	cholesterol	and	triglyceride	levels	[96],	thus	providing	enhanced	native	LDL	for	oxidation	and	uptake	by	arterial	macrophages.			Taken	together,	these	studies	indicate	that	IL-18	is	an	important	mediator	in	the	pro-atherogenic	immune	response	and	mediates	its	effects	via	IFN-γ	production.	As	well	as	 this,	 these	 studies	 indicate	 that	 IL-18	 can	 function	 to	 enhance	 early	 stage	atherogenesis	by	modulating	cholesterol	metabolism	in	vivo.		
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1.9.3 IL-2		IL-2	 belongs	 to	 a	 super	 family	 of	 cytokines,	 which	 –	 in	 combination	with	 different	subunits	 –	 signal	 via	 the	 type-1	 receptor	 family.	 IL-2	 exerts	 a	 range	 of	 effects	 on	different	immune	subsets,	with	T-cells	being	the	most	prominent.	Upon	activation,	T-cells	express	copious	amounts	of	IL-2,	followed	by	increased	expression	of	the	IL-2R.	Working	in	a	paracrine	manner,	IL-2	influences	the	expansion	of	antigen	experienced	effector	T-cell	populations	in	vivo	[97].	As	well	as	inducing	effector	T-cell	responses,	IL-2	maintains	 immune	 tolerance	 by	 influencing	 CD4+	 CD25+	 T-regulatory	 (T-reg)	cells	in	the	thymus	[98-100].			The	role	of	 IL-2	 in	atherosclerosis	was	 first	addressed	 in	studies	using	apoE-/-	mice	treated	 with	 IL-2	 or	 IL-2	 blocking	 antibodies.	 IL-2	 was	 found	 to	 exacerbate	atherosclerosis	 formation,	 while	 blockade	 of	 IL-2	 protein	 resulted	 in	atheroprotection	[101].	In	contrast	to	these	findings,	IL-2	has	been	shown	by	some	to	reduce	atherosclerosis	formation	in	vivo,	in	a	T-reg	dependent	manner	[102].	Recent	studies	 have	 supported	 this	 finding,	 with	 anti-CD3/IL-2	 therapy	 being	 effective	 in	reducing	atherosclerosis	in	apoE-/-	mice	via	a	T-reg	dependent	manner	[103].			Together,	these	studies	provide	evidence	indicating	the	role	of	IL-2	in	maintaining	a	balance	 between	 pro-atherogenic	 effector	 T-cell	 and	 athero-protective	 T-reg	responses	in	vivo.												
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1.9.4 T-bet		T-box	 transcription	 factor	 TBX21	 (T-bet)	 is	 attributed	 as	 the	 Th1	 cell	 master	regulator	of	 function.	Particularly,	T-bet	 induces	the	expression	of	 IFN-γ	 in	naïve	T-cells	 [104].	 Furthermore,	 T-bet	 has	 been	 shown	 to	 re-direct	 lineage-committed	 T-helper	 2	 (Th2)	 cells	 to	 a	 Th1	 cell	 programme,	 thus	 suppressing	 Th2	 development	[104].			Due	 to	 its	 effects	 on	 IFN-γ	 production	 and	 role	 in	 Th1	 cell	 development,	 T-bet	 has	received	 considerable	 attention	 in	 cardiovascular	 research.	 Using	 T-bet	 deficient	LDLR-/-	 mice,	 some	 have	 shown	 that	 T-bet	 deficiency	 significantly	 reduces	 plaque	formation	 in	vivo	[105].	Coupled	with	 this,	T-bet	deficiency	also	results	 in	enhanced	Th2	cell	expression,	resulting	in	increased	athero-protective	E06	antibodies	[105].	As	well	 as	 affecting	 Th1	 cell	 responses	 in	 vivo,	 these	 studies	 indicate	 that	 T-bet	deficiency	 functions	 to	 promote	 athero-protective	 antibody	 responses	 in	 vivo.	 As	such,	 T-bet	 modulation	 in	 vivo	 may	 prove	 to	 be	 a	 powerful	 tool	 in	 modulating	atherosclerosis.																		
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 T-helper	2	Cells	in	Atherosclerosis	
Th2	 cells	 are	 generally	 perceived	 to	 convey	 an	 athero-protective	 function	 in	atherosclerosis,	via	their	influence	on	antibody	production	and	cytokine	secretion.	In	testament	 to	 the	 athero-protective	 effects	 of	 Th2	 cells,	 BALB/c	 mice	 –	 which	 are	characterised	 by	 a	 Th2	 cell	 response	 –	 are	 resistant	 to	 atherosclerosis	 formation	[106].	 In	 contrast	 to	 this,	 C57BL6/J	 mice	 –	 which	 are	 characterised	 by	 a	 Th1	 cell	response	-	are	susceptible	to	atherosclerosis	formation	[106].	As	Th2	cells	exert	their	athero-protective	effects	via	the	production	of	cytokines,	this	section	will	discuss	the	influence	of	Th2	derived	cytokines	on	atherosclerosis.			
1.10.1 IL-4	IL-4	represents	one	of	 the	signature	Th2	cytokines	and	 its	role	 in	atherosclerosis	 is	debated.	Exogenous	administration	of	IL-4	to	apoE-/-	mice	has	been	reported	to	afford	no	 athero-protective	 or	 pro-atherogenic	 effect,	 with	 no	 change	 in	 T-cell	 or	macrophage	infiltration	compared	to	control	mice	[107].	Moreover,	both	IL-4-/-/apoE-/-	 and	 IL-4-/-/LDLR-/-	mice	 do	 not	 display	 increased	 or	 decreased	 plaque	 formation	[107].	 In	 contrast	 to	 this,	 long-term	studies	using	HFD	 fed	 IL-4-/-/apoE-/-	mice	have	reported	 a	 27%	 reduction	 in	 lesion	 area	 in	 comparison	 to	 control	 groups	 [108].	Adding	 to	 this,	 IL-4-/-	 :	 LDLR-/-	 chimeric	 mice	 display	 significantly	 reduced	 lesion	formation	than	respective	control	animals	[109].		Together,	these	studies	suggest	that	the	role	IL-4	In	atherosclerosis	is	controversial.									
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1.10.2 IL-5		In	contrast	to	IL-4’s	role	in	atherosclerosis,	IL-5’s	role	is	more	defined	and	consistent	throughout	 the	 literature.	 A	 variety	 of	 studies	 have	 reported	 the	 athero-protective	functions	of	 IL-5	 in	vivo.	 In	particular,	vaccination	with	MDA-Ox-LDL	in	apoE-/-	mice	results	in	reduced	atherosclerosis	in	an	IL-5	dependent	manner	[110].	Moreover,	this	reduction	 is	 associated	 with	 enhanced	 natural,	 athero-protective	 IgM	 production	[110].	 Using	 a	 chimeric	 approach,	 some	 have	 reported	 that	 IL-5-/-	 :	 LDLR-/-	 mice	develop	 enhanced	 atherosclerosis,	 coupled	 with	 reduced	 natural	 IgM	 production	[110].			Taken	 together,	 these	 studies	 suggest	 that	 IL-5	 may	 play	 variable	 roles	 in	atherosclerosis.	They	also	suggest	that	IL-5	exerts	is	effects	via	modulation	of	natural	IgM	antibodies	that	convey	protective	roles	in	atherosclerosis.	As	such,	modulation	of	IL-5	may	be	a	powerful	tool	in	the	induction	of	athero-protective	antibody	responses.			
1.10.3 IL-33	Attributed	 as	 another	 Th2	 cell	 cytokine,	 IL-33	 is	 present	 in	 the	 arteries	 of	 both	healthy	 and	 diseased	 arteries	 [111].	 In	vivo	 administration	 of	 IL-33	 in	 apoE-/-	mice	induces	a	 switch	 from	dominant	Th1	cell	 to	Th2	cell	 response	 [111].	This	 switch	 is	complimented	 by	 a	 rise	 in	 IL-4,	 IL-5	 and	 IL-13	 production	 and	 a	 reduction	 in	 pro-inflammatory	IFN-γ	production	[111].	Influencing	early	atherogenesis,	IL-33	has	been	shown	 to	 reduce	pathological	 foam	cell	 formation	 [112],	 a	process	attributed	 to	 IL-33’s	ability	to	reduce	CD36	expression	and	enhance	cholesterol	efflux	in	macrophages	[112].	 As	 such,	 these	 studies	 suggest	 that	 IL-33	 may	 function	 to	 inhibit	 pro-atherogenic	processes	while	promoting	athero-protective	mechanisms.						
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 T-helper	17	Cells	in	Atherosclerosis		
After	 the	 initial	 discovery	 of	 T-helper	 17	 (Th17)	 cells,	 their	 role	 in	 atherosclerosis	was	quickly	addressed.	IL-17	secreting	cells	have	been	described	in	both	mouse	[113,	114]	and	human	lesions	[115,	116].	Although	initially	associated	with	plaque	stability	in	humans	[117],	subsequent	studies	reported	that	IL-17A	production	was	linked	to	plaque	instability	[116].			Animal	 studies	 have	 provided	 contradictory	 data	 as	 to	 the	 role	 of	 Th17	 cells	 in	atherosclerosis.	 Suggesting	 a	 pro-atherogenic	 role,	 apoE-/-/Fcγ-/-	 mice	 display	reduced	 lesion	 formation,	 associated	with	 inhibition	of	Th17	 cells	 [118].	As	well	 as	this,	 apoE-/-	 mice	 treated	 with	 anti-IL-17A	 antibodies	 display	 reduced	 lesion	formation	[113]	,	as	well	as	reduced	VCAM-1,	IL-6	and	TNF-α	production	[119].		Supporting	 an	 athero-protective	 role	 of	 Th17	 cells,	 some	 have	 reported	 that	neutralisation	 of	 IL-17	 –	 with	 anti-IL-17A	 antibodies	 –	 enhances	 atherosclerosis	formation	 [120].	 Subsequent	 studies,	 using	 apoE-/-	 IL-17A-/-	 mice,	 have	 supported	these	 findings	 [121].	More	recently,	 IL-17A	has	been	 linked	 to	 induction	of	a	 stable	plaque	phenotype	[122]															
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 Υδ	T-cells	in	Atherosclerosis	
γδ	T-cells	 comprise	 approximately	 5%	of	 all	 T-cell	 populations	 and	 are	 specifically	found	 in	 areas	 exposed	 to	 antigen,	 such	 as	 the	 skin	 and	 the	 gastrointestinal	 tract	[123].	 Interestingly,	 γδ	T-cell	 numbers	 are	 greatly	 expanded	 in	 context	 of	 infection	and	autoimmunity	[124-126]	and	respond	rapidly	to	 infection.	Believed	to	be	a	 link	between	both	innate	and	adaptive	immune	systems,	γδ	T-cells	do	not	require	antigen	processing	and	presentation	on	MHC	molecules	[127].			γδ	T-cells	 are	 found	 in	 the	atherosclerotic	 arteries	of	both	humans	and	mice	 [128].	Data	from	early	and	more	recent	work	has	suggested	the	redundant	role	of	γδ	T-cells	in	 plaque	 formation	 and	 progression	 [129,	 130],	 with	 classical	 αβ	 T-cells	 being	responsible	 for	 lesion	 formation	 [129].	 These	 findings	 are	 however	 conflicted	 by	studies	 using	 apoE-/-/γδ-/-	 double	 knock	 out	 mice,	 in	 which	 loss	 of	 γδ	 T-cell	expression	significantly	attenuates	lesion	formation	by	up	to	44%	[128].																		
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 T-regulatory	Cells	in	Atherosclerosis		
T-reg	 cells	 represent	 the	 suppressive	 arm	 of	 the	 adaptive	 immune	 system	 and	function	 to	 prevent	 aberrant	 T-helper	 cell	 responses	 that	 may	 result	 in	 breach	 of	tolerance	and	detrimental	processes	[131].	T-regs	can	be	classified	as	natural	T-regs	(nT-regs),	where	thymic	processes	lead	to	the	development	of	T-reg	populations,	or	inducible	T-regs	(iT-regs),	where	peripheral	stresses	induce	their	formation	[132].	T-regs	 exert	 their	 effects	 via	 cell-cell	 interactions,	 as	 well	 as	 the	 production	 of	 anti-inflammatory	 cytokines	 such	 as,	 IL-10	 and	 TGF-β	 [132].	 As	 a	 consequence	 of	 their	function,	T-regs	play	an	important	role	in	maintaining	balance	between	effective	and	detrimental	T-cell	responses	[132].			Several	 studies	 have	 addressed	 the	 role	 of	 T-regs	 in	 the	 development	 of	 arterial	lesions.	 Particularly,	 hypercholesterolemic	 apoE-/-	 mice	 display	 reduced	 T-reg	expression	 patterns	 than	 C57BL/6	 control	 mice	 [133],	 a	 finding	 associated	 with	deficient	suppressor	activity	[133].		Subsequent	transfer	of	T-regs	into	apoE-/-	mice	is	sufficient	 to	 reduce	 atherosclerosis	 formation	 [133].	 Complimenting	 this	 finding,	enhanced	Th17	profiles	in	apoE-/-	mice	has	been	linked	to	defective	T-reg	expression	patterns	[114].		
 IL-10	
A	range	of	immune	cells	secrete	IL-10,	however,	its	T-reg	role	has	gained	significant	attention.	In	testament	to	its	anti-atherogenic	role,	LDLR-/-	mice	transplanted	with	IL-10-/-	 bone	 marrow	 cells	 display	 enhanced	 atherosclerosis,	 coupled	 with	 increased	inflammatory	 cell	 infiltrates	 [134].	 Conversely,	 over-expression	 of	 IL-10	 in	lymphocytes,	 from	 LDLR-/-	 mice,	 has	 been	 shown	 to	 significantly	 reduce	atherosclerosis	formation	[135].					
	 47	
 CD8+	T-cells	in	Atherosclerosis		
Unlike	CD4+	T-helper	cells,	CD8+	cytotoxic	T-cells	have	gained	little	attention	in	the	area	 of	 atherosclerosis.	 Surprisingly,	 CD8+	 T-cells	 represent	 the	 biggest	 leukocyte	population	 in	 advanced	 human	 lesions	 [136].	 In	 animal	 models,	 CD8+	 T-cells	 are	readily	 found	 at	 early	 stages	 of	 disease	 [137]	 and	 increase	 in	 number	 as	 lesions	become	more	advanced	[138].	Initial	studies,	using	β-2-microglobluin	deficient	mice,	in	 which	MHC-I	 expression	was	 inhibited,	mice	 developed	 enhanced	 lesions	 [139].	Questions	 over	 the	 exclusivity	 of	 this	 approach	 in	 depleting	 all	 CD8+	 T-cell	populations	has	cast	doubt	over	 its	validity.	Moreover,	mice	deficient	 in	MHC-I	-	via	Tap-I	ablation	–	do	not	show	modified	atherosclerosis	formation	[140].			With	 the	 development	 of	 more	 refined	 approaches,	 involving	 anti-CD8	 depleting	antibodies,	 researchers	 have	 demonstrated	 the	 true	 role	 of	 CD8+	 T-cells	 in	atherosclerosis.	Using	this	approach,	CD8+	depletion	has	been	shown	to	significantly	reduce	 lesion	 formation	 in	 vivo	 by	 reducing	 apoptosis,	 macrophage	 accumulation,	VCAM-1	expression	and	IFN-γ	production	to	name	a	few	[41].	Furthermore,	transfer	of	 CD8+	 T-cells	 into	 apoE-/-	 mice	 results	 in	 enhanced	 lipid	 and	 macrophage	accumulation,	 as	well	 as	 necrotic	 core	 formation	 [41].	 Adding	 to	 this,	 CD8+	 T-cells	deficient	in	perforin	and	granzyme	B	are	unable	to	enhance	atherosclerosis	formation	
in	vivo	[41].			More	recently,	the	role	of	CD8+	CD25+	T-regs	in	atherosclerosis	has	gained	extensive	attention.	Depletion	of	regulatory	CD8+	CD25	T-regs	has	been	shown	to	enhance	the	cytolytic	activity	of	CD8+	T-cells	in	atherosclerosis	[141].	In	contrast	to	this,	adoptive	transfer	 of	 CD8+	 CD25+	 T-cells	 functions	 to	 limit	 CD4+	 T-cell	 expansion	 [141].	Suggesting	 a	 protective	 effect	 in	 atherosclerosis,	 CD8+	 T-regs	 have	 also	 been	suggested	to	regulate	atherogenic	T-cell	responses	via	a	modulation	of	the	Tfh	cell	 :	GC	B-cell	axis	–	where	high	affinity	isotype	antibodies	are	produced	[142].			Taken	together,	these	studies	suggest	that	CD8+	T-cells	function	to	enhance	apoptosis	induced	necrotic	debris	formation.	As	such,	CD8+	T-cells	may	represent	an	important	population	in	atherosclerosis.	Reinforcing	the	heterogeneous	effects	of	immune	cells	in	 atherosclerosis,	 these	 studies	 also	 elude	 to	 the	 therapeutic	 potential	 of	 CD8+	CD25+	T-regs	in	atherosclerosis.			
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 B-cells	in	Atherosclerosis		
Along	with	T-cells,	B-cells	represent	an	important	component	of	the	adaptive	immune	system.	 Phenotypically,	 B-cells	 are	 distinguished	 from	 all	 other	 leukocytes	 by	 their	expression	 of	 a	 B-cell	 receptor	 (BCR).	 Involved	 in	 binding	 to	 cognate	 antigen	presented	 in	 context	 of	 major	 MHC,	 B-cells	 are	 charged	 with	 the	 task	 of	immunoglobulin	production.	Peripherally,	B-cells	can	be	classified	as	B1	cells	or	B2	cells,	with	B1	 cells	 being	 further	 refined	 into	B1a	 and	B1b	 cells	 [143].	 In	mice,	 the	surface	marker	CD5	is	commonly	used	to	distinguish	between	subsets,	with	B1a	cells	being	CD5+	and	B1b	and	B2	cells	being	CD5-.	B1	cells	arise	early	in	development	and	produce	 vast	 amounts	 of	 natural	 IgM	 antibodies	 in	 a	 T-cell	 independent	 manner	[144].	 Enriched	 in	 the	 peritoneal	 and	 pleural	 cavities,	 B1	 cells	 are	 rarely	 found	 in	secondary	 lymphoid	organs	 [143,	145].	 In	comparison	 to	 this,	B2	cells	–	also	called	conventional	B-cells	–	express	a	variety	of	diverse	BCRs	and	are	responsible	 for	the	production	of	isotype	switched	antibodies	[146].	Crucially,	B2	cells	require	T-cell	help	for	 the	 production	 of	 switched	 antibodies	 and	 as	 a	 result	 are	 found	 in	 significant	numbers	in	secondary	lymphoid	organs.																		
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 Antibodies	–	Structure	and	Function	
Antibodies	–	or	Immunoglobulins	(Igs)	–	are	Y-shaped	glycoproteins	produced	by	B-cells	in	vivo.	Specific	for	a	single	antigen,	or	a	group	of	related	epitopes,	antibodies	are	responsible	 for	 the	 effective	 neutralisation	 of	 invading	pathogens	 [147].	 To	protect	from	 infection,	 antibodies	 may	 initiate	 a	 range	 of	 processes.	 The	 first	 of	 these	 is	referred	 to	 as	 the	 complement	 pathway,	 where	 antibodies	 bind	 pathogens	 and	initiate	degrading	complement	proteins	in	the	blood	[147].	Moreover,	antibodies	may	potentiate	 the	 uptake	 of	 pathogens	 by	 additional	 cell	 types	 (e.g.	 macrophages),	resulting	in	pathogen	neutralisation	[147].	As	such,	antibodies	comprise	an	important	component	of	the	adaptive	immune	response	to	invading	pathogens.		Structurally,	all	antibodies	are	composed	of	 two	heavy	and	 two	 light	chains	(Fig	1).	Following	 recombination	 of	 germ	 line	DNA,	 a	 single	 antibody	may	 be	 composed	 of	two	λ	or	 two	κ	 light	chains	as	well	as	 two	γ,	δ,	α,	μ	or	ε	heavy	chains	(Fig	1)	 [148].	Both	 light	 and	heavy	 chains	may	be	 subdivided	 into	 variable	 and	 constant	 regions.	Variable	 regions	 are	 responsible	 for	 antigen	 binding,	 while	 constant	 regions	 are	conserved	 throughout	 subtypes	 [148].	 Based	 on	 variations	 in	 the	 amino	 acid	sequence	 of	 the	 constant	 region	 of	 the	 heavy	 chain,	 Immunoglobulins	 can	 be	subdivided	into	5	major	classes	–	IgG,	IgD,	IgA,	IgM	and	IgE.	Expression	of	the	γ,	δ,	α,	μ	or	 ε	 heavy	 chain	 corresponds	 to	 the	 production	 of	 IgG,	 IgD,	 IgA,	 IgM	 and	 IgE	antibodies	respectively	[148].	These	classes	may	be	divided	further	based	on	subtle	changes	 in	 the	 amino	 acid	 sequence	 of	 the	 heavy	 chain,	 thus	 providing	 enhanced	specificity.			Common	 to	 all	 immunglobulins	 is	 the	 fragment	 antigen	 binding	 (Fab)	 region	 and	fragment	crystallisable	 (Fc)	region	 [148].	The	variable	region	of	 the	Fab	segment	 is	responsible	 for	 antigen	 specificity,	 while	 the	 constant	 region	 of	 the	 heavy	 chain	 is	responsible	 for	 Fc	 receptor	 mediated	 effector	 functions	 and	 activation	 of	 the	complement	 cascade	 (Fig	 1)	 [148].	 As	 such,	 antibodies	 are	 important	 in	 the	recognition	of	foreign	antigen	as	well	as	the	activation	of	host	cells	for	eradication	of	pathogens.	An	example	of	this	may	be	found	in	the	actions	of	IgE.	IgE	are	secreted	at	epithelial	barriers	and	play	an	important	role	in	allergic	reactions.	Binding	of	IgE	Fc	regions	to	mast	cells	and	other	granulocytes	significantly	enhances	degranulation	and	the	release	of	effector	chemicals	such	as	histamine.	As	such,	 IgE	plays	an	 important	
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role	 in	 antigen	 recognition	 (Fab	 mediated),	 as	 well	 as	 effector	 cell	 activation	 (Fc	mediated).							 								
	
Figure	1:	Subunit	composition	of	antibody	classes		Immunoglobulins	 share	 a	 common	 4-chain	 structure.	 Arranged	 in	 various	conformations,	 these	 subunits	 comprise	 the	 more	 readily	 distinguished	 antibody	subsets,	 IgG,	 IgE,	 IgD,	 IgA	 and	 IgM.	 All	 units	 comprise	 2	 heavy	 chains	 and	 2	 light	chains	 that,	 following	 germ	 line	 recombination,	 yield	 functional	 antibody	 subunits.	Located	distal	to	the	antibody,	the	Fab	region	is	responsible	for	antigen	recognition,	while	 the	 proximal	 end	 (Fc	 region)	 is	 responsible	 for	 antibody	 mediated	 effector	functions.									
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1.17.1 Role	of	Antibodies	in	Atherosclerosis		Antibodies	 have	 long	 been	 associated	 with	 protective	 immunity	 against	 infectious	disease.	 Exploiting	 this	 notion,	 many	 modern	 vaccinations	 influence	 the	 immune	system	 to	 produce	 vast	 quantities	 of	 protective	 antibodies.	 As	 a	 result,	 hosts	 may	display	lifelong	immunity	to	potentially	lethal	pathogens.		As	well	as	infection,	antibody	mediated	immunity	has	gained	significant	attention	in	atherosclerosis.	Clues	to	the	importance	of	antibodies	in	atherosclerosis	can	be	found	in	human	studies,	where	patients	with	atherosclerosis	display	antibody	titres	to	Ox-LDL	 and	 other	 atherogenic	 antigens	 [149-152].	 Moreover,	 mice	 immunized	 with	atherogenic	 molecules	 display	 increased	 antibody	 responses	 in	 vivo	 [153,	 154].	Animal	studies	have	also	provided	an	insight	into	the	role	of	antibodies	in	regulating	atherosclerosis	 formation.	 Specifically,	 splenectomised	 apoE-/-	 mice	 develop	significantly	 aggravated	 atherosclerosis	 [155,	 156].	 Interestingly,	 the	 adoptive	transfer	of	B-cells	remedies	this	effect,	thus	suggesting	an	athero-protective	effect	of	B-cells	[156].	Moreover,	in	comparison	to	WT	mice,	B-cell	deficient	mice	display	a	30	%	 -	 40	 %	 increase	 in	 lesion	 size	 [157].	 As	 such,	 the	 notion	 that	 B-cells	 confer	protective	 immunity	 in	 atherosclerosis,	 via	 antibody	 production,	 has	 gained	significant	attention.			Although	B-cells	may	 confer	 athero-protective	properties,	B-cells	may	also	produce	large	 amounts	 of	 potentially	 pro-atherogenic	 antibodies.	As	 such,	 it	 is	 important	 to	consider	 antibody	 classes	 and	 B-cell	 subsets	 involved	 in	 their	 production.	 To	 date,	specific	 attention	 has	 been	 focused	 on	 the	 atherogenic	 role	 of	 IgM	 and	 IgG	 in	atherosclerosis.	Although	much	debate	remains	as	to	their	atherogenic	role,	IgM	has	more	 frequently	 been	 linked	 to	 reduced	 CV	 risk,	 while	 IgG	 has	 been	 linked	 to	enhanced	risk	[158,	159].			Using	 anti-CD20	 antibodies,	 some	 have	 shown	 that	 B-cell	 depletion	 is	 athero-protective	 [120].	 Importantly,	 this	 protection	 was	 conferred	 by	 reduced	 B2	 B-cell	responses,	while	maintaining	protective	 IgM	responses.	Highlighting	the	association	between	T-cells,	B2	cells	and	pathology,	anti-CD20	depletion	of	B2	B-cells	significant	attenuates	 pro-atherogenic	 T-cell	 responses	 [120].	 Supporting	 the	 notion	 that	 B1a	cells	are	atheroprotective,	adoptive	transfer	of	B1a	B-cells	into	splenectomised	apoE-
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/-	mice	has	been	shown	to	significantly	attenuate	necrotic	core	and	lesion	formation	
in	vivo	[160].	 Conversely,	 adoptive	 transfer	 of	B2	B-cells	 enhances	 lesion	 formation	[160].	Further	supporting	a	protective	role	of	IgM	and	B1	cells,	LDLR-/-	mice	deficient	in	 serum	 IgM	 display	 significantly	 aggravated	 atherosclerosis	 [161].	 Adding	 to	 the	differential	 protective	 role	 of	 IgM	 in	 atherosclerosis,	 several	 studies	 have	 provided	evidence	 indicative	 of	 an	 inverse	 correlation	 between	 IgM	 titres	 and	 clinical	manifestations	 of	 arterial	 disease	 [162,	 163].	 Together,	 these	 findings	 confirm	 the	differential	effects	of	both	IgM	and	IgG	antibodies	in	atherosclerosis.			Functionally,	 IgM	 antibodies,	 specific	 for	 Ox-LDL	 epitopes,	 have	 been	 shown	 to	 be	important	 in	 maintaining	 lipid	 equilibrium	 in	 atherosclerosis.	 Specifically,	 the	 EO6	IgM	clone	prevents	Ox-LDL	binding	to	CD36	and	SR-B1	 in	vitro	 [164].	As	such,	EO6	antibodies	 may	 be	 important	 in	 preventing	 Ox-LDL	 accumulation	 and	 foam	 cell	formation.	 In	 contrast,	 conclusive	 data	 demonstrating	 a	 functional	 pro-atherogenic	effect	of	IgG	antibodies	remain	elusive.																		
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1.17.2 New	Players	in	Atherosclerosis?	Interestingly,	over	the	past	few	years	the	role	of	T-cell	dependent	antibody	responses	has	gained	significant	attention	in	autoimmune	disease	such	as	Rheumatoid	Arthritis	(RA)	 and	 Systemic	 Lupus	 Erythematosus	 (SLE).	 This	 may,	 in	 part,	 be	 due	 to	 the	success	of	biologic	therapies,	and	in	particularly	those	that	target	B-cell	populations	and	antibody	production.			As	part	of	these	developments,	a	new	subset	of	T-cells,	called	T	follicular	helper	cells	has	 been	 documented	 and	 characterised.	 Involved	 in	 high	 affinity,	 class	 switched	antibody	 production;	 Tfh	 cell	 numbers	 are	 increased	 in	 the	 blood	 of	 RA	 and	 SLE	patients	 [165-167].	 Interestingly,	 although	 antibodies	 play	 an	 important	 role	 in	plaque	 progression,	 the	 role	 of	 Tfh	 cells	 in	 atherosclerosis	 remains	 to	 be	 fully	determined.																			
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1.17.3 T-follicular	Helper	Cells	Tfh	cells	were	first	described	at	the	start	of	the	21st	century.	At	the	time,	two	studies	described	the	presence	of	a	CD4+	T-helper	cell	population	in	human	tonsil	tissue	[44,	168].	This	population	was	subsequently	described	as	being	able	to	migrate	to	B-cell	follicles	 and	 help	 GC	 B-cells	 in	 the	 production	 of	 high	 affinity,	 isotype	 switched	antibodies	[44,	168].	Taking	 into	account	their	 location	and	function,	 these	CD4+	T-cell	 populations	 became	 known	 as	 Tfh	 cells.	 Dissecting	 their	 role	 further,	 Tfh	 cells	became	define	as,			“The	T-helper	cell	subset,	able	to	migrate	to	B-cell	follicles	in	a	C-X-C	motif	ligand-13	(CXCL13)	 dependent	manner	 and	 aid	 GC	 B-cells	 in	 the	 production	 of	 high	 affinity,	isotype	switched	antibodies”.				Tfh	 cells	 differ	 from	 other	 T-cell	 subsets	 by	 their	 constitutive	 expression	 of	membrane	bound	C-X-C	chemokine	receptor	type	5	(CXCR5)	[169].	Coupled	with	this,	Tfh	 cells	 up-regulate	 a	wealth	 of	 additional	 co-stimulatory	molecules,	 including	 the	signalling	lymphocytic	activation	molecule	(SLAM),	programmed	cell	death	protein-1	(PD-1)	and	inducible	co-stimulatory	molecule	(ICOS),	which	bind	to	their	respective	ligands	on	B-cells	[169].	As	well	as	this,	Tfh	cells	express	enhanced	amounts	of	their	implicated	 transcription	 factor	 -	 B-cell	 lymphoma-6	 (Bcl-6)	 and	 secrete	 vast	quantities	of	their	signature	cytokine	IL-21.	Both	Bcl-6	and	IL-21	function	to	enhance	Tfh	cell	and	GC	B-cell	differentiation	in	vivo	[170,	171].			Functionally,	 Tfh	 cells	 provide	 help	 to	 GC	 B-cells	 in	 the	 form	 of	 TCR	 :	 MHC	engagement,	 co-stimulation	 and	 paracrine	 IL-21.	 Initiating	 a	 range	 of	 effects,	 the	importance	of	Tfh	cells	to	GC	B-cell	biology	will	be	discussed	herein.							
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 T-follicular	Regulatory	(Tfr)	Cells	
Alongside	 Tfh	 cells,	 another	 subset	 of	 CD4+	 T-cells	 is	 able	 to	 migrate	 to	 and	participate	 in	GC	processes.	Termed	T-follicular	Regulatory	(Tfr)	cells,	Tfrs	 function	to	control	and	limit	aberrant	Tfh	cell	and	GC	B-cell	responses	in	vivo	by	preventing	IL-21	production	and	class	switching	[172].	Highlighting	the	role	of	Tfr	cells,	absence	of	Tfr	cells	results	in	enhanced	GC	B-cell	numbers,	resulting	in	reduced	antigen	specific	clones	and	aberrant	antibody	production	 [173,	174].	 Interestingly,	Tfr	 cells	express	markers	characteristic	of	both	Tfh	cell	and	conventional	T-reg	populations,	including	CXCR5,	 ICOS,	PD-1	and	Bcl-6	 (Tfh),	GITR,	FoxP3	and	CTLA-4	 (T-reg)	 [173-176]	and	display	 memory	 capacity	 [172].	 Moreover,	 conventional	 Tfh	 cell	 differentiation	signals	are	also	 required	 for	Tfr	 formation	 [173],	 as	well	as	 the	expression	of	Bcl-6	[174].	 Adding	 evidence	 to	 their	 disconnect	 from	 both	 Tfh	 cell	 and	 T-reg	 lineages,	however,	Tfr	cells	maintain	distinct	transcriptional	and	lineage	differences	from	both	populations	 [173]	 and	 arise	 from	 thymic	 derived	 precursors	 [173,	 174].	 Of	importance	to	this	thesis,	Tfr	cells	may	play	an	integral	role	in	regulating	both	Tfh	cell	and	 GC	 B-cell	 responses	 in	 the	 atherogenic	 process.	 Indeed,	 recently,	 CD8+	 T-regs	have	 been	 shown	 to	 limit	 aberrant	 Tfh	 cell	 responses	 in	 atherosclerosis	 [142],	however	the	atherogenic	significance	of	Tfr	cells	remains	to	be	elucidated.	It	is	clear	however,	 that	 modulation	 of	 the	 Tfr	 cells	 may	 hold	 therapeutic	 and	 research	significance.	 Whether	 these	 compartments	 are	 affected	 in	 the	 studies	 discussed	throughout	this	thesis	remains	to	be	determined.												
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 B-cell	Development	and	Maturation		
Essential	to	the	adaptive	immune	response,	B-cells	play	important	roles	in	antibody	production,	 antigen	 presentation	 and	 cytokine	 secretion	 in	 vivo	 [177,	 178].	 To	participate	 in	 such	 processes,	 B-cells	 differentiate	 in	 a	 multi-stage	 developmental	pathway.	 Subdivided,	 these	 stages	 are	 referred	 to	 as	 the	 antigen	 independent	 and	antigen	 dependent	 phases	 [179].	 The	 antigen	 independent	 stage	 occurs	within	 the	bone	marrow	and	results	 in	 the	 formation	of	a	mature	membrane	bound	BCR	via	a	tightly	controlled	set	of	processes	termed	V(D)J	recombination	(Figure	2).	In	contrast,	the	antigen	dependent	phase	occurs	peripherally	within	secondary	lymphoid	organs	(SLO),	where	immature	B-cells	meet	their	cognate	antigen,	resulting	in	memory	B-cell	and	plasma	cell	formation.			Interactions	 with	 bone	 marrow	 resident	 somatic	 cells	 are	 crucial	 for	 the	 antigen	independent	phase.	 In	particular,	bone	marrow	resident	stromal	cells	play	a	pivotal	role	 in	 the	 initial	differentiation	of	B-cells	 from	B-cell	precursors	 to	pro-B-cells	and	then	 pre-B-cells	 [179].	 Supporting	 the	 antigen	 independent	 pathway,	 stromal	 cells	express	 adhesion	 molecules,	 including	 VCAM-1	 and	 other	 CAMs	 (cellular	 adhesion	molecules)	 [179].	 Binding	 of	 the	 integrin	 VLA-4	 on	 progenitor	 B-cells	 to	 VCAM-1	ensures	 tight	 binding	 and	 long-lived	 interactions	 with	 stromal	 cells,	 thus	 ensuring	sufficient	access	to	growth	factors.	Following	adhesive	interactions,	pro-B-cell	bound	receptor	tyrosine	kinase	KIT	binds	to	stromal	bound	stem	cell	factor	(SCF),	inducing	kinase	 activity	 and	 cellular	 proliferation,	 therefore	 expanding	 B-cell	 numbers.	Towards	late	stage	pro-B-cell	development,	secreted	cytokines	play	an	important	role	in	terminal	differentiation.	In	particular,	stromal	derived	IL-7	binds	to	IL-7Rs	located	on	 late-pro-B-cells,	 resulting	 in	 enhanced	 proliferation	 and	 pro-B-cell	 growth.	Highlighting	 the	 importance	 of	 IL-7	 and	 adhesion	 molecules	 to	 the	 antigen	independent	 pathway,	 loss	 of	 either	 molecules	 result	 in	 impaired	 or	 absent	 B-cell	development	[180,	181].			In	addition	to	stromal	cell	:	B-cell	interactions,	the	bone	marrow	is	the	site	of	intrinsic	changes	to	DNA	encoding	the	BCR	of	developing	B-cells.	Termed	VDJ	recombination,	these	changes	allow	for	a	wealth	of	antigen	specificities	and	BCR	diversity.	As	such,	this	section	will	discuss	the	process	in	which	VDJ	recombination	occurs.			
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All	 Immunoglobulins	are	composed	of	 the	same	basic	units	–	 two	heavy	chains	and	two	light	chains	(discussed	elsewhere).	This	structure	is	identical	to	that	which	forms	the	BCR.	The	germ	line	DNA	that	encodes	for	heavy	and	light	chains	is	comprised	of	multiple	 gene	 segments,	 termed	 V	 (variable),	 D	 (diversity)	 and	 J	 (joining)	 [179].	Ensuring	 a	 range	 of	 specificities,	 many	 different	 copies	 of	 V,	 D	 and	 J	 genes	 exist,	combinations	 of	 which	 yield	 approximately	 1014	 different	 BCRs	 [182].	 Resulting	heavy	 and	 light	 chain	 recombination,	 results	 in	 the	 expression	 of	 a	 functional	 and	unique	BCR	specific	for	a	unique	antigen	[182].		When	 transitioning	 from	 progenitor	 B-cell	 to	 early	 B-cell	 stage,	 developing	 B-cells	first	 undergo	 heavy	 chain	 recombination	 (Figure	 2).	 As	 part	 of	 this	 process,	 D	segments	 are	 initially	 recombined	 with	 J	 segments,	 followed	 by	 subsequent	recombination	of	DJ	segments	with	V	segments.	To	participate	in	recombination,	V,	D	and	 J	 segments	 are	 flanked	 by	 a	 sequence	 of	 DNA	 termed	 recombination	 signal	sequences	 (RSS)	 [182].	 These	 sequences	 recognise	 two	 enzymes	 termed	(recombination	 activating	 gene-1)	 RAG-1	 and	 (recombination	 activating	 gene-2)	RAG-2.	Forming	a	complex	with	each	other,	RAG-1	and	RAG-2	cleave	DNA	strands	at	RSS	 sites,	 creating	a	 resulting	DNA	hairpin	 [183].	Additional	 enzymes	–	 involved	 in	DNA	repair	–	including	DNA	ligase	IV,	DNA-dependent	protein	kinase	(DNA-PK)	and	Ku	-	cleave	the	resulting	DNA	hairpin	and	join	open	ends,	yielding	a	linear	length	of	DNA	 containing	 one	 D	 segment	 and	 one	 J	 segment	 (Figure	 2).	 Highlighting	 the	importance	 of	 both	 RAG-1	 and	 RAG-2,	 loss	 of	 the	 gene	 encoding	 their	 expression	results	in	impaired	B-cell	development	and	subsequent	immunodeficiency	[184,	185].	Utilizing	 this,	 scientists	 commonly	 use	 RAG1-/-	 and	 RAG2-/-	 mice	 to	 study	 the	pathological	importance	of	lymphocytes	in	disease.		To	 complete	 VDJ	 recombination,	 DJ	 segments	 are	 subsequently	 recombined	with	 a	single	V	segment.	Using	the	same	enzymes	described	above,	recombined	DJ	segments	are	combined	with	a	single	V	gene	copy.	As	a	result,	this	process	yields	a	linear	strand	of	DNA,	encoding	the	heavy	chain	and	contains	a	single	V,	D	and	J	gene	(Figure	2).		Following	 recombination	 of	 the	 heavy	 chain,	 the	 light	 chain	 of	 the	 antibody	glycoprotein	 is	 recombined.	 Unlike	 the	 heavy	 chain,	 DNA	 encoding	 the	 light	 chain	does	not	comprise	D	segments	and	contains	copies	of	V	and	J	genes	only.	Following	
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the	same	process	described	above,	a	single	V	gene	is	recombined	with	a	single	J	gene,	yielding	a	bonafide	BCR	light	chain	comprised	of	2	heavy	and	2	light	chains	(Figure	2).		Successful	 recombination	 of	 heavy	 and	 light	 chains	 of	 the	 BCR	 results	 in	 the	expression	of	a	mature,	membrane	bound	BCR	–	usually	IgM	as	well	as	IgD	[186].	As	a	result,	 B-cells	 (immature)	 are	 permitted	 to	 continue	 development	 as	 part	 of	 the	antigen	dependent	phase.		To	participate	 in	 the	antigen	dependent	phase	of	B-cell	differentiation,	B-cells	must	egress	 from	 the	 bone	 marrow	 and	 migrate	 to	 SLOs.	 Although	 variations	 in	 B-cell	transition	state	exist	between	spleen	and	pLNs,	this	section	will	discuss	the	entry	and	movement	of	B-cells	in	the	pLNs.		Entry	 into	 pLNs	 is	 a	 precise	 and	 regulated	 set	 of	 processes	 controlled	 by	 the	interactions	of	various	chemokines	and	chemokine	 receptors.	As	with	T-cells,	naïve	B-cells	 express	 CCR7,	 and	 use	 this	 receptor	 to	 travel	 along	 a	 CCL19	 and	 CCL21	gradient	in	high	endothelial	venules	(HEVs),	where	both	ligands	are	expressed	at	high	levels	[187,	188].	Although	some	dispute	the	importance	of	CCR7	and	its	ligands	in	B-cell	migration	[189,	190],	others	have	shown	its	importance	alongside	CXCR4	in	B-cell	re-location	[191].	Further	supporting	B-cell	migration;	B-cells	use	CXCR4	to	migrate	along	 a	 CXCL12	 gradient	 towards	 B-cell	 follicles.	 To	 partake	 in	 GC	 processes	 and	complete	 their	 differentiation,	 B-cells	 must	 migrate	 to	 B-cell	 follicles.	 Using	membrane	bound	CXCR5;	B-cells	migrate	along	a	CXCL13	gradient	 to	B-cell	 follicles	[192,	 193],	 where	 they	 remain	 positioned	 for	 terminal	 differentiation	 and	involvement	 in	 GC	 processes.	 Upon	 recognition	 of	 MHC	 bound	 antigen,	 B-cells	differentiate	 towards	plasma	cell	and	memory	B-cell	phenotypes	 in	an	anatomically	segregated	 GC	 reaction	 (discussed	 elsewhere).	 Importantly,	 chemokine	 mediated	retainment	 in	 the	GC	allows	B-cells	 to	 receive	differentiation	 signals	 from	 follicular	dendritic	cells	and	Tfh	cells.		
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 B-cell	Tolerance		
As	with	T-cells,	 B-cells	 become	 educated	 so	 as	 not	 to	 react	 to	 self-antigen	when	 in	circulation.	This	system	of	education	can	be	subdivided	into	two	anatomically	distinct	processes,	 termed	central	and	peripheral	 tolerance.	Central	 tolerance	occurs	within	the	 bone	 marrow,	 where	 circulating	 antigen	 can	 bind	 to	 BCRs,	 resulting	 in	 clonal	deletion	of	B-cell	clones	or	the	reorganisation	of	germ	line	DNA	in	a	process	termed	receptor	editing.	BCR	signalling	strength	has	been	shown	to	play	an	important	role	in	determining	these	fates,	where	strong	BCR-auto-antigen	binding	results	in	deletion	or	editing,	 while	 intermediate	 binding	 permits	 B-cell	 survival	 and	 progression	 [186]	[194].		In	 contrast,	 peripheral	 tolerance	 occurs	 within	 the	 periphery	 and	 functions	 to	eliminate	 self-reacting	 clones	 that	 bypass	 central	 tolerance	 mechanisms	 or	 are	specific	 for	self-antigen	absent	 in	the	bone	marrow.	As	part	of	these	processes,	self-reactive	B-cells	–	in	competition	with	foreign	specific	B-cells	-	may	be	prevented	from	entering	 B-cell	 follicles	 and	 thus	 involvement	 in	 GC	 processes.	 Moreover,	 if	 B-cell	clones	 bind	 self-antigen	 with	 high	 affinity	 they	 may	 enter	 a	 state	 of	 anergy,	characterised	by	substantial	down	regulation	of	IgM	[195].	In	the	event	that	a	T-cell	clone,	 specific	 for	 the	same	auto-antigen	as	an	auto-reactive	B-cell	develops,	B-cells	may	use	FAS-FASL	interactions	to	induce	cellular	apoptosis.		Taken	 together,	 central	 and	 peripheral	 tolerance	 function	 to	 reduce	 the	 risk	 of	aberrant	B-cell	responses	in	vivo.	In	the	absence	of	such	checkpoints,	aberrant	B-cell	clones	survive	and	seed	the	basis	of	autoimmunity.						 		
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 Germinal	Centre	B-cells		
GCs	 are	 distinct,	 transient	 structures	 found	 in	 the	 B-cell	 follicles	 of	 secondary	lymphoid	organs	[196].	First	described	over	100	years	ago,	we	now	understand	the	importance	 of	 GC	 reactions	 to	 the	 formation	 of	 protective	 and	 aberrant	 adaptive	immune	 responses.	 In	 particular,	 GCs	 are	 sites	 in	 which	 the	 processes	 of	 clonal	expansion,	somatic	hypermutation	and	affinity	maturation	occur	[196].	As	part	of	this	section,	the	importance	of	these	processes	to	B-cell	development	will	be	discussed.	As	well	 as	 this,	 the	 role	 Tfh	 cells	 play	 in	 guiding	 B-cell	 development	 will	 also	 be	discussed.			On	 leaving	 the	 bone	 marrow,	 immature	 B-cells	 migrate	 to	 secondary	 lymphoid	organs,	where	they	acquire	antigen	form	follicular	dendritic	cells	(fDCs)	and	in	turn	present	 it	 to	 cognate	 CD4+	 Tfh	 cells	 at	 the	 border	 between	 T	 cell	 zone	 and	 B	 cell	follicles	 (Fig	 2).	 Upon	 activation	 by	 a	 T-cell	 dependent	 antigen,	 B-cells	 being	 the	process	of	translocation	to	B-cell	rich	areas	 in	the	cortex	of	 lymph	nodes	(LNs)	(Fig	2).	This	movement	initiates	a	process	in	which	a	new	GC	reaction	is	formed.			Specific	 for	 a	 single	 antigen,	 activated	B-cells	 –	 now	 called	 centroblasts	 –	 initiate	 a	programme	 of	 intense	 proliferation	 termed	 clonal	 expansion	 (Fig	 2)	 [197].	 At	 the	same	 time,	 centroblasts	 up	 regulate	 the	 production	 of	 activation	 induced	 cytidine	deaminase	(AID)	–	an	enzyme	involved	in	introducing	point	mutations	in	the	variable	region	 of	 antibodies,	 in	 a	 process	 termed	 somatic	 hypermutation	 (Fig	 2)	 [198]	Located	 in	 the	 dark	 zone	 (DZ)	 of	 the	 GC,	 so	 called	 due	 to	 the	 high	 nucleus	 to	cytoplasm	ratio	of	resident	B-cells	[199],	DZ	centroblasts	represent	the	beginnings	of	high	affinity	antibody	production.			As	 a	 result	 of	 clonal	 expansion	 and	 somatic	 hypermutation,	 activated	 centroblasts	significantly	alter	their	range	of	affinity	for	a	single	antigen.	Due	to	the	random	nature	of	AID,	not	every	centroblast	 is	of	 improved	affinity	 for	 its	 respective	antigen.	This,	therefore,	 conveys	 a	 disadvantage.	 To	 preserve	 high	 specificity,	 low	 binding	centroblasts	 are	 removed	 in	 a	 selection	 process	 termed	 affinity	 maturation	 in	 the	light	zone	(LZ)	of	the	GC	(Fig	2)	[197].			
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Upon	moving	to	the	LZ,	centroblasts	(now	termed	centrocytes)	interact	with	resident	fDCs	and	Tfh	cells	that	present	cognate	antigen	on	their	surface	(Fig	2).	Depending	on	the	affinity	of	 their	 surface	 antibody	 to	 the	antigen,	developing	 centrocytes	 acquire	two	different	fates.	These	fates	are	described	below.		1. Centrocytes	of	low	affinity	for	cognate	antigen	presented	in	the	LZ	
Ø Cannot	make	contact	with	resident	fDCs	or	Tfh	cells		
Ø Become	apoptotic			2. Centrocytes	of	high	affinity	for	cognate	antigen	presented	in	the	LZ		
Ø Can	make	contact	with	resident	fDCs	or	Tfh	cells		
Ø Selected	for	class	switching	and	differentiation				 						 							
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Figure	 3:	 Schematic	 representation	 of	 B-cell	 differentiation	 through	 the	
germinal	centre	reaction	Upon	encountering	its	cognate	antigen	in	the	paracortex	(1),	mature	B-cells	develop	down	a	differentiation	programme	that	results	in	the	formation	of	antibody	secreting	plasma	cells	and	B-cell	memory.	Leaving	the	paracortex,	activated	centroblasts	enter	the	dark	zone	of	 the	germinal	centre,	where	 they	proliferate	 in	a	process	known	as	clonal	 expansion	 (2).	 Subsequent	 somatic	 hypermutation	 (3)	 of	 heavy	 and	 light	chains	results	in	a	range	of	antigen	affinities.	In	a	process	termed	affinity	maturation	
(4),	centrocytes	are	tested	by	Tfh	cells	and	fDCs	for	their	relative	affinity	for	a	single	cognate	antigen.	Those	of	low	affinity	are	eliminates	via	apoptosis,	while	those	of	high	affinity	are	selected	for	plasma	cell,	memory	B-cell	and	class	switching	(5-6).																									
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 	Importance	of	Tfh	cells	in	the	GC	Reaction	
Although	the	number	of	GC	T-cells	is	relatively	low	in	comparison	to	GC	B-cells,	their	role	 in	 the	GC	reaction	 is	one	of	great	 importance.	Testament	 to	 this,	 athymic	nude	mice	fail	to	develop	functional	GC	reactions	[200].	Moreover,	GC	formation	is	restored	solely	by	 the	adoptive	 transfer	of	 thymocytes	 [200].	Adding	 further	evidence	 to	 the	role	of	T-cells	in	the	GC,	CD40-CD40L	interaction	is	required	for	the	formation	of	GCs,	with	CD40-CD40L	blockade	being	 sufficient	 to	drive	GC	dissolution	 in	vivo	[201].	 In	humans,	deficient	CD40	or	CD40L	expression	results	in	the	absence	of	GC	formation.	Coupled	with	the	presence	of	excess	amounts	of	low-affinity,	un-switched	antibodies,	such	individuals	are	highly	susceptible	to	infection	[202,	203].		The	role	of	Tfh	cells	in	the	GC	has	more	recently	been	addressed.	GC	resident	Tfh	cells	secrete	 large	 amounts	 of	 their	 signature	 cytokine	 –	 IL-21.	 Working	 in	 both	 an	autocrine	and	paracrine	manner,	IL-21	exerts	a	multitude	of	effects	via	its	dedicated	IL-21R.	 Located	 on	 the	 surface	 of	 both	 GC	 B-cells	 and	 Tfh	 cells,	 IL-21R	 has	 been	shown	 to	 affect	 both	 cell	 subtypes	 and	 activates	 important	molecules	 required	 for	cellular	function	–	most	notably	Bcl-6	[204].	The	importance	of	Tfh	cell	derived	IL-21	is	demonstrated	by	 the	 finding	 that	 IL-21	deficient	or	 IL-21R	deficient	mice	display	reduced	GC	 formation,	 antibody	production	 and	B-cell	 proliferation	 [205,	 206]	 (Fig	3).			As	well	as	influencing	GC	reactions	via	the	secretion	of	IL-21,	Tfh	also	provide	crucial	co-stimulatory	 signals	 to	 GC	 B-cells	 [207-212].	 Binding	 B-cell	 expressed	 ligands,	engagement	 of	 co-stimulatory	molecules	 facilitates	 Tfh	 cell	 –	 B-cell	 interactions,	 as	well	 as	 Tfh	 cell	 and	 GC	 B-cell	 activation.	 Specifically	 ICOS	 –	 inducible	 t-cell	 co-stimulator	 ligand	 (ICOSL)	 interaction	 enhances	 the	production	of	B-cell	 stimulating	cytokine	IL-21	[206].	Loss	of	co-stimulation	not	only	alters	Tfh	cell	responses	but	also	significantly	 affects	 the	productivity	 and	 integrity	 of	GC	B-cells	 and	GC	 reactions	 in	mice	and	humans	[207,	210,	213,	214].						
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Figure	4:	Schematic	representation	of	the	effects	Tfh	cell	derived	IL-21	has	on	
both	GC	B-cells	and	Tfh	cells		Working	in	both	an	autocrine	and	paracrine	manner,	IL-21	exerts	its	effects	directly	upon	both	GC	B-cells	and	Tfh	cells.	Acting	via	a	dedicated	IL-21R,	IL-21	indices	GC	B-cell	and	Tfh	cell	differentiation,	B-cell	class	switching,	Bcl-6	up-regulation	and	the	up-regulation	of	other	related	nuclear	transcripts.																
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 Aortic	Tertiary	Lymphoid	Organs	(ATLOs)	
Throughout	 development,	 structures	 termed	 primary	 and	 secondary	 lymphoid	organs	direct	lymphocyte	development	and	differentiation.	Primary	lymphoid	organs	(PLOs),	 such	 as	 the	 thymus	 and	bone	marrow	direct	T-cell	 and	B-cell	 development	respectively,	 while	 SLOs,	 including	 pLNs	 and	 the	 spleen,	 orchestrate	 the	differentiation	of	T-cells	and	B-cells	towards	various	terminal	fates.			Until	 recently,	 PLOs	 and	 SLOs	 were	 considered	 the	 sole	 sites	 of	 T-cell	 and	 B-cell	development	 and	 differentiation.	 More	 recently	 however,	 the	 formation	 of	 highly	organised	tertiary	lymphoid	organs	(TLOs)	have	been	identified	in	various	conditions	[215-218].	 Differing	 from	 SLOs,	 TLOs	 do	 not	 form	 during	 ontogeny	 but	 form	 in	 an	undetermined	manner	 at	 sites	 of	 chronic,	 non-resolving	 inflammation.	 In	 common	with	SLOs,	TLOs	are	highly	organised	and	are	 characterised	as	 containing	T-cell,	B-cell	and	GC	zones.	 In	context	of	 this	thesis,	aortic	 tertiary	 lymphoid	organs	(ATLOs)	have	 also	 been	 identified	 in	 animal	 models	 and	 in	 biopsy	 samples	 from	 aortic	aneurysms	 [45,	 142,	 219,	 220].	Moreover,	 ATLOs	 comprise	 a	wealth	 of	 innate	 and	adaptive	 immune	 subsets,	 including	 CD4+	 T-cells,	 CD8+	 T-cells,	 B-cells,	 GC	 B-cells,	and	dendritic	cells	[45].			ATLOs	form	preferentially	within	the	abdominal	aorta	in	aged	chow	fed	apoE-/-	mice	[45].	 Interestingly,	 recent	 data	 has	 indicated	 a	 lymphotoxin-beta	 receptor	 (LTβR)	pathway	 that	 orchestrates	 cellular	 organisation	 within	 ATLOs	 [45].	 Activation	 of	intimal	smooth	muscle	cells	via	LTβR	has	been	shown	to	enhance	expression	of	 the	lymphorganogenic	chemokines	CXCL13	and	CCL21	[45].	The	receptor	and	ligand	for	CXCR5	and	CCR7	respectively,	CXCL13	and	CCL21	are	pivotal	to	the	homing	of	B-cells	and	T-cells	to	SLOs	and,	in	this	case,	ATLOs.	As	such,	the	LTβR	mediated	pathway	is	crucial	 to	 lymphocyte	 homing	 and	 accumulation	 in	 advanced	 atherosclerosis.	Importantly,	ATLOs	have	been	confirmed	to	be	sites	of	active	naïve	T-cell	recruitment	and	induced	T-reg	formation	[219].			Although	present	in	late	stage	atherosclerosis,	the	pathological	significance	of	ATLOs	was	not	eluded	to	until	recently.	Working	in	a	SMC	LTβR	dependent	manner,	ATLOs	have	been	shown	to	confer	protective	functions	in	vivo	[219].	Indicative	of	this,	loss	of	LTβR	expression	has	been	shown	attenuate	ATLO	formation,	while	enhancing	luminal	
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lesion	formation	and	atherosclerosis	progression	[219].	Of	importance	to	this	thesis,	ATLOs	 have	 been	 shown	 to	 contain	 the	 relevant	 lymphogenic	 and	 anatomical	subdivisions	 for	 Tfh	 cell	 and	 GC	 B-cell	 processes	 [219].	 Moreover,	 human	 studies	have	identified	Tfh	cells	in	the	ATLOs	[142].			
 	Scope	of	Current	Study	
Despite	 sharing	 common	 inflammatory	 signatures	 with	 other	 autoimmune	conditions,	 the	 role	 of	 Tfh	 cells	 and	 GC	 B-cells	 have	 not	 been	 fully	 addressed	 in	context	 of	 atherosclerosis.	 As	 such,	 the	 studies	 described	 herein	 aimed	 to	 address	whether	the	Tfh	cell	:	GC	B-cell	axis	is	of	pathological	significance	in	atherosclerosis.			Employing	 a	 question	 and	 answer	 approach,	 the	 studies	 presented	 in	 this	 thesis	aimed	to:	1. Determine	whether	Tfh	cell,	GC	B-cell	and	antibody	kinetics	followed	a	pattern	in	line	with	atherosclerosis	progression	in	the	apoE-/-	mouse;	2. Determine	 whether	 the	 results	 obtained	 in	 point	 1	 were	 the	 result	 of	pathology	and	not	the	loss	of	functional	apoE	protein;	3. Study	 the	 effects	 of	 IL-21R	 deficiency	 on	 the	 Tfh	 cell	 :	 GC	 B-cell	 axis	 and	pathology	in	the	LDLR-/-	mouse.		Figure	5	overleaf	summarises	the	aims	and	objectives,	as	well	as	the	methodological	approach,	of	each	results	chapter.										
	 68	
	
		
		
	
Figure	 5:	 Flow	 diagram	 depicting	 the	 aims,	 objectives	 and	 direction	 of	 the	
chapters	described	herein.			
	
Chapter(5:(Effects(of(IL221R(De7iciency(on(the(Development(of(
Atherosclerosis(!
Aim(and(Objectives:((To! modulate! T+h! cell! integrity! in# vivo# via! IL621R! ablation! and! determine! its! effects! on!atherosclerosis!formation.!!!
Methods:((
1.   Flowcytometry-analysis-of!T+h! cells! and!GC!B6cells! from!SLOs!of!C57BL/6NJ! :! LDLR6/6!and!IL621R6/6!:!C57BL/6NJ!chimeric!mice.!!
2.   Histochemical-analysis-of!T+h!cell!marker!expression!!and!location!in!splenic!tissue!
3.   Histochemical- assessment- of! lesion! composition! and! plaque! burden! following! IL621R!ablation!!
4.   ELISA-analysis-of!antibody!kinetics!following!IL621R!ablation.!!
Chapter(3:(Characterising(T7h(cell(&(GC(B2cell((
Populations(in(the(apoE2/2(Mouse(Model(of(Atherosclerosis(((!
Aim(and(Objectives:((To! determine! whether! T+h! cell! and! GC! B6cell! kinetics! change! in! line! with! atherosclerosis!formation!in#vivo.!!
Methods:((
1.   Flowcytometry-analysis-of!T+h! cells! and!GC!B6cells! from!SLOs!of! apoE6/6!mice! fed! chow!or!HFD!for!variable!lengths!of!time!(1,!2,!4,!8!&!12!weeks).!!
2.   Histochemical-analysis-to!determine!T+h!cell!location!and!marker!expression.!!
3.   ELISA- analysis- to! determine! functional! consequences! of! differential! T+h! cell! :! GC! B6cell!kinetics.!!
Chapter(4:(Elucidating(the(Role(of(Apolipoprotein2E(in(Adaptive(Immunity(!
Aim(and(Objectives:((To!determine!whether!loss!of!apolipoprotein6E!affects!T+h!cell!and!GC!B6cell!populations!in!the!apoE6/6!mouse.!!
Methods:((
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Chapter	2:	Materials	and	Methods		
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 Animals		
Twelve-week-old	 B6.129P2-Apoe(tm1Unc)/J	 (apoE-/-)	 mice	 (originally	 purchased	from	 Jackson	 Laboratories,	 Bar	 Harbor,	 Maine,	 USA)	 were	 bred	 in	 house	 (central	research	facility,	The	University	of	Glasgow,	Scotland,	United	Kingdom),	or	purchased	from	Charles	Rivers	Laboratories	(Margate,	England,	United	Kingdom).	Age-matched	C57BL/6	mice	were	purchased	from	Charles	Rivers	Laboratories	(Margate,	England,	United	Kingdom)	and	used	as	respective	controls.	For	other	experiments,	five	to	eight	week	 old	 C57BL/6NJ,	 IL-21R-/-	 and	 B6.129S7-Ldlrtm1Her/J	 (LDLR-/-),	 mice	 were	obtained	from	Jackson	Laboratories	(Bar	Harbor,	Maine,	USA)	and	housed	at	central	research	facility	(The	University	of	Glasgow,	Scotland,	United	Kingdom).		Unless	 stated	 elsewhere,	 animals	 were	 allowed	 free	 access	 to	 food	 and	 water	 and	maintained	 in	 a	 12/12-	 hour	 light/dark	 cycle.	 All	 procedures	 were	 performed	 in	accordance	to	local	ethical	and	UK	Home	Office	guidelines.			
 High	Fat	Diet	(HFD)		
Where	 relevant,	mice	were	 allowed	 free	 access	 to	 high	 fat	 diet	 (HFD)	 (Special	Diet	Services,	 Essex,	 United	 Kingdom).	 For	 a	 full	 description	 of	 the	 diet	 composition,	please	 refer	 to	 appendix	 1.	 For	 studies	 conducted	 as	 part	 of	 chapter	 3,	mice	were	allowed	access	 to	diet	 for	1,	2,	4,	8	and	12	weeks	 (Fig	6).	For	 studies	 conducted	as	part	of	chapter	5,	mice	were	allowed	access	to	diet	for	14	weeks.			
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Figure	6:	Experimental	protocol	and	time	line	for	the	assessment	of	Tfh	cell	and	
GC	B-cell	kinetics	in	apoE-/-	mice		Three	 groups	 of	 mice,	 aged	 12	 weeks	 at	 time	 point	 0,	 were	 supplied	 with	 chow	(C57BL/6	and	apoE-/-)	or	HFD	(apoE-/-)	for	varying	lengths	of	time	(1wk,	2wks,	4wks,	8wks	 and	 12wks).	 Upon	 completion	 of	 each	 respective	 time	 point,	 secondary	lymphoid	 organs	 (pLNs,	 spleen	 and	 pao-LNs)	 were	 harvested	 and	 processed	 for	staining	via	flow	cytometry	and/or	IF	(half	of	spleen).	As	well	as	this,	serum	samples	from	all	 groups	were	 tested	 for	anti-MDA-Ox-LDL	 IgM,	 IgG,	 IgG1	and	 IgG2c	 antibody	titres.		
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 Preparation	 of	 Tissue	 Samples	 for	 Flow	 Cytometry	
Staining		
Mice	 were	 placed	 under	 terminal	 anaesthesia.	 Following	 ablation	 of	 the	 hind-limb	flexor	withdrawal	reflex,	peripheral	 lymph	nodes	(pLNs)	(inguinal,	axillary,	brachial	and	 cervical),	 spleen	 and	 para-aortic	 lymph	 nodes	 (pao-LNs)	 were	 dissected	 and	placed	 in	 hanks	 balanced	 salt	 solution	 (HBSS)	 (Life	 Technologies,	 Paisley,	 United	Kingdom)	containing	10%	foetal	calf	serum	(FCS)	(Life	Technologies,	Paisley,	United	Kingdom).	 Samples	 were	 subsequently	 disrupted	 through	 a	 40	 μm	 cell	 strainer	(Corning,	New	York,	USA).	The	resulting	cell	suspensions	were	centrifuged	at	400	g	for	5	mins	in	preparation	for	flow	cytometry	staining.			
 Flow	Cytometry	Staining	
After	washing	cell	suspensions	in	HBSS	containing	10%	FCS,	samples	were	incubated	in	 FC-Receptor	 block	 (2.4G	 hybridoma	 supernatant)	 for	 20	 mins	 at	 4oC	 degrees.	Samples	 were	 subsequently	 incubated	with	 antibodies	 for	 the	 detection	 of	 cells	 of	interest.	For	a	full	description	of	the	antibodies	used,	please	refer	to	appendix	2.	After	incubation,	cells	were	washed	twice	in	HBSS	containing	10%	FCS	and	resuspended	in	the	 same	 buffer.	 Samples	 were	 analysed	 using	 the	 MACSQuant	 Analyzer	 (Miltenyi	Biotech,	 Bisley,	 United	 Kingdom)	 and	 data	 analysis	 was	 performed	 using	 FlowJo	software	(Tree	Star	Inc,	Olten,	Switzerland).		
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 Enzyme	Linked	Immunosorbent	Assays	(ELISAs)		
This	section	refers	to	ELISAs	conducted	as	part	of	chapter	3.	
1.29.1 Antigen	Specific	Antibody	Titres		For	the	detection	of	anti-MDA-Ox-LDL	specific	antibodies,	microtitre	plates	(Thermo	Scientific,	England,	United	Kingdom)	were	coated	with	100	µl	of	12.5	µg/ml	MDA-Ox-LDL	(Nordic	Biosite,	Sweden)	 in	PBS	overnight	at	4°C	degrees.	The	next	day,	plates	were	washed	 in	 PBS	 containing	 0.05%	 tween.	 Plates	were	 subsequently	 incubated	with	serum	samples	diluted	1:25	in	PBS	for	24	hours	at	4°C	degrees.			The	 next	 day,	 plates	 were	 washed	 4	 times	 in	 PBS	 containing	 0.05%	 tween	 and	incubated	with	horseradish	peroxidase	 (HRP)	 conjugated	goat	anti-mouse	 IgG,	 IgM,	IgG1	 or	 IgG2C	for	 1	 hour	 at	 room	 temperature.	 To	 account	 for	 intra-plate	 variation,	serum	 from	8	week-old	C57BL/6	WT	mice	was	 included	on	each	plate	and	used	 to	normalise	 OD	 readings.	 After	 washing	 in	 PBS	 containing	 0.05%	 tween,	 100	 µl	 of	SureBlueTM	TMB	microwell	peroxidase	 substrate	 (KPL,	Gaithersburg,	MD,	USA)	was	added	to	each	well.	To	stop	the	reaction,	100	µl	of	10%	hydrochloric	acid	was	added	to	each	well.			Using	the	sunrise	ELISA	reader	(Tecan,	Mannedorf,	Switzerland),	plates	were	read	at	450	 nm	 with	 a	 reference	 of	 630	 nm.	 Results	 were	 normalised	 to	 internal	 control	C57BL/6	serum	and	expressed	as	normalised	relative	light	units	(R.L.U).	R.L.Us	were	obtained	 by	 dividing	 the	 optical	 density	 (OD)	 of	 each	 samples	with	 the	OD	 yielded	from	the	highest	dilution	of	C57BL/6	serum.			For	a	full	description	of	the	antibodies	used	to	detect	antibody	subtypes,	please	refer	to	appendix	3.								
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This	section	refers	to	ELISAs	conducted	as	part	of	chapter	5.	For	the	detection	of	anti-MDA-Ox-LDL	specific	antibodies,	microtitre	plates	(Thermo	Scientific,	England,	United	Kingdom)	were	coated	with	100	μl	of	12.5	μg/ml	MDA-Ox-LDL	 (Nordic	Biosite,	Propellervagen,	 Sweden)	 in	PBS	overnight	 at	4°C	degrees.	The	next	day,	plates	were	washed	in	PBS	containing	0.05%	tween	and	blocked	using	10	%	FCS	for	2	hours	at	37°C.	After	another	washing	step,	plates	were	incubated	overnight	with	serial	dilutions	of	serum	from	either	C57BL/6NJ	:	LDLR-/-	or	IL-21R-/-	 :	LDLR-/-		mice.	Dilutions	started	from	1:25	to	1:600	for	IgM	and	IgG	and	1:10	to	1:640	for	IgG2C,	IgG1	 and	 IgG3.	 The	 next	 day,	 plates	were	washed	 and	 subsequently	 incubated	with	horseradish	peroxidase	(HRP)	conjugated	goat	anti-mouse	IgG,	IgM,	IgG2C	or	IgG1	for	1	 hour	 at	 room	 temperature.	After	 a	 final	washing	 step,	 100	μl	 of	 SureBlueTM	TMB	microwell	 peroxidase	 substrate	 (KPL,	 Gaithersburg,	 MD,	 USA)	 was	 added	 to	 each	well.	To	stop	the	reaction,	100	μl	of	10%	hydrochloric	acid	was	added	to	each	well.		To	account	 for	 intra-plate	variation,	serum	from	8	week-old	C57BL/6	WT	mice	was	included	on	each	plate	and	used	to	normalise	OD	readings.		For	a	full	description	of	the	antibodies	used	to	detect	antibody	subtypes,	please	refer	to	appendix	4.		
1.29.2 Total	Serum	Antibody	ELISAs		
1.29.2.1 Total	IgM	and	IgG	For	 the	detection	 of	 total	 IgM,	microtitre	 plates	 (Thermo	Scientific,	 England,	United	Kingdom)	were	coated	with	serially	diluted	serum	 from	C57BL/6NJ	 :	LDLR-/-	or	 IL-21R-/-	 :	LDLR-/-	mice	(1:400	–	1:10240)	in	PBS	overnight	at	4°C.	The	next	day,	plates	were	washed	in	PBS	containing	0.05%	tween	and	subsequently	blocked	using	10	%	FCS	 for	2	hours	at	37°C.	Plates	were	subsequently	washed	and	 incubated	with	HRP	conjugated	rat	anti-mouse	IgM	for	1	hour	at	room	temperature.			For	the	detection	of	total	 IgG,	plates	were	coated	with	100	μl	of	20	μg/ml	goat-anti-mouse	 IgM/G	 capture	 antibody	 (Jackson	 ImmunoResearch	 Laboratories,	 Sohan,	United	Kingdom)	 in	PBS	overnight	at	4°C.	The	next	day,	plates	were	washed	 in	PBS	containing	 0.05%	 tween	 and	 subsequently	 blocked	 using	 10%	 FCS	 for	 2	 hours	 at	
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37°C.	Plates	were	subsequently	washed	and	incubated	overnight	with	serially	diluted	of	serum	from	either	C57BL/6NJ	:	LDLR-/-	or	IL-21R-/-	:	LDLR-/-	mice.	Dilutions	ranged	from	1:400	to	1:5120.		To	account	 for	 intra-plate	variation,	serum	from	8	week-old	C57BL/6	WT	mice	was	included	on	each	plate	and	used	to	normalise	OD	readings.	
	
1.29.2.2 Total	IgE	For	the	detection	of	total	IgE	a	Ready-SET-Go	Kit	was	used	(Affymetrix,	eBioscience).	Briefly,	plates	were	coated	with	100	μl	of	1X	anti-mouse	IgE	monoclonal	antibody	and	incubated	 at	 4°C	 degrees	 overnight.	 The	 next	 day,	 plates	 were	 washed	 in	 PBS	containing	 0.05%	 tween	 and	 incubated	with	 200	 μl	 of	 2X	 blocking	 buffer	 at	 room	temperature	for	2	hours.	After	washing,	plates	were	incubated	overnight	with	serial	dilutions	 of	 serum	 from	 C57BL/6NJ	 :	 LDLR-/-	 or	 IL-21R-/-	 :	 LDLR-/-	mice.	 Dilutions	started	 from	1:50	 to	1:3200.	The	next	day,	plates	were	washed	and	 incubated	with	100	μl	of	1X	biotin	conjugated	anti-mouse	monoclonal	antibody	at	room	temperature	for	1	hour.	After	washing,	plates	were	 incubated	with	100	μl	of	streptavidin-HRP	at	room	temperature	for	30	mins.	After	a	final	washing	step,	wells	were	incubated	with	100	μl	of	substrate	solution.	To	stop	the	reaction,	100	μl	of	stop	solution	was	added	to	each	well.		For	a	full	description	of	the	antibodies	used	to	detect	antibody	subtypes,	please	refer	to	appendix	4.										
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 ELISA	Plate	Development	and	Normalisation		
All	microtitre	 plates,	 from	 each	 chapter,	were	 read	 using	 the	 sunrise	 ELISA	 reader	(Teacan,	Mannedorf,	 Switzerland).	 Plates	were	 read	 at	 450	 nm	with	 a	 reference	 of	630	nm.	Resulting	OD	readings	were	normalised	to	internal	control	C57BL/6	serum	and	expressed	as	normalised	R.L.Us.	R.L.Us	were	obtained	by	dividing	the	ODs	of	each	sample	with	the	OD	from	the	highest	dilution	of	C57BL/6	internal	control	serum.			
 Immunofluorescence	
1.31.1 Identification	of	Tfh	cells	and	GC	B-cells	Spleen	sections	from	12	week	old	and	4	week	old	mice	were	stained	for	Tfh	cells	and	GC	B-cells	respectively.	Prior	to	staining,	8	micron	thick	frozen	sections	were	fixed	in	100%	acetone	for	10	mins	and	allowed	to	air	dry	for	a	further	5	mins.	Sections	were	subsequently	 re-hydrated	 in	 PBS	 for	 10	 mins	 and	 incubated	 in	 FC-receptor	 block	(2.4G2	hybridoma	supernatant)	for	30	mins	at	room	temperature.	Following	another	washing	step,	sections	were	incubated	in	10%	horse	serum	for	30	minutes.			Sections	from	the	12-week	time	point	were	subsequently	 incubated	with	antibodies	for	 the	 detection	 of	 Tfh	 cells,	 while	 sections	 from	 the	 4	 week	 time	 point	 were	incubated	with	 antibodies	 for	 the	 detection	 of	 GC	 B-cells.	 Samples	were	 incubated	overnight	 at	 4°C	degrees,	 after	which	 sections	were	 rinsed	 in	 PBS	 for	 20	mins	 and	mounted	 in	 Prolong	 Gold	 mountant	 (Life	 Technologies,	 Paisley,	 United	 Kingdom)	containing	 DAPI	 (where	 appropriate).	 Samples	 were	 analysed	 using	 the	 LSM510	metaconfocal	microscope	 (Zeiss,	Germany)	and	assessed	on	Volocity	 (Perkin	Elmer,	USA)	quantification	software.		For	a	full	description	of	the	antibodies	used	to	detect	Tfh	cells	and	GC	B-cells	via	IF,	please	refer	to	appendix	5.			
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1.31.2 Quantitate	Analysis	of	GC	Formation	Following	staining	with	respective	antibodies	(see	appendix	5),	spleen	sections	were	visualised	 using	 the	 LSM510	 metaconfocal	 microscope	 (Zeiss,	 Germany).	 Three	sections	from	each	mouse	(n	=	5	in	each	group)	were	analysed	for	GC	formation	using	the	image	quantification	software	-	Volocity	(Perkin	Elmer,	USA).	Total	splenic	area,	B220+	 areas	 and	PNA+	areas	were	measured	using	 the	 area	 tool	 and	 the	 value	 for	each	measurement	recorded.		
1.31.3 Qualitative	Analysis	of	Tfh	Cell	Formation	Confocal	 microscopy	 was	 used	 to	 determine	 whether	 Tfh	 cells	 migrated	 to	 B-cell	follicles	in	the	spleen	of	mice,	and	expressed	important	markers	for	Tfh	cell	function	(Bcl-6).	 Using	marker	 expression	 and	 anatomical	 location,	 bonafide	 Tfh	 cells	 were	identified.			
1.31.4 En	Face	Analysis	Whole	 aortas	were	 dissected	 from	C57BL/6NJ	 :	 LDLR-/-	and	 IL-21R-/-	 :	 LDLR-/-	mice	and	fixed	in	10%	formalin	solution	for	24	hours.	Samples	were	subsequently	bathed	in	 filtered	 oil-red-o	 (ORO)	 solution,	made	with	 3-parts	 concentrated	 ORO	 (0.5%	 in	isopropanol)	and	2-parts	distilled	water.	After	incubation	for	2	hours,	samples	were	rinsed	in	100%	isopropanol	to	remove	excess	ORO	stain	and	then	in	distilled	water.	Using	 fine	 dissection,	 the	 intimal	 surface	 was	 exposed	 by	 a	 single	 longitudinal	 cut	through	 the	 aortic	 arch	 towards	 the	 anterior	 edge	 of	 the	 aorta.	 Using	 dissection	needles,	 aortas	 were	 pinned	 on	 a	 black	 rubber	 dissection	 board.	 Images	 were	captured	using	a	standard	8-mega-pixel	camera.			Total	 aortic	 area	 and	 ORO	 stained	 plaque	 area	 was	 measured	 using	 ImageJ	quantification	 software	 (National	 Institutes	 of	 Health	 Imagining:	http://rsbweb.nih.gov/ij)	 and	 calculated	 in	 mm2.	 Using	 the	 calculation	 shown	 in	figure	7,	percentage	area	of	aorta	covered	in	ORO	positive	plaque	was	measured.		
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Figure	 7:	 Schematic	 representation	 of	 En	 Face	 approach	 used	 to	 quantify	 the	
percentage	of	aorta	comprised	of	ORO	positive	plaques	Aortas	from	both	C57BL/6NJ	:	LDLR-/-	and	IL-21R-/-	:	LDLR-/-	mice	were	fixed	in	10%	formalin	 and	 stained	 in	 ORO	 solution	 for	 2	 hours.	 Total	 aorta	 area	 was	measured	alongside	 plaque	 area	 positive	 for	 ORO	 stain.	 Using	 these	 two	 parameters,	 the	percentages	of	aorta	comprised	of	ORO	stained	plaques	was	calculated.		
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1.31.5 Aortic	Sinus	Plaque	Quantification	Aortic	 sinuses	 were	 harvested	 from	 both	 and	 C57BL/6NJ	 :	 LDLR-/-	 and	 IL-21R-/-	 :	LDLR-/-	 mice	 and	 placed	 in	 an	 OCT	 medium	 filled	 moulds.	 Eight-micron	 thick	sequential	sections	were	subsequently	cut,	starting	at	0	microns	and	finishing	at	660	microns.			Sections	 were	 fixed	 in	 100%	 acetone	 for	 10	 minutes,	 after	 which	 they	 were	 re-hydrated	 in	PBS.	Sections	were	stained	 for	1	hour	 in	an	ORO	solution	containing	3-parts	 concentrated	 ORO	 (0.5	 %	 ORO	 in	 isopropanol)	 and	 2-parts	 distilled	 water.	Sections	were	subsequently	rinsed	in	100%	isopropanol,	followed	by	distilled	water	and	mounted	using	a	water	soluble	mounting	medium	(Vector	Labs,	California,	USA).		Total	 area	 positive	 for	 ORO	 was	 measured	 using	 ImageJ	 quantification	 software	(National	 Institutes	 of	 Health	 Imaging:	 http://rsbweb.nih.gov/ij)	 and	 calculated	 in	mm2.	 Plaque	 burden	 was	 measured	 every	 60	 microns	 (from	 0	 microns	 to	 660	microns)	and	the	average	area	plotted	for	every	animal	at	each	point.	The	process	of	aortic	sinus	plaque	quantification	is	shown	in	figure	8.																		
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Figure	8:	Schematic	representation	of	approach	used	to	quantify	ORO	positive	
area	of	aortic	sinus	sections	Aortic	sinus	sections	from	both	C57BL/6NJ	:	LDLR-/-	and	IL-21-/-	:	LDLR-/-		mice	were	fixed	 in	 10%	 formalin	 and	 stained	 in	 ORO	 solution	 for	 2	 hours.	 Using	 a	 total	 12	sections	 per	 animal,	 mean	 ORO	 positive	 plaque	 area	 was	 measured	 using	 Imagej	quantification	software.	These	values	were	plotted	in	60	micron	increments,	starting	from	 0	 to	 660	 microns.
Sequen&al)Sec&ons)
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1.31.6 CD68+	Macrophage	Staining		Eight	micron	 thick	 sections	 from	 C57BL/6NJ	 :	 LDLR-/-	 and	 IL-21R-/-	 :	 LDLR-/-	 mice	were	fixed	in	100%	acetone	for	10	minutes.	Sections	were	subsequently	air	dried	and	rehydrated	 in	 PBS.	 After	 washing	 in	 PBS,	 sections	 were	 incubated	 in	 FC-receptor	block	(2.3G2	hydridoma	supernatant)	for	15	mins	and	subsequently	washed	twice	in	PBS	for	10	minutes.	To	detect	CD68,	samples	were	stained	with	rat-anti-mouse	CD68	antibody	 (AbD	 Serotec,	 Oxford	 United	 kingdom)	 in	 1%	 blocking	 reagent	 (Perkin	Elmer,	 Cambridge,	 United	 kingdom)	 and	 0.3%	 Triton	 X-100	 in	 PBS	 overnight.	 The	next	 day,	 samples	were	washed	 in	TNT	buffer	 (Tris-HCL;	 pH	7.5;	 0.15	mol/L	NaCl;	and	 0.05%	 Tween-20),	 dried	 and	 incubated	 with	 Texas	 Red-donkey	 anti-rat	 IgG	(Jackson	ImmunoResearch	Laboratories,	Sohan,	United	Kingdom)	 for	30	mins.	After	washing	in	TNT	buffer,	sections	were	dried	and	mounted	in	Prolong	Gold	containing	DAPI	(Life	Technologies,	Paisley,	United	Kingdom).		Respective	 isotype	 controls	 were	 prepared	 in	 an	 identical	 manner	 as	 described	above,	with	rat-anti-mouse	CD68	being	replaced	with	rat-IgG2a	(AbD	Serotec,	Oxford,	United	 Kingdom).	 For	 a	 full	 description	 of	 the	 antibodies	 used	 to	 detect	 CD68	staining,	please	refer	to	appendix	6.		Sections	 were	 viewed	 using	 the	 Axioimager	 M2	 epifluorescent	 microscope	 (Zeiss,	Germany)	and	CD68+	macrophage	content	was	quantified	using	ImageJ	quantification	software	(National	Institutes	of	Health	Imaging:	http://rsbweb.nih.gov/ij).			Colour	 thresholds	determined	CD68+	positive	staining	and	results	are	presented	as	percentage	area	of	 sinus	positive	 for	CD68	staining.	A	 total	of	 thirteen	 sections	per	animal	were	used	for	quantification	purposes.	
	
1.31.7 Collagen	Staining		Eight	micron	 thick	 sinus	 sections	 from	C57BL/6NJ	 :	 LDLR-/-	 and	 IL-21R-/-	 :	 LDLR-/-	mice	 were	 fixed	 in	 10%	 formalin	 for	 10	 minutes.	 Sections	 were	 subsequently	 re-hydrated	 in	 distilled	 water	 for	 a	 further	 10	 minutes.	 Using	 a	 Picro	 Sirius	 Red	 kit	(Abcam,	Cambridge,	United	Kingdom),	sections	were	stained	in	a	1X	solution	of	Picro	
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Sirius	Red	for	1	hour	at	room	temperature.	To	differentiate	the	Picro	Sirius	Red	stain,	sections	were	rinsed	in	two	changes	of	0.5%	acetic	acid.	Sections	were	subsequently	de-hydrated	in	3	changes	of	100%	alcohol	and	mounted	using	DPX	mounting	media	(ThermoFisher	Scientific,	Loughborough,	United	Kingdom).		Sections	 were	 viewed	 using	 the	 AxioStar	 Plus	 transmitted	 light	 microscope	 (Zeiss,	Germany)	with	 the	aid	of	polarised	 lenses.	Picro	Sirius	Red	 staining	was	quantified	using	 ImageJ	 quantification	 software	 (National	 Institutes	 of	 Health	 Imaging:	http://rsbweb.nih.gov/ij).	 Picro	 Sirius	 Red	 staining	 was	 determined	 by	discrimination	of	threshold	staining	and	results	are	presented	as	percentage	of	sinus	comprising	 collagen.	 A	 total	 of	 thirteen	 sections	 per	 animal	 were	 used	 for	quantification	purposes.	
	
 Immunization	Protocol		
C57BL/6	(n	=	6)	and	apoE-/-	 (n	=	6)	were	 immunised	s.c.	with	100	μg	of	ovalbumin	(OVA)	emulsified	in	100	μl	of	complete	freund’s	adjuvant	(CFA).	Mice	were	allowed	to	recover	 for	 9-days,	 throughout	 which	 they	 were	 allowed	 free	 access	 to	 food	 and	water.	After	9-days,	both	groups	were	 culled	via	CO2	 inhalation	and	 scruff-draining	lymph	nodes	removed	for	flow	cytometry	analysis.			Figure	9	summarises	the	immunization	protocol	employed.	
	
 Bone	Marrow	Processing	and	Retrieval		
Using	complete	RPMI	(Life	Technologies,	Paisley,	United	Kingdom),	bone	marrow	was	flushed	from	the	femurs	and	tibias	of	donor	mice	(C57BL/6NJ	and	IL-21R-/-).	Expelled	bone	marrow	was	subsequently	passed	through	a	40-μm	nylon	cell	strainer	(Falcon,	New	York,	USA).	The	resulting	cell	suspension	was	centrifuged	at	400	g	for	5	minutes	and	re-suspended	in	complete	RPMI,	ready	for	i.v.	Injection	of	4	X	106	cells	per	mouse.		
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Figure	9:	Schematic	representation	of	Immunization	protocol	used	to	induce	an	
adaptive	immune	response	in	C57BL/6	WT	and	apoE-/-	mice	Two	groups	of	mice	 [C57BL/6	WT	(n	=	6)	and	apoE-/-	(n	=	6)]	were	 immunized	s.c.	with	 100	 µg	 of	 OVA	 protein	 in	 100	 µl	 CFA.	 Nine	 days	 later,	 draining	 lymph	 nodes	(axillary	and	brachial)	were	dissected	and	prepared	for	flow	cytometry	analysis.	
	
	
	
	
	
	
	
	
	
	
	
LDLR$/$&
LDLR$/$&
IL$21R$/$&
C57BL/6NJ&
4&X&106&
BMSC& IL$21R$/$&:LDLR$/$&
C57BL/6NJ&:&LDLR$/$&
Donor% Recipient% Resulting%Chimera%
4&X&106&
BMSC&
10.5&Grays&
10.5&Grays&
1.%
2.%
C57BL/6(
LDLR$/$&
LDLR$/$&
IL$21R$/$&
C57BL/6NJ&
4&X&106&
BMSC& IL$21R$/$&:LDLR$/$&
C57BL/6NJ&:&LDLR$/$&
Donor% Recipient% Resulting%Chimera%
4&X&106&
BMSC&
10.5&Grays&
10.5&Grays&
1.%
2.%
apoE-/-(
100(µg(OVA(in(100(µl(CFA((
Axillary(&(brachial(lymph(nodes(dissected(for(6low(cytometry(
analysis(of(adaptive(immune(response(((
(
D0( D9(
100(µg(OVA(in(100(µl(CFA((
	 84	
 Chimera	Generation		
Two	groups	of	recipient	LDLR-/-	mice	were	lethally	irradiated	with	a	single	dose	with	10.5	 Grays	 X-ray	 Radiation	 (Precision	 X-ray,	 Connecticut.	 USA).	 Mice	 were	subsequently	 injected	 i.v.	 with	 4	 x	 106	bone	 marrow	 derived	 haematopoietic	 stem	cells	 from	donor	 C57BL/6NJ	 or	 IL-21R-/-	mice.	Mice	were	 allowed	 to	 recover	 for	 4	hours	and	subsequently	placed	on	HFD	(Special	Diet	services,	Essex,	United	Kingdom)	for	a	period	of	14	weeks	(for	composition	refer	to	appendix	1).	Chimeric	mice	were	administered	1%	Enrofloxacin	in	drinking	water	for	the	duration	of	the	study	(Henry	Schein,	Dumfries,	United	Kingdom).		Resulting	chimeras	generated	were	as	follows,			
1.	IL-21R-/-	:	LDLR-/-			 	 	 	 (n	=	9)		
2.	C57BL/6NJ	:	LDLR-/-		 	 (control)		 (n	=	10).			Figure	10	summarises	the	process	in	which	chimeric	mice	were	generated.		
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Figure	10:	Schematic	representation	of	approach	used	to	develop	C57BL/6NJ	:	
LDLR-/-	and	IL-21R-/-	:	LDLR-/-	chimeric	mice	Two	 groups	 of	 LDLR-/-	 mice	 were	 lethally	 irradiated	 with	 10.5	 Grays	 of	 X-ray	radiation.	One	group	was	reconstituted	i.v.	with	bone	marrow	derived	from	IL-21R-/-	mice,	while	 the	other	 group	was	 reconstituted	with	bone	marrow	 from	C57BL/6NJ	mice.	As	a	consequence,	two	chimeric	animals	were	formed	–	1.	IL-21R-/-	:	LDLR-/-	and	2.	C57BL/6NJ	:	LDLR-/-	.	
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 Confirmation	of	Chimera	Status		
LDLR	expression	was	determined	on	 the	 surface	of	peripheral	blood	monocytes	10	weeks	post-reconstitution.	Blood	was	 retrieved	via	 tail	 vein	puncture	 and	 collected	into	a	vial	containing	50	μl	of	ethylenediaminetetraacetic	acid	(EDTA).	Red	blood	cells	were	lysed	by	adding	2	ml	of	red	blood	cell	lysis	buffer	(Ebioscience,	San	Diego,	USA)	and	subsequently	washed	in	HBSS	(Life	Technologies,	Paisley,	United	Kingdom)	ready	for	flow	cytometry	staining.			
1.35.1 Statistics		Statistical	 analysis	was	 performed	 using	 GraphPad	 Prism.	 An	 unpaired	 student’s	 t-test	was	performed	when	comparing	two	groups	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001.	When	 comparing	 three	 or	 more	 groups,	 a	 one-way-ANOVA	 was	 conducted	 with	 a	post-hoc-tukey’s	test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001.	
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Chapter	 3:	 Characterising	 Tfh	 cell	 &	 GC	 B-cell	
Populations	 in	 the	 apoE-/-	 Mouse	 Model	 of	
Atherosclerosis.	
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 Introduction	
With	over	 two	decades	of	 research	 into	 the	 immunological	basis	of	 atherosclerosis,	researchers	 have	 gained	 an	 extensive	 understanding	 of	 the	 fundamental	 processes	that	 lead	 to	 lesion	 development.	 As	 a	 result,	 a	 range	 of	 immune	 cells	 have	 been	identified	 as	 being	 attractive	 therapeutic	 targets.	 Interestingly,	 although	 much	research	has	been	dedicated	to	the	role	of	CD4+	T-cells	in	atherosclerosis,	the	role	of	Tfh	 cells	 is	 only	 just	 being	 addressed.	 Recent	 studies	 have	 indicated	 the	 potential	significance	 of	 Tfh	 cells	 in	 driving	 lesion	 formation	 in	 vivo	 [142],	 indicating	 an	increase	in	Tfh	cell	kinetics	with	lesion	progression.	Involved	in	helping	GC	B-cells	in	the	 production	 of	 isotype	 switched,	 high	 affinity	 antibodies,	 Tfh	 cells	 play	 an	important	 role	 in	 GC	 B-cell	 differentiation	 and	 the	 formation	 of	 protective	 and	pathological	 antibodies.	 Therefore,	 this	 chapter	 determined	 Tfh	 cell	 and	 GC	 B-cell	kinetics	 in	 context	 of	 atherosclerosis	 by	 using	 the	 apoE-/-	 mouse	 model	 of	atherosclerosis.	
	
1.36.1 Aims	The	aims	of	this	chapter	were	to:		 1. Determine	 whether	 Tfh	 cell	 and	 GC	 B-cell	 kinetics	 changed	 in	 line	 with	atherosclerosis	progression	in	apoE-/-	mice	fed	diet	for	varying	lengths	of	time;	2. Assess	whether	 antibody	 titres	 to	modified	 forms	of	 low-density	 lipoprotein	(LDL)	changed	in	line	with	atherosclerosis	progression	and	Tfh	cell	/	GC	B-cell	kinetics.									
89		
 Results	
 Gating	Strategies	for	The	Detection	of	Tfh	cells	in	vivo	
To	date,	there	remains	much	confusion	as	to	the	exact	phenotypic	markers	to	be	used	for	Tfh	cell	analysis.	As	a	result,	there	is	little	consistency	between	published	studies.	In	 an	 attempt	 to	 address	 this	 issue,	 the	 studies	 described	 herein	 characterised	 Tfh	cells	 using	 two	 gating	 strategies.	 Both	 strategies	 took	 into	 account	 that	 Tfh	 cells	originate	 from	 the	 CD4+	 T-cell	 lineage	 and	 migrate	 to	 B-cell	 follicles	 in	 a	 CXCR5	dependent	 manner	 [44,	 168].	 As	 such,	 both	 strategies	 included	 CD4	 and	 CXCR5.	Moreover,	 the	fact	that	GC	Tfh	cells	express	high	levels	of	PD-1	[171,	221,	222]	was	taken	into	account.	With	this	in	mind,	PD-1	was	included	as	a	marker	of	Tfh	cells	in	both	strategies.			
1.38.1 First	Gating	Strategy	–	CD4+	CXCR5+	PD-1+	Tfh	Cells		The	 first	approach	 involved	using	the	gating	style	shown	in	 figure	11.	Lymphocytes	were	gated	for	on	the	basis	of	forward	and	side	scatter	(FSC)	(SSC)	parameters	(Fig	11).	This	was	followed	by	a	subsequent	CD4+	T-cell	gate,	upon	which	CXCR5+	PD-1+	cells	were	gated	(Fig	11).	In	combination,	the	first	gating	strategy	defined	Tfh	cells	as	CD4+	CXCR5+	PD-1+	expressing	cells.			
1.38.2 Second	Gating	Strategy	–	CD4+	CD44hi	CXCR5+	PD-1+	Tfh	
cells		As	 well	 as	 profiling	 Tfh	 cells	 as	 CD4+	 CXCR5+	 PD-1+	 cells,	 the	 cell	 surface	glycoprotein	 CD44	was	 included	 in	 the	 second	 gating	 strategy.	 Involved	 in	 cell-cell	interaction	by	binding	extracellular	hyaluronic	acid	(HA)	[223],	CD44	is	up	regulated	on	 the	 surface	 of	 antigen	 experienced	 and	 activated	 T-cells	 [223].	 As	 Tfh	 cells	encounter	antigen	and	subsequently	migrate	to	B-cell	follicles	for	participation	in	the	GC	reaction,	they	up-regulate	CD44	on	their	surface.	Moreover,	CD44	has	previously	been	used	–	in	combination	with	other	markers	–	as	a	faithful	representation	of	Tfh	cell	phenotype	[222].			
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	Therefore,	as	part	of	the	second	gating	strategy,	Tfh	cells	were	characterised	as	CD4+	CXCR5+	CD44hi	PD-1+	cells.			Using	the	gating	style	shown	in	figure	12,	lymphocytes	were	gated	for	on	the	basis	of	FSC	and	SSC	parameters.	This	was	followed	by	a	subsequent	CD4+	T-cell	gate,	upon	which	CD4+	CD44hi	T-cells	were	selected.	CXCR5+	PD-1+	Tfh	cells	were	 then	gated	for	(Fig	12).					
	
				
	
Figure	11:	Generation	of	CD4+	CXCR5+	PD-1+	Tfh	cell	gating	strategy	Lymphocytes	were	gated	for	on	the	basis	of	FSC	and	SSC	parameters.	Using	a	B220	/	CD4	gate	to	exclude	B220+	cells,	CD4+	were	selected.	Using	this	parent	gate,	CXCR5+	PD-1+	Tfh	cells	were	selected	for.	Using	this	gating	strategy,	Tfh	cells	were	defined	as	CD4+	CXCR5+	PD-1+	Tfh	cells.	Representative	plots	were	obtained	 from	analysis	of	pao-LN	samples.				
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 Tfh	cell	Kinetics	in	Atherosclerosis		
1.39.1 Peripheral	Lymph	Node	CD4+	CXCR5+	PD-1+	Tfh	Cell	 and	
CD4+	CD44hi	CXCR5+	PD-1+	Tfh	Cell	 Populations	 Increase	 in	
Line	with	Atherosclerosis	Progression		PLNs	 represent	 an	 important	 network	 of	 structures	 that	 allow	 for	 the	 peripheral	circulation	 of	 immune	 cells.	 As	 such,	 lymph	 nodes	 represent	 an	 important	 location	where	antigen	presenting	cells	(APCs)	uptake	and	present	cognate	antigen	to	resident	T-cells.	 To	 determine	 whether	 pLN	 Tfh	 cell	 populations	 changed	 in	 line	 with	atherosclerosis	progression,	Tfh	cell	expression	patterns	were	assessed	 in	 the	pLNs	of	C57BL/6	wild	type	(WT)	and	apoE-/-	mice	fed	chow	or	HFD	for	variable	lengths	of	time.			Using	the	first	gating	strategy,	no	difference	in	the	percentage	of	pLN	CD4+	CXCR5+	PD-1+	Tfh	cells	was	observed	in	WT	at	any	time	point	(Fig	13A).	In	contrast,	a	peak	in	CD4+	CXCR5+	PD-1+	Tfh	cell	populations	in	the	pLNs	of	apoE-/-	mice	fed	chow	or	HFD	for	12	weeks	was	observed	(Fig	13A).		In	 comparing	 intra-group	variation,	 apoE-/-	mice	 fed	HFD	 for	12	weeks	displayed	 a	significant	increase	in	the	percentage	of	CD4+	CXCR5+	PD-1+	Tfh	cells	than	WT	and	apoE-/-	mice	 fed	 chow	 for	 the	 same	 length	of	 time	 (Fig	13A).	 In	 contrast,	pLN	CD4+	CXCR5+	PD-1+	Tfh	 cell	populations	peaked	 in	apoE-/-	mice	 fed	 chow	or	HFD	 for	12	weeks	(Fig	13A).		When	including	CD44hi	cells,	a	similar	trend	in	Tfh	cell	expression	–	as	found	using	gating	strategy	one	–	was	observed.	Remaining	low	throughout,	no	difference	in	the	percentage	of	CD4+	CD44hi	CXCR5+	PD-1+	Tfh	cells	in	the	pLNs	of	WT	mice	(Fig	13B)	was	found.	In	contrast,	both	apoE-/-	chow	and	HFD	fed	mice	peaked	in	CD4+	CD44hi	CXCR5+	 PD-1+	 Tfh	 cell	 formation	 at	 12	 weeks	 post-diet	 (Fig	 13B).	 Mirroring	 the	results	obtained	via	gating	strategy	one,	apoE-/-	mice	fed	HFD	for	12	weeks	displayed	
93		
significantly	enhanced	percentages	of	CD4+	CD44hi	CXCR5+	PD-1+	Tfh	cell	than	WT	and	apoE-/-	mice	fed	chow	for	the	same	length	of	time	(Fig	13B).	
94		
										
	
	
	
	
	
	
	
						
Fi
gu
re
	1
3:
	P
er
ce
nt
ag
e	
of
	C
XC
R5
+	
PD
-1
+	
Tf
h	
ce
lls
	in
	p
LN
s	
of
	m
ic
e	
fo
llo
w
in
g	
ad
m
in
is
tr
at
io
n	
of
	c
ho
w
	o
r	
H
FD
	fo
r	
va
ri
ab
le
	le
ng
th
s	
of
	ti
m
e	 Individ
ual	gro
ups	of	
mice	w
ere	pro
vided	w
ith	HFD
	(apoE
-/- )	or	c
how	di
et	(apo
E-/- 	and
	C57BL
/6	WT
)	for	a	
period
	of	1,	2
,	4,	8	a
nd	12	
weeks.
	Pao-L
Ns	wer
e	harve
sted	at
	each	t
ime	po
int	and
	using	
two	ga
ting	str
ategies
,	Tfh	ce
ll	popu
lations
	were	
assesse
d.	Tfh	
cells	w
ere	
charac
terised
	as	CD
4+	CXC
R5+	PD
-1+	(A
)	and	C
D4+	CD
44hi	C
XCR5+
	PD-1+
	(B)	ex
pressin
g	cells.
	Repre
sentati
ve	plot
s	displ
ay	the	
12	
week	t
ime	po
int.	Op
en	bar
s	repre
sent	C5
7BL/6	
WT	(n
	=	5	-	
6)	mic
e	fed	s
tandar
d	labor
atory	c
how	di
et.	Sha
ded	gr
ey	and
	black	
bars	
represe
nt	apoE
-/- 	mice
	fed	sta
ndard	
laborat
ory	cho
w	diet	
(n	=	3	
-	5) or	
HFD	(n
	=	3	-	5
),	respe
ctively
.	Statis
tical	an
alysis	w
as	perf
ormed
	
using	G
raphPa
d	Prism
	and	by
	condu
cting	a
	one-w
ay-ANO
VA	wit
h	a	pos
t-hoc-t
ukey’s	
test.	*	P
	<	0.05
,	**	P	<
	0.01,	*
**	P	<	0
.001	
012345
%(of(CD4+(CXCR5+(
PD11+(Cells(
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!*** *
012345
%(of(CD4+(CD44+(
CXCR5+(PD11+(Cells
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!** **
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
38
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
17
8
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
60
7
CD4+%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*%
Chow%%
apoE*/*%
HFD%%
CD4+%C
D44hi%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*%
Chow%%
apoE*/*%
HFD%%
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
09
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
25
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
87
0.
17
8&
0.
60
7&
3.
38
&
1.
09
&
1.
25
&
3.
87
&
0.
17
8&
0.
60
7&
3.
38
&
012345
%(of(CD4+(CXCR5+(
PD11+(Cells(
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!*** *
012345
%(of(CD4+(CD44+(
CXCR5+(PD11+(Cells
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!** **
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
38
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
17
8
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
60
7
CD4+%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*% C
how%%
apoE*/*% H
FD%%
CD4+%C
D44hi%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*% C
how%%
apoE*/*% H
FD%%
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
09
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
25
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
87
0.
17
8&
0.
60
7&
3.
38
&
1.
09
&
1.
25
&
3.
87
&
012345
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!*** *
012345
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!** **
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
38
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
17
8
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
60
7
CD4+%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*% C
how%%
apoE*/*% H
FD%%
CD4+%C
D44hi%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*% C
how%%
apoE*/*% H
FD%%
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
09
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
25
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
87
0.
17
8&
0.
60
7&
3.
38
&
1.
09
&
1.
25
&
3.
87
&
012345
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!*** *
012345
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!** **
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
38
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
17
8
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
60
7
CD4+%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*% C
how%%
apoE*/*% H
FD%%
CD4+%C
D44hi%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*% C
how%%
apoE*/*% H
FD%%
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
09
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
25
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
87
0.
17
8&
0.
60
7&
3.
38
&
1.
09
&
1.
25
&
3.
87
&
3.
87
&
1.
25
&
1.
09
&
012345
%(of(CD4+(CXCR5+(
PD11+(Cells(
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!*** *
012345
%(of(CD4+(CD44+(
CXCR5+(PD11+(Cells
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!** **
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
38
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
17
8
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
60
7
CD4+%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*%
Chow%%
apoE*/*%
HFD%%
CD4+%C
D44hi%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*%
Chow%%
apoE*/*%
HFD%%
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
09
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
25
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
87
0.
17
8&
0.
60
7&
3.
38
&
1.
09
&
1.
25
&
3.
87
&
&&&&
&&&&
1&
w
k&
&&2
&w
k&
&4
&w
k&
&&8
&w
k&
&1
2&
w
k&
012345
%(of(CD4+(CXCR5+(
PD11+(Cells(
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!*** *
012345
%(of(CD4+(CD44+(
CXCR5+(PD11+(Cells
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!** **
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
38
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
17
8
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
60
7
CD4+%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*%
Chow%%
apoE*/*%
HFD%%
CD4+%C
D44hi%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*%
Chow%%
apoE*/*%
HFD%%
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
09
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
25
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
87
0.
17
8&
0.
60
7&
3.
38
&
1.
09
&
1.
25
&
3.
87
&
%&of&C4+&CXCR5+&&
PD81+&Cells&
%&of&C+&CD44+&&
CXCR5+&PD81+&Cells&&&&&
&&&&
1&
w
k&
&&2
&w
k&
&4
&w
k&
&&8
&w
k&
&1
2&
w
k&
WT#
apoE(/(#
Chow#
apoE(/(#
HFD#
apoE(/(#
HFD#
apoE(/(#
Chow#
WT#
CD4+#C
XCR5+#
PD(1+#T
7h#Cells
#
CD4+#C
D44hi#C
XCR5+#
PD(1+#T
7h#Cells
#
CX
CR
5&
PD81&
CX
CR
5&
PD81&
012345
%(of(CD4+(XCR5+(
PD11+(Cells(
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!*** *
012345
%(of(CD4+(4+(
CXCR5+(PD11+(Cells
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!** **
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
38
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
17
8
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
60
7
CD4+%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*%
Chow%%
apoE*/*%
HFD%%
CD4+%C
D44hi%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*%
Chow%%
apoE*/*%
HFD%%
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
09
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
25
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
87
0.
17
8&
0.
60
7&
3.
38
&
1.
09
&
1.
25
&
3.
87
&
0.
17
8&
0.
60
7&
3.
38
&
012345
%(of(CD4+(XCR5+(
PD11+(Cells(
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!*** *
012345
%(of(CD4+(4+(
CXCR5+(PD11+(Cells
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!** **
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
38
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
17
8
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
60
7
CD4+%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*% C
how%%
apoE*/*% H
FD%%
CD4+%C
D44hi%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*% C
how%%
apoE*/*% H
FD%%
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
09
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
25
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
87
0.
17
8&
0.
60
7&
3.
38
&
1.
09
&
1.
25
&
3.
87
&
012345
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!*** *
012345
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!** **
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
38
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
17
8
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
60
7
CD4+%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*% C
how%%
apoE*/*% H
FD%%
CD4+%C
D44hi%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*% C
how%%
apoE*/*% H
FD%%
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
09
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
25
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
87
0.
17
8&
0.
60
7&
3.
38
&
1.
09
&
1.
25
&
3.
87
&
012345
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!*** *
012345
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!** **
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
38
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
17
8
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
60
7
CD4+%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*% C
how%%
apoE*/*% H
FD%%
CD4+%C
D44hi%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*% C
how%%
apoE*/*% H
FD%%
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
09
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
25
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
87
0.
17
8&
0.
60
7&
3.
38
&
1.
09
&
1.
25
&
3.
87
&
3.
87
&
1.
25
&
1.
09
&
012345
%(of(CD4+(XCR5+(
PD11+(Cells(
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!*** *
012345
%(of(CD4+(4(
CXCR5+(PD11(Cells
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!** **
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
38
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
17
8
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
60
7
CD4+%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*%
Chow%%
apoE*/*%
HFD%%
CD4+%C
D44hi%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*%
Chow%%
apoE*/*%
HFD%%
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
09
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
25
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
87
0.
17
8&
0.
60
7&
3.
38
&
1.
09
&
1.
25
&
3.
87
&
&&&&
&&&&
1&
w
k&
&&2
&w
k&
&4
&w
k&
&&8
&w
k&
&1
2&
w
k&
012345
%(of(CD4+(XCR5+(
PD11+(Cells(
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!*** *
012345
%(of(CD4+(4+(
CXCR5+(PD11(Cells
!!1!wk!!!
!!!2!wk!!
!!!!4!wk!
!!!!!!8!wk
!!!!!!12!w
k!!** **
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
38
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
17
8
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
0.
60
7
CD4+%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*%
Chow%%
apoE*/*%
HFD%%
CD4+%C
D44hi%C
XCR5+%
PD*1+%T
-h%Cells
%%
WT%%
apoE*/*%
Chow%%
apoE*/*%
HFD%%
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
09
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
1.
25
0
10
2
10
3
10
4
10
5
0
10
2
10
3
10
4
10
5
3.
87
0.
17
8&
0.
60
7&
3.
38
&
1.
09
&
1.
25
&
3.
87
&
%&of&C4+&CXCR5+&&
PD81+&Cells&
%&of&C+&CD44+&&
CXCR5+&PD81+&Cells&&&&&
&&&&
1&
w
k&
&&2
&w
k&
&4
&w
k&
&&8
&w
k&
&1
2&
w
k&
WT#
apoE(/(#
Chow#
apoE(/(#
HFD#
apoE(/(#
HFD#
apoE(/(#
Chow#
WT#
CD4+#C
XCR5+#
PD(1+#T
7h#Cells
#
CD4+#C
D44hi#C
XCR5+#
PD(1+#T
7h#Cells
#
CX
CR
5&
PD81&
CX
CR
5&
PD81&A	 B	
95		
1.39.2 Spleen	 CD4+	 CXCR5+	 PD-1+	 Tfh	 Cell	 and	 CD4+	 CD44hi	
CXCR5+	 PD-1+	 Tfh	 Cell	 Populations	 Increase	 in	 Line	 with	
Atherosclerosis	Progression		The	 spleen	 is	 a	 multifunctional	 organ	 with	 roles	 in	 red	 blood	 cell	 metabolism,	immunity	 and	 blood	 filtration	 [224].	 Underlining	 the	 role	 of	 the	 spleen	 in	atherosclerosis,	 splenectomised	 mice	 develop	 enhanced	 lesions,	 with	 significantly	lower	antibody	titres	[155,	156].	As	well	as	this,	and	of	particular	relevance	to	Tfh	cell	biology,	the	spleen	is	a	major	site	of	antibody	production	in	vivo	[224].	As	atherogenic	antigens	 (oxidised	 forms	 of	 low	 density	 lipoprotein)	 circulate	 in	 the	 blood,	 the	percentage	of	Tfh	cell	populations	in	spleen	of	all	three	groups	was	assessed.	As	such,	it	was	determined	whether	the	spleen	housed	significant	Tfh	cell	populations,	in	the	context	of	atherosclerosis.			Little	variation	in	the	percentage	of	CD4+	CXCR5+	PD-1+	Tfh	cells	in	the	spleen	of	WT	mice	at	early	time	points	(1wk	–	4wk)	(Fig	14A)	was	observed.	This	was	followed	by	a	slight	 increase	 towards	 later	 time	points	 (8wk	–	12wk)	(Fig	14A).	As	observed	 in	pLN	 samples,	 CD4+	 CXCR5+	 PD-1+	 Tfh	 cell	 populations	 peaked	 in	 apoE-/-	mice	 fed	HFD	for	12	weeks	(Fig	14A).	This	peak	was	significantly	greater	than	the	percentage	of	CD4+	CXCR5+	PD-1+	Tfh	cells	in	the	spleen	of	WT	and	apoE-/-	mice	fed	chow	diet	for	the	same	length	of	time	(Fig	14A).	Mirroring	this,	apoE-/-	mice	fed	chow	or	HFD	at	early	 time	 points	 (1wk)	 also	 displayed	 enhanced	 CD4+	 CXCR5+	 PD-1+	 Tfh	 cell	percentages	when	compared	to	WT	and	apoE-/-	mice	fed	chow	diet	(Fig	14A).		When	 including	 CD44+	 cells,	 apoE-/-	 mice	 fed	 chow	 or	 HFD	 for	 1	 week	 displayed	significantly	enhanced	percentages	of	CD4+	CD44hi	CXCR5+	PD-1+	Tfh	cells	than	WT	mice	 (Fig	 14B).	 In	 comparing	 apoE-/-	 groups,	 this	 rise	 was	 significantly	 greater	 in	apoE-/-	mice	 fed	HFD	 (Fig	 14B).	 Following	 a	 similar	 pattern,	 apoE-/-	mice	 fed	 chow	diet	 for	 4	 weeks	 displayed	 significantly	 enhanced	 percentages	 of	 CD4+	 CD44hi	CXCR5+	PD-1+	Tfh	cells	than	WT	mice	(Fig	14B).			
96		
Interestingly,	 WT	 mice	 fed	 diet	 for	 8	 weeks	 displayed	 significantly	 enhanced	percentages	of	CD4+	CD44hi	CXCR5+	PD-1+	Tfh	cells	 than	apoE-/-	mice	 fed	chow	or	HFD	 for	 the	 same	 length	 of	 time	 (Fig	 14B)
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1.39.3 Para-aortic	CD4+	CXCR5+	PD-1+	Tfh	Cell	and	CD4+	CD44hi	
CXCR5+	 PD-1+	 Tfh	 Cell	 Populations	 Increase	 in	 Line	 with	
Atherosclerosis	Progression		The	 inflammatory	 response	 that	occurs	within	 the	 aortic	 vessel	 is	 important	 to	 the	development	 and	 progression	 of	 lesions	 [225].	 During	 established	 pathology,	 cells	from	 both	 the	 adaptive	 and	 innate	 compartments	 converge	 to	 orchestrate	 the	progression	of	luminal	plaques	[225].	Acting	via	cell-cell	interaction	and	the	secretion	of	 chemical	 mediators	 (to	 recruit	 more	 cells),	 the	 delicate	 balance	 of	 arterial	inflammation	can	have	a	profound	effect	upon	pathological	outcome.	In	testament	to	this,	modulation	of	many	immune	cells	discussed	in	the	introduction	of	this	chapter	significantly	affect	lesion	progression.			To	 obtain	 immune	 cells	 from	 highly	 fibrous	 aortas,	 aortas	 must	 be	 subjected	 to	enzymatic	 digestion,	 using	 a	 cocktail	 of	 collagenase,	 hylauronadase	 and	 DNAse.	Unfortunately,	from	previous	experiments,	it	became	apparent	that	this	very	process	results	in	diminished	aortic	CXCR5	detection	(data	not	shown).			To	confirm	this	finding	wasn’t	a	result	of	deficient	CXCR5	expression	in	the	aorta,	pLN	and	spleen	samples	were	assessed	for	CXCR5	expression	post-digestion.	Confirming	our	 findings,	 no	 CXCR5	 positive	 staining	 was	 detected	 after	 digestion	 (data	 not	shown).	 To	 address	 this	 issue,	 a	 variety	 of	 techniques	 were	 used,	 including	biotinylated	CXCR5	 antibody	 and	 streptavidin	 treatment,	 and	 fluorescently	 labelled	CXCL13	(the	 ligand	for	CXCR5).	Unfortunately,	 these	techniques	were	 insufficient	 in	detecting	CXCR5	expression	(data	not	shown).			As	such,	 to	gain	an	understanding	of	what	Tfh	cell	expression	may	be	 like	 in	a	 local	environment,	 Tfh	 cell	 populations	 were	 assessed	 in	 the	 para-aortic	 lymph	 nodes	(pao-LNs)	of	mice.			The	pao-LNs	are	a	group	of	 lymph	nodes	that	 lie	parallel	to	the	abdominal	aorta.	Of	particular	importance	to	atherosclerosis,	these	LNs	receive	drainage	from	the	aortic	trunk,	and	hence	plaques	[219].		
99		
Both	WT	and	apoE-/-	mice	fed	chow	diet	for	1	–	12	weeks	displayed	little	variation	in	pao-LN	CD4+	CXCR5+	PD-1+	Tfh	cell	populations.	(Fig	15A).	In	contrast,	apoE-/-	mice	fed	HFD	for	12	weeks,	displayed	a	significant	peak	in	the	percentage	of	CD4+	CXCR5+	PD-1+	Tfh	cells	(Fig	15A).		In	 comparing	 earlier	 time	 points,	 apoE-/-	mice	 fed	 chow	 diet	 for	 1	week	 displayed	enhanced	 percentages	 of	 CD4+	 CXCR5+	 PD-1+	 Tfh	 cells	 than	WT	 control	mice	 (Fig	15A).	Following	a	similar	pattern,	both	apoE-/-	chow	and	apoE-/-	HFD	mice	fed	diet	for	4	 weeks	 displayed	 significantly	 enhanced	 percentages	 of	 CD4+	 CXCR5+	 PD-1+	 Tfh	cells	than	their	respective	WT	controls	(Fig	15A).		When	 including	 CD44,	WT	mice	 displayed	 no	 difference	 in	 the	 expression	 of	 CD4+	CD44hi	CXCR5+	PD-1+	Tfh	cells	at	any	time	point	(Fig	15B).	In	contrast,	apoE-/-	mice	fed	 chow	 diet	 for	 8	 weeks	 displayed	 a	 significant	 peak	 in	 pao-LN	 CD4+	 CD44hi	CXCR5+	PD-1+	Tfh	cell	populations	(Fig	15B).			Moreover,	apoE-/-	mice	fed	HFD	for	12	weeks	displayed	a	significant	peak	in	pao-LN	CD4+	 CD44hi	 CXCR5+	 PD-1+	 Tfh	 cell	 populations	 (Fig	 15B).	 This	 peak	 was	significantly	greater	 than	WT	and	apoE-/-	mice	 fed	chow	diet	 for	 the	same	 length	of	time	 (Fig	 15B).
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1.39.4 Summary	 of	 Tfh	 cell	 Kinetics	 in	 Experimental	
Atherosclerosis		In	summary,	remaining	consistently	low,	WT	mice	displayed	little	variation	in	Tfh	cell	populations	 in	all	organs	assessed.	 Interestingly,	 apoE-/-	mice	 fed	HFD	 for	12	weeks	displayed	significantly	enhanced	Tfh	cell	percentages	in	all	organs	assessed.	Peaking	at	 12	 weeks,	 this	 time	 point	 co-insides	 with	 the	 formation	 of	 advanced	 plaques,	enhanced	 arterial	 inflammation	 and	 established	 pathology	 in	 the	 apoE-/-	 mouse	model.	As	such,	Tfh	cells	may	comprise	a	significant	population	at	advanced	stages	of	atherosclerosis.	 Moreover,	 our	 data	 suggests	 that	 extreme	 hyperlipidaemia	 may	function	to	drive	Tfh	cell	formation	in	vivo.																						
102		
 Gating	Strategies	for	The	Detection	of	GC	B-cells	In	vivo	
As	 well	 as	 Tfh	 cells,	 GC	 B-cells	 comprise	 an	 important	 component	 of	 every	 GC	reaction.	Via	cell-cell	 interactions	and	production	of	IL-21,	Tfh	cells	guide	GC	B-cells	through	their	differentiation	programme,	to	form	antibody-secreting	memory	B-cells	and	plasma	cells	[226].	The	interaction	between	GC	B-cells	and	Tfh	cells	is	therefore	essential	to	the	successful	mounting	of	adaptive	immune	responses.			Using	 surface	 flow	 cytometry	 staining,	 GC	 B-cell	 populations	 were	 assessed	 in	 the	pLNs,	spleen	and	pao-LNs	of	apoE-/-	mice	fed	chow	or	HFD	for	1,	2,	4,	8	and	12	weeks.	Using	this	data,	we	aimed	to	determine	whether	GC	B-cell	kinetics	followed	a	pattern	in	line	with	the	Tfh	cell	kinetics	described	above.			As	a	means	of	determining	GC	B-cell	kinetics	in	the	pLNs,	spleen	and	pao-LNs	of	mice,	the	gating	strategy	shown	in	figure	16	was	devised.	Using	an	initial	lymphocyte	gate,	B220+	 cells	 were	 gated	 for	 alongside	 a	 CD4	 exclusion	 gate.	 B220+	 cells	 were	subsequently	gated	for	their	expression	of	the	GC	B-cell	markers	–	peanut	agglutinin	(PNA)	and	FAS.						 			 							
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Figure	16:	Generation	of	B220+	PNA+	FAS+	GC	B-cell	gating	strategy	Lymphocytes	were	 gated	 for	 on	 the	 basis	 of	 FSC	 and	 SSC	 parameters.	 B220+	 cells	were	 subsequently	 gated.	 Doublet	 gating	 followed	 this,	 upon	 which	 PNA+	 FAS+	expressing	cells	were	gated.																												
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1.40.1 Peripheral	 Lymph	Node	GC	B-cell	Populations	 Increase	 in	
Line	with	Atherosclerosis	Progression	No	difference	in	the	percentage	of	WT	pLN	B220+	FAS+	PNA+	GC	B-cell	populations	was	observed	at	any	time	point	(Fig	17).	In	comparison,	a	significant	increase	in	the	percentage	of	GC	B-cells	in	the	pLNs	of	apoE-/-	mice	fed	chow	or	HFD	diet	for	4	and	12	weeks	was	observed	(Fig	17).	When	comparing	intergroup	variation,	apoE-/-	mice	fed	HFD	(for	4	or	12	weeks)	displayed	significantly	greater	percentages	of	GC	B-cells	than	apoE-/-	mice	fed	chow	diet	for	the	same	length	of	time	(Fig	17).																								
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1.40.2 Splenic	 GC	 B-cell	 Populations	 Increase	 in	 Line	 with	
Atherosclerosis	Progression	As	with	Tfh	cell	populations,	we	studied	B220+	PNA+	FAS+	GC	B-cell	 expression	 in	systemic	 compartments.	 As	 such,	 we	 determined	 whether	 Tfh	 cell	 and	 GC	 B-cell	kinetics	followed	a	distinct	pattern,	thus	suggesting	active	GC	reaction	formation.			As	with	pLNs,	little	variation	in	the	percentage	of	splenic	GC	B-cells	was	observed	in	WT	mice	at	any	time	point	(Fig	18).	In	contrast,	and	in	comparison	to	WT	mice,	apoE-/-	mice	 fed	chow	diet	displayed	a	significant	peak	 in	GC	B-cell	 formation	at	4	weeks	post-diet	(Fig	18).		Interestingly,	 mice	 fed	 HFD	 at	 early	 (1wk	 and	 2wk)	 and	 late	 time	 points	 (12	 wk)	displayed	 significantly	 greater	 percentages	 of	 GC	 B-cells	 than	 respective	 WT	 and	apoE-/-	chow	 fed	 groups	 (Fig	 18).	 This	 pattern	 was	 also	 observed	 between	 apoE-/-	HFD	and	WT	mice	fed	diet	for	4	and	8	weeks	(Fig	18).																			
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1.40.3 Para-aortic	Lymph	Node	GC	B-cell	Populations	Increase	in	
Line	with	Atherosclerosis	Progression	WT	 mice	 fed	 chow	 diet	 displayed	 consistently	 low	 percentages	 of	 GC	 B-cells	throughout	all	time	points	(Fig	19).	In	contrast	to	this,	both	apoE-/-	chow	and	apoE-/-	HFD	 fed	mice	displayed	a	 significant	peak	 in	 the	percentage	of	GC	B-cells	when	 fed	diet	for	4	weeks	(Fig	19).		In	comparing	 intergroup	variation,	apoE-/-	mice	 fed	HFD	at	all	 time	points,	with	 the	exception	of	8	weeks,	displayed	significantly	greater	percentages	of	GC	B-cells	 than	WT	and	apoE-/-	mice	fed	chow	diet	for	the	same	length	of	time	(Fig	19).																								
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1.40.4 Summary	 of	 GC	 B-cell	 Kinetics	 in	 Experimental	
Atherosclerosis		In	summary,	WT	mice	fed	chow	diet	displayed	little	variation	in	the	percentage	of	GC	B-cell	populations	 throughout	 all	 time	points.	 Interestingly,	 however,	pLN	and	pao-LNs	from	apoE-/-	mice	fed	chow	or	HFD	for	4	weeks	displayed	significantly	enhanced	GC	B-cell	populations.	Moreover,	in	comparison	to	WT	controls,	apoE-/-	chow	or	HFD	fed	mice	displayed	 significantly	 enhanced	 splenic	GC	B-cells	populations	 at	 all	 time	points	 assessed.	 Taken	 together,	 our	 data	 suggests	 that	 hyperlipidemia	 may	 be	 a	driving	force	in	GC	B-cell	formation.																									
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 MDA-Ox-LDL	antibody	Titres		
Both	 Tfh	 cells	 and	 GC	 B-cells	 play	 important	 roles	 in	 the	 production	 if	 isotype	switched,	high	affinity	antibodies.	 Specific	 for	a	 single	antigen,	 antibodies	produced	from	 the	 Tfh	 cell	 :	 GC	 B-cell	 axis	 are	 potent	 in	 their	 ability	 to	 recognise	 a	 specific	target	 then	 their	 un-switched	 counterparts.	 This	 process,	 therefore,	 holds	 great	importance	in	the	area	of	disease	and	immunization.	As	such,	many	researchers	have	assessed	 the	 potential	 of	modulating	 the	Tfh	 cell	 :	 GC	B-cell	 axis	 for	 better	 vaccine	development.			Of	 the	 potential	 antigens	 described	 in	 atherosclerosis,	 one	 has	 gained	 extensive	attention.	 Oxidised	 low-density	 lipid	 (Ox-LDL)	 is	 a	 modified	 form	 of	 the	 native,	homeostatic	 transport	 molecule	 LDL.	 Implicated	 as	 an	 important	 molecule	 in	 the	development	 of	 atherosclerosis,	 many	 have	 focused	 on	 studying	 its	 role	 in	 lesion	formation.			Via	 exposure	 to	 a	 wealth	 of	 oxidising	 agents	 in	 diseased	 arteries,	 LDL	 becomes	progressively	oxidised	and	forms	Ox-LDL.	Attempting	to	resolve	the	Ox-LDL	overload,	resident	 macrophages	 engage	 Ox-LDL	 via	 SRs	 and	 become	 overwhelmed.	 Once	overloaded,	 these	 macrophages	 cease	 to	 function	 and	 form	 the	 characteristic	hallmark	of	atherosclerosis	–	the	foam	cell.		As	a	result	of	the	intimate	association	between	Tfh	cells,	GC	B-cells	and	antibodies,	we	wished	 to	 determine	 serum	 antibody	 titres	 to	 the	 pathogenic	molecule	Ox-LDL.	 To	obtain	modified	forms	of	LDL,	native	LDL	can	be	incubated	with	one	of	two	oxidising	agents	 –	 malondialdehyde	 or	 Copper.	 Exposing	 oxidised	 sites,	 such	 as	phosphorylcholine	(PC),	oxidation	of	LDL	results	 in	the	formation	of	pathogenic	Ox-LDL.			Once	modified,	prefixed	MDA	or	Cu2+	refers	to	the	method	of	oxidation.	As	part	of	our	study,	Cu2+	modified	LDL	bound	variable	levels	of	serum	antibodies,	and	as	such	were	unreliable	 (data	 now	 shown).	 To	 address	 this	 issue,	 MDA-Ox-LDL	 –	 which	 yielded	more	reliable	and	consistent	results	–	was	used	throughout.		
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Using	ELISAs,	serum	anti-MDA-Ox-LDL	IgG,	IgM,	IgG2c	and	IgG1	antibody	titres	were	measured.			
1.41.1 Determining	MDA-Ox-LDL	Antigen	Coating	Concentration		To	 determine	 the	 concentration	 of	 MDA-Ox-LDL	 required	 for	 coating	 microtitre	ELISA	plates,	plates	were	coated	with	varying	concentrations	of	MDA-Ox-LDL	(6.25,	12.5,	 25,	 50	 and	100	μg/ml).	 Plates	were	 subsequently	 incubated	with	 serum	 from	WT	and	apoE-/-	mice	fed	chow	or	HFD	for	12	weeks.	Using	HRP	conjugated	anti-IgM,	IgG,	 IgG2C	and	 IgG1,	 respective	 isotypes	were	detected.	For	a	detailed	description	of	the	ELISA	protocol	used,	please	refer	to	the	materials	and	methods	section.		Equivalent	detection	of	anti-MDA-Ox-LDL	 IgM,	 IgG,	 IgG2c	and	 IgG1	was	 found	across	all	 antigen	 concentrations	 in	 all	 groups	 (WT,	 apoE-/-	chow	 fed	 and	 apoE-/-	HFD	 fed)	(Fig	20).	As	a	 consequence,	we	used	MDA-Ox-LDL	at	a	 concentration	of	12.5	μg/ml	was	used	for	all	ELISA	coating	purposes.		 			 								 	 		
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Figure	20:	Optimising	MDA-Ox-LDL	antigen	coating	concentration		Microtitre	 plates	 were	 coated	 with	 varying	 concentrations	 of	 MDA-Ox-LDL	 (6.25,	12.5,	25,	50	and	100	μg/ml	and	incubated	overnight	at	4°C	degrees.	Serum	samples	from	one	C57BL/6	WT	and	apoE-/-	mouse	fed	chow	or	HFD	for	12	weeks	was	added	and	 incubated	overnight	at	4°C	degrees.	 IgM,	 IgG,	 IgG2c	and	 IgG1	antibodies	 isotypes	were	detected	using	HRP	conjugated	antibodies	and	subsequent	incubation	with	TMB	substrate.	 To	 account	 for	 intra-plate	 variation	 in	 OD	 readings,	 all	 values	 were	normalised	 by	 dividing	 OD	 values	 with	 a	 fixed	 reading	 from	 C57BL/6	 WT	 serum	present	 on	 each	 plate.	 Graphs	 represent	 one	 animal	 from	 the	 12	week	 time	 point.	Open	bars	represent	C57BL/6	WT	mice	 fed	chow	diet,	while	shaded	grey	and	black	bars	represent	apoE-/-	mice	fed	chow	or	HFD	respectively.																					
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1.41.2 Anti-MDA-Ox-LDL	 Serum	 Antibody	 Titres	 Change	 in	 Line	
with	GC	B-cell	Kinetics	Following	 the	 increase	 in	 GC	 B-cell	 formation	 at	 4	 weeks,	 antibody	 titres	 to	 the	pathogenic	molecule	MDA-Ox-LDL	were	assessed.	Using	a	single	point	serum	dilution	of	 1:25,	 anti-MDA-Ox-LDL	 serum	 antibody	 titres	 to	 IgM,	 IgG,	 IgG2c	 and	 IgG1	 were	determined.			Remaining	 consistently	 stable,	 no	 difference	 in	 serum	MDA-Ox-LDL	 IgM	 titres	was	found	between	WT	and	apoE-/-	groups	at	any	time	point.			Following	 a	 similar	 pattern,	 no	 difference	 in	 serum	 MDA-Ox-LDL	 IgG	 titres	 was	observed	 between	WT	 animals	 at	 any	 time	 point.	 In	 comparison,	MDA-Ox-LDL	 IgG	titres	 peaked	 in	 apoE-/-	 mice	 fed	 HFD	 mice	 for	 12	 weeks,	 with	 this	 peak	 being	significantly	 greater	 than	 titres	 observed	 at	 earlier	 time	points	 (4	weeks	post-diet)	(Fig	21).	Although	indifferent	to	levels	detected	in	apoE-/-	mice	fed	chow	diet,	apoE-/-	mice	 fed	 HFD	 at	 later	 time	 points	 (8	 week	 and	 12	 week	 post-diet)	 displayed	significantly	 enhanced	 serum	 MDA-Ox-LDL-IgG	 titres	 than	 their	 respective	 WT	controls	(Fig	21).		Remaining	low	throughout,	no	change	in	basal	MDA-Ox-LDL	IgG2c	titres	was	observed	in	WT	mice.	Although	not	reaching	significance,	an	increasing	trend	in	MDA-Ox-LDL-IgG2C	 titres	 in	apoE-/-	 chow	and	HFD	animals,	with	 titres	peaking	at	12	weeks	post-diet	(Fig	21).		WT	mice	displayed	a	decreasing	trend	in	MDA-Ox-LDL-IgG1titres	(Fig	21).	Although	following	a	similar	pattern,	no	change	in	MDA-Ox-LDL-IgG1	titres	in	apoE-/-	chow	or	HFD	fed	mice	was	detected	(Fig	21).					
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Figure	21:	Anti-MDA-Ox-LDL	antibodies	in	serum	of	mice	fed	diet	for	4,	8	and	12	
weeks	Microtitre	plates	were	coated	with	12.5	μg/ml	MDA-Ox-LDL	and	incubated	overnight	for	 4°C	 degrees.	 Serum	 samples	 from	mice	 fed	 chow	 (C57BL/6	WT	 and	 apoE-/-)	 or	HFD	 (apoE-/-)	 for	 4,	 8	 or	 12	 weeks	 were	 added	 and	 incubated	 overnight	 at	 4°C	degrees.	 IgM,	 IgG,	 IgG2c	 and	 IgG1	 antibody	 isotypes	 were	 detected	 using	 HRP	conjugated	antibodies	and	subsequent	incubation	with	TMB	substrate.	To	account	for	intra-plate	variation	in	OD	readings,	all	values	were	normalised	by	dividing	OD	values	with	 fixed	 an	 OD	 reading	 from	 C57BL/6	 serum	 present	 on	 each	 plate.	 Open	 bars	represent	C57BL/6	WT	mice	(n	=	5)	fed	chow	diet,	while	shaded	grey	and	black	bars	represent	apoE-/-	mice	fed	chow	(n	=	4	-5)	or	HFD	(n	=	4	-5),	respectively.	Statistical	analysis	was	performed	using	prism	graph	pad	and	by	conducting	a	one-way-ANOVA	with	a	post-hoc-tukey’s	test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001.						
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1.41.3 Summary	 of	 Antibody	 Titres	 in	 Experimental	
Atherosclerosis		In	 summary,	we	 have	 shown	 that	 anti-MDA-Ox-LDL	 serum	 antibody	 titres	 follow	 a	pattern	 in	 line	with	GC	B-cell	kinetics.	Specifically,	we	found	a	step	wise	 increase	 in	anti-MDA-Ox-LDL	 IgG2c	 titres	 in	 the	 serum	 of	 apoE-/-	 mice	 fed	 chow	 or	 HFD	 fed.	Coupled	with	this,	we	found	a	decreasing	trend	in	anti-MDA-Ox-LDL	serum	IgG1	titres	in	WT	and	apoE-/-	mice.	Interestingly,	we	found	no	variation	in	anti-MDA-Ox-LDL	IgM	serum	titres	in	all	groups. 																									
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 Histochemical	 Analysis	 of	 Tfh	 cell	 and	 GC	 B-cell	
Populations	
1.42.1 Qualitative	Assessment	of	Tfh	cell	Populations		As	 well	 as	 using	 flow	 cytometry	 based	 approaches,	 early	 studies	 employed	 IF	 to	visualise	 Tfh	 cell	 location	 and	marker	 expression	 ex	vivo	[44].	 Using	 this	 approach,	early	researchers	characterised	Tfh	cells	as	CD4+	T-cells	located	within	B-cell	follicles	[44].	 With	 this	 in	 mind,	 we	 used	 IF	 to	 obtain	 a	 qualitative	 assessment	 of	 Tfh	 cell	marker	 expression	 and	 anatomical	 location	 in	 the	 spleen	 of	mice	 fed	 chow	or	HFD	diet	for	12	weeks	(peak	of	Tfh	cell	response).			Using	 fluorochrome	 conjugated	 antibodies,	 we	 stained	 for	 CD4,	 B220,	 and	 Bcl-6.	Using	 this	 combination,	 Tfh	 cells	 were	 defined	 as	 CD4+	 Bcl-6+	 T-cells	 located	 in	B220+	 areas.	 Taken	 together,	 we	 determined	 whether	 Tfh	 cells	 observed	 via	 flow	cytometry	were	located	in	the	follicle.		
1.42.2 Spleen	Sections	from	WT,	apoE-/-	chow	and	apoE-/-	HFD	fed	
Mice	Show	Variable	Tfh	Marker	Expression	Patterns	Spleen	sections	from	WT	mice	fed	chow	diet	for	12	weeks	showed	little	CD4+	T-cell	infiltration	into	B220+	areas	(Fig	22).	Of	those	CD4+	T-cell	detected,	none	expressed	Bcl-6	 within	 their	 nuclei	 (Fig	 22).	 In	 contrast,	 we	 found	 that	 spleen	 sections	 from	apoE-/-	mice	fed	chow	diet	for	12	weeks	displayed	enhanced	CD4+	T-cell	 infiltration	into	 B220+	 areas	 (Fig	 22).	 Similar	 to	 WT	 mice,	 these	 migrating	 T-cells	 did	 not,	however,	express	Bcl-6	(Fig	22).		Interestingly,	 we	 found	 that	 spleen	 sections	 from	 apoE-/-	 mice	 fed	 HFD	 displayed	enhanced	 CD4+	 T-cell	 migration	 into	 B-cell	 follicles	 (Fig	 22).	 Most	 importantly,	migrating	T-cells	expressed	the	Tfh	cell	 transcription	factor	–	Bcl-6	–	 in	their	nuclei	(Fig	22	and	Fig	23).		
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Figure	 22:	 Qualitative	 analysis	 of	 Tfh	 cell	marker	 expression	 and	 anatomical	
location	in	spleen	of	mice	fed	diet	for	12	weeks	8	micron	thick	sections	from	mice	fed	chow	(C57BL/6	WT	and	apoE-/-)	or	HFD	(apoE-/-)	for	12	weeks	were	assessed	for	Tfh	cell	infiltration	into	B220+	B-cell	areas.	Tfh	cell	phenotype	 was	 determined	 by	 using	 anti-mouse-CD4	 and	 anti-mouse-Bcl-6.	Anatomical	 location	of	Tfh	cells	was	determined	by	 the	presence	of	CD4+	Bcl-6+	T-cells	in	B220+	B-cell	areas.	Images	were	acquired	using	the	X40	objective	of	the	LSM-510	 meta-confocal	 microscope.	 Bar	 =	 150	 μm.	 Final	 images	 were	 analysed	 using	volocity	image	analysis	software.			
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Figure	23:	Cellular	resolution	of	Bcl-6	expressing	Tfh	cells	 in	spleen	of	apoE-/-	
mice	fed	HFD	for	12	weeks	Spleen	sections	from	apoE-/-	mice	fed	HFD	were	assessed	for	Bcl-6	expression	in	the	nuclei	of	CD4+	T-cells.	Yellow	boxes	highlight	areas	containing	Bcl-6	expressing	CD4+	T-cells	 located	in	B220+	areas.	Images	were	acquired	using	the	X40	objective	of	the	LSM-510	meta-confocal	microscope.	Bars	=	150	μm.	Right	 image	shows	red	channel	removed	to	reveal	nuclear	expression	of	Bcl-6	in	CD4+	T-cells.	Bottom	panel	displays	high	magnification	images	(X63)	depicting	Bcl-6	(blue)	expression	in	nucleus	of	CD4+	T-cells	 (green)	 located	 in	 B220+	 areas.	 Final	 images	 were	 analysed	 using	 volocity	image	analysis	software.						
apoE%/%'HFD' CD4+'Bcl%6+'
B220$ CD4$ Bcl*6$
120		
	
1.42.3 Quantitative	Assessment	of	GC	Formation	Via	IF		Using	a	 similar	approach	as	described	above,	we	stained	spleen	sections	 from	mice	fed	chow	or	HFD	diet	for	4	weeks	were	assessed	for	GC	formation.	GCs	were	defined	as	PNA+	 cells	 located	 in	B220+	 areas.	Used	 as	 a	marker	 of	 germinal	 centre	B-cells,	PNA	binds	to	high	levels	of	galactosyl	residues	found	on	GC	B-cells	and	can	therefore	be	used	via	flow	cytometry	and	IF	to	identify	GC	B-cells	[227].	To	discriminate	B-cell	and	T-cell	areas,	the	T-cell	marker	CD4	was	included	in	the	staining	panel.	Using	this	approach,	we	determined	whether	GC	size	–	and	thus	antibody	producing	capacity	–	varied	between	groups.				
1.42.4 ApoE-/-	mice	 fed	HFD	for	4	weeks	Display	Larger	GCs	than	
C57BL/6	WT	Control	Mice		Few	and	small	PNA+	GCs	were	found	in	the	spleens	of	WT	mice	fed	chow	diet	for	4	weeks	 (Fig	 24A).	 Although	 increasing	 in	 size,	 no	 significant	 difference	 in	 GC	 size	between	WT	and	apoE-/-	mice	 fed	chow	diet	 for	 the	same	 length	of	 time	was	 found	(Fig	 24A	 and	 24B).	 Interestingly,	 apoE-/-	 mice	 fed	 HFD	 for	 4	 weeks	 displayed	significantly	larger	GCs	than	C57BL/6	WT	mice	(Fig	24A	and	24B).	This	increase	was,	however,	not	different	from	that	observed	in	apoE-/-	mice	fed	chow	diet	for	the	same	length	of	time	(Fig	24A	and	24B).												
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Figure	24:	Quantitative	analysis	of	GCs	in	spleen	sections	from	mice	fed	chow	or	
HFD	diet	for	4	weeks	Eight	micron	 thick	 sections	 from	mice	 fed	 chow	(C57BL/6	WT	and	apoE-/-)	or	HFD	(apoE-/-)	for	4	weeks	were	assessed	for	GC	formation.	GCs	were	determined	via	IF	by	using	 fluorochrome	 conjugated	 PNA	 and	 anti-mouse-CD4	 and	B220	 antibodies	 (A).	Images	 were	 acquired	 using	 the	 X40	 objective	 of	 the	 LSM-510	 meta-confocal	microscope	 and	 final	 images	were	 analysed	using	 volocity	 image	 analysis	 software.	Bars	=	150	μm.	Graph	 represents	 analysis	of	 spleen	area	 containing	PNA+	GCs	(B).	Statistical	 analysis	 was	 performed	 using	 GraphPad	 Prism	 and	 by	 conducting	 an	unpaired	student’s	t-test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001.								
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1.42.5 Summary	of	Tfh	cell	and	GC	B-cell	Profiles	Assessed	via	IF	In	summary,	we	have	shown	that	Tfh	cells	from	WT	and	apoE-/-	mice	(chow	and	HFD	fed)	 display	 the	 ability	 to	 translocate	 to	 B-cell	 rich	 areas	 in	 the	 spleen	 of	 mice.	Interestingly,	 although	 all	 groups	 display	 this	 ability,	 only	 apoE-/-	 mice	 fed	 HFD	display	 up-regulation	 of	 the	 Tfh	 cell	 transcription	 factor	 –	 Bcl-6.	 As	 such,	 our	 data	supports	 the	 notion	 that	 hyperlipidemia	 may	 drive	 bonafide	 Tfh	 cell	 marker	expression	in	vivo.		In	 addition	 to	 this,	 we	 have	 demonstrated	 that	 apoE-/-	 mice	 fed	 HFD	 display	significantly	larger	GCs	than	WT	mice.	As	such,	our	data	suggests	that	apoE-/-	mice	fed	HFD	may	display	enhanced	capacity	for	antibody	production	in	vivo.																							
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 Discussion	
1.43.1 Summary	of	Aims	and	Objectives	As	part	of	 this	chapter,	we	aimed	to	assess	whether	Tfh	cell	and	GC	B-cell	numbers	changed	 in	 line	 with	 atherosclerosis	 formation	 in	 hyperlipidemic	 apoE-/-	mice.	 We	also	 determined	 whether	 variations	 in	 Tfh	 cell	 and	 GC	 B-cell	 populations	 had	 an	impact	on	 the	production	of	high	affinity,	 isotype	switched	antibodies.	Using	 IF,	we	studied	whether	GC	size	varied	between	groups	and	if	Tfh	cells	were	distinguishable	via	marker	expression	and	anatomical	location.	
1.43.2 Summary	 of	 Findings	 -	 Tfh	 cell,	 GC	 B-cell	 and	 Antibody	
Titres	 Increase	 in	 Line	 with	 Hyperlipidemia	 and	
Atherosclerosis	Severity	Using	surface	 flow	cytometry	staining	we	found	that	apoE-/-	mice	HFD	for	extended	periods	of	 time	 (12	weeks)	displayed	significantly	enhanced	Tfh	cell	populations	 in	all	 organs	 assessed	 (pLNs,	 spleen	 and	 pao-LNs).	 Confirming	 an	 effect	 due	 to	hyperlipidemia	-	and	not	age	-	we	found	little	variation	in	Tfh	cell	percentages	–	in	all	compartments	–	in	WT	and	apoE-/-		mice	fed	chow	diet	at	all	time	points.			Interestingly,	 the	percentage	of	GC	B-cells	 in	apoE-/-	chow	and	apoE-/-	HFD	 fed	mice	peaked	at	4	weeks	post-diet,	in	all	organs	assessed.	Again,	indicative	of	the	effects	of	hyperlipidemia	and	disease	progression,	few	GC	B-cells	were	detectable	in	the	organs	of	WT	mice	fed	chow	diet	at	all	time	points.			Linking	both	Tfh	cell	and	GC	B-cell	kinetics,	we	 found	that	apoE-/-	chow	and	apoE-/-	HFD	 fed	mice	displayed	an	 increasing	 trend	 in	anti-MDA-Ox-LDL	 IgG2C	serum	 titres,	peaking	at	the	12-week	time	point.		Using	IF,	we	found	that	apoE-/-	mice	fed	HFD	displayed	significantly	larger	GCs	than	WT	and	apoE-/-	mice	fed	chow	diet.	Along	with	their	 location	in	B-cell	areas,	apoE-/-	mice	 fed	 HFD	 comprised	 the	 sole	 group	 that	 expressed	 bonafide	 Tfh	 cell	 markers	(CD4+	and	Bcl-6).			
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Taken	 together,	we	 have	 provided	 evidence	 that	 indicates	 that	 Tfh	 cells	 and	GC	B-cells	 follow	 a	 pattern	 in	 line	 with	 atherosclerosis	 progression.	 Moreover,	 we	 have	demonstrated	 that	 severe	 hyperlipidemia	 functions	 as	 an	 important	 cue	 in	 the	induction	 of	 Tfh	 cell	 and	 antibody	 responses.	 As	well	 as	 this,	 we	 have	 shown	 that	hyperlipidemia	is	required	for	the	optimal	expression	of	Bcl-6	in	bonafide	Tfh	cells.			
1.43.3 T-follicular	Helper	Cells	Represent	a	Significant	Population	
in	other	Autoimmune	Conditions	Supporting	the	pro-inflammatory	nature	of	atherosclerosis,	hyperlipidemia	is	 linked	to	 the	 expansion	 of	 various	 inflammatory	 immune	 cell	 subsets,	 including	 CD4+	 T-cells,	 B-cells,	 macrophages	 and	 neutrophils	 [228-230].	 	 Adding	 to	 this,	 we	 have	demonstrated	that	Tfh	cell	and	GC	B-cells	also	increase	in	line	with	hyperlipidemia.		As	such,	we	hypothesise	that	hyperlipidemia	comprises	an	important	driving	force	in	the	development	of	Tfh	cells	and	GC	B-cells	in	experimental	atherosclerosis	and	that	the	 Tfh	 cell	 /	 GC	 B-cell	 axis	 –	 via	 antibody	 production	 -	 may	 be	 important	 in	 the	development	of	experimental	atherosclerosis.			In	line	with	our	findings,	others	investigating	the	role	of	the	Tfh	cell	/	GC	B-cell	axis	in	autoimmunity	have	reported	similar	results	to	ours.	In	particular,	elevated	numbers	of	Tfh	cells	can	be	 identified	 in	the	blood	of	both	rheumatoid	arthritis	and	systemic	lupus	erythematosus	sufferers	[165,	231].	Interestingly,	Tfh	cells	have	been	identified	in	the	inflamed	joints	in	patients	with	RA	[232].	Moreover,	both	RA	and	SLE	sufferers	show	 significantly	 elevated	 blood	 concentrations	 of	 the	 Tfh	 cell	 cytokine	 -	 IL-21;	 a	finding	that	correlates	with	disease	severity	and	antibody	load	[233].	Underlining	the	role	 of	 Tfh	 cells	 in	 autoimmunity,	 patients	 treated	 with	 the	 anti-arthritic	 drugs,	methotrexate	 or	 methotrexate	 and	 sulfasalazine,	 display	 reduced	 serum	 IL-21	concentrations	along	with	reduced	disease	severity	[233].			Importantly,	we	have	demonstrated	that	Tfh	cell	kinetics	also	follow	a	pattern	in	line	with	 atherosclerosis	 progression.	 It	 is	 therefore	 plausible	 that	 Tfh	 cells	 may	 be	important	role	in	modulating	the	atherogenic	immune	response	in	atherosclerosis.	As	
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such,	 Tfh	 cells	 may	 hold	 potential	 as	 therapeutic	 targets	 for	 the	 modulation	 of	atherosclerosis	formation	in	vivo.																													
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1.43.4 T-follicular	 Helper	 Cell	 Expression	 in	 Atherosclerosis	 is	
Consistent	with	that	from	Published	Studies		Much	 of	 what	 researchers	 know	with	 regards	 to	 Tfh	 cell	 kinetics	 has	 been	 gained	from	 studies	 using	 infection	 models	 [214,	 221,	 222,	 234-237].	 Given	 this,	 using	published	marker	combinations,	we	have	demonstrated	that	Tfh	cell	profiles	found	in	our	studies	share	similarities	with	those	reported	in	such	studies.	In	particular,	Bcl-6	–	the	implicated	transcription	factor	of	Tfh	cells	–	is	required	for	the	up-regulation	of	various	 Tfh	 cell	molecules	 and	 as	 such	 is	 important	 to	 Tfh	 cell	 function	 [221].	We	detected	 Bcl-6	 expression	 solely	 in	 the	 spleen	 of	 apoE-/-	 mice	 with	 severe	hyperlipidemia	(12	week	HFD),	 thus	suggesting	the	need	for	hyperlipidemia	 for	the	induction	of	Tfh	transcripts.		Used	 as	 a	 common	 method	 to	 induce	 Tfh	 cell	 formation,	 immunization	 induces	profuse	Tfh	cell	differentiation	in	an	antigen	dependent	manner.	Importantly,	as	part	of	our	study	we	used	no	infection	or	immunization	to	induce	Tfh	cell	formation.	Our	sole	atherogenic	stimulus	was	HFD	fed	to	mice	ad	libitum,	leading	to	increased	levels	of	 circulating	 antigens	 (such	 as	 Ox-LDL)	 overtime	 [238].	 The	 finding	 that	 natural	pathological	 progression	 is	 sufficient	 to	 drive	 Tfh	 cell	 differentiation	 indicates	 a	potential	 involvement	of	Tfh	cells	 in	atherosclerosis	formation	and	development.	As	such,	 the	 mechanisms	 by	 which	 Tfh	 cells	 may	 modulate	 atherosclerosis	 merit	significant	attention.													
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1.43.5 T-follicular	 Helper	 Cells	 Regulate	 the	 Germinal	 Centre	
Reaction	and	Antibody	Production	in	vivo	We	 propose	 that	 Tfh	 cells	 represent	 an	 important	 subset	 that	 regulates	 pro-atherogenic	antibody	responses	in	vivo.	We,	therefore,	hypothesise	that	Tfh	cells	and	GC	B-cells	from	HFD	fed	apoE-/-	mice	expand	in	response	to	cognate	antigen	(oxidised	LDL),	resulting	in	elevated	pro-atherogenic	serum	antibody	titres.			Supporting	 our	 findings,	 anti-Ox-LDL	 IgG2c	 antibodies	 have	 been	 suggested	 as	important	 mediators	 in	 the	 pro-atherogenic	 immune	 response	 [120].	 Moreover,	depletion	 of	 B2	 cells,	 responsible	 for	 IgG	 production,	 significantly	 attenuates	atherosclerosis	formation	in	vivo	[120,	239,	240].	Interestingly,	and	of	importance	to	Tfh	cell	kinetics,	loss	of	B2	cells	also	significant	reduces	CD4+	T-cell	proliferation	and	differentiation	 [240].	 However	 the	 role	 of	 Tfh	 cells	 in	 this	 context	 has	 not	 been	addressed.		In	 our	 hands,	 we	 found	 that	 anti-MDA-Ox-LDL	 IgG2C	 antibodies	 peak	 at	 advanced	stages	 of	 atherosclerosis,	 concomitantly	 when	 CXCR5+	 PD-1hi	 Bcl-6+	 Tfh	 cell	populations	 peak.	 It	 is	 therefore	 plausible	 that	 following	 elevated	 serum	hyperlipidemia,	 bonafide	 CXCR5+	 Bcl-6+	 Tfh	 cells	 facilitate	 the	 production	 of	enhanced	 anti-Ox-LDL	 IgG2C	antibodies.	 Comprising	 a	 functional	 outcome	 of	 the	 GC	reaction,	 these	Ox-LDL	specific	 IgG2C	antibodies	 function	 to	enhance	atherosclerosis	progression.		Further	 supporting	 the	 role	 of	 Tfh	 cells	 in	 atherosclerosis,	 CXCL13	 -	 the	 ligand	 for	membrane	 bound	 CXCR5	 –	 is	 highly	 expressed	 in	 aortic	 tertiary	 lymphoid	 organs	(ATLO)	 of	 aged	 atherosclerotic	 mice,	 as	 well	 as	 in	 human	 plaques	 [45,	 241].	Specifically,	loss	of	CXCL13	-	CXCR5	interactions	attenuates	atherosclerosis	formation	in	LDLR-/-	mice,	although	the	contributing	role	of	Tfh	cells	to	this	finding	has	not	been	addressed.	 Confirming	 our	 findings,	 recent	 published	 data	 has	 reported	 findings	correlating	with	those	described	in	chapter	2.	Specifically,	Clement	et	al	reported	an	increasing	 trend	 in	 Tfh	 cell	 kinetics,	 in	 line	 with	 pathology	 in	 an	 animal	 model	 of	atherosclerosis.	 Indicating	 a	 potential	 role	 of	 Tfh	 cells	 in	 regulating	 antibody	responses,	the	role	of	Tfh	cells	in	atherosclerosis	merits	significant	attention.	
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1.43.6 Summary	of	Findings		
• Tfh	 cell	 expression	 follows	 a	 pattern	 in	 line	with	 the	 development	 of	 advanced	atherosclerosis		
• Hyperlipidemia	functions	to	drive	bonafide	Tfh	cell	formation		
• GC	B-cell	expression	increases	in	line	with	atherosclerosis	formation			
• Antibody	titres	to	MDA-Ox-LDL	follow	Tfh	cell	and	GC	B-cell	kinetics				
1.43.7 Concluding	Remarks		In	combination,	we	have	provided	data	to	support	the	significant	involvement	of	Tfh	cells	 in	 atherosclerosis.	 We	 have	 demonstrated	 that	 hyperlipidemia	 functions	 as	 a	driving	 force	 for	 the	 formation	 of	 such	 cells	 and	 their	 actions	may	be	 important	 in	regulating	pro-atherogenic	antibody	responses	in	vivo.		To	 report	 with	 certainty	 that	 Tfh	 cells	 are	 important	 in	 atherosclerosis,	 one	 must	modulate	 their	 function	 in	 vivo.	 To	 address	 this	 issue,	 chapter	 5	 describes	 the	development	 of	 a	 chimeric	 mouse,	 in	 which	 Tfh	 cell	 development	 is	 impaired	 by	ablation	of	IL-21R	in	hyperlipidemic	LDLR-/-	mice.																 	
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Chapter	 4:	 Elucidating	 the	 Role	 of	
Apolipoprotein-E	in	Adaptive	Immunity			
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 Introduction		
1.44.1 Apolipoproteins	 –	 Multifunctional	 Proteins	 Involved	 in	
Lipid	Metabolism	Apolipoproteins	(apo)	represent	a	class	of	proteins	involved	in	lipoprotein	transport,	lipid	 clearance	 and	 enzyme	 activation	 [19,	 242].	 Synthesised	 in	 the	 liver	 and	intestines,	 apolipoproteins	 are	 important	 to	 the	 homeostatic	 balance	 of	 plasma	lipoproteins	 in	 vivo	 [242].	 Embedded	 in	 the	 surface	 of	 lipoprotein	 molecules	 -	composed	of	triglycerides,	cholesterol	esters,	and	phospholipids	-	apolipoproteins	are	fundamental	to	the	movement	of	otherwise	immiscible	lipid	molecules	[19].	As	a	class	of	 proteins,	 apolipoproteins	 are	 subdivided	 into	 9	 different	 subclasses,	 all	 with	varying	 functions	 in	 lipid	 transport	 and	 metabolism.	 Designated,	 apoA(I-IV),	apoB100,	apoB48,	apoC(I-III),	apoD,	apoE(I-IV),	apoF,	apoG	and	apoH,	these	isoforms	are	 comprised	 at	 varying	 degrees	 in	 different	 lipoproteins	 [243].	 To	 date,	 several	factors	 have	 been	 implicated	 in	 the	 dynamic	 regulation	 of	 plasma	 apolipoproteins,	including	race,	sex	and	genetic	predisposition	[243].		As	part	of	this	 introduction,	the	role	of	apolipoproteins	will	be	discussed.	Particular	focus	 will	 be	 given	 to	 apoE	 and	 its	 role	 in	 pathology	 and	 immunity,	 as	 well	 as	 its	emerging	roles	in	other	conditions.			The	aim	of	the	current	chapter	was	to	investigate	whether	elevated	Tfh	cell	and	GC	B-cell	 populations	 observed	 in	 apoE-/-	 HFD	 fed	 mice	 (chapter	 2)	 was	 the	 result	 of	disease	progression	or	the	effects	of	apoE	ablation.										
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1.44.2 Apolipoproteins	 and	 Their	 Multifunctional	 Role	 in	
Lipoprotein	Homeostasis		Apolipoproteins	 are	 intimately	 associated	 with	 spherical	 structures	 termed	lipoproteins	 [19].	 Composed	 of	 apolipoproteins,	 triglycerides,	 cholesterol	 and	phospholipids,	 plasma	 lipoproteins	 can	 be	 classified	 into	 6	 broad	 groups	 based	 on	their	 physical	 properties	 when	 separated	 via	 ultracentrifugation	 [19].	 Classed	 as,	chylomicrons	(CM),	VLDL,	IDL,	LDL	and	HDL,	lipoproteins	are	highly	dynamic	and	in	many	cases	readily	convert	from	one	form	to	the	other	[19].			In	testament	to	the	dynamic	regulation	of	 lipoproteins	and	the	multi-functional	role	of	apolipoproteins,	VLDL	is	converted	to	LDL	via	the	enzyme	activating	properties	of	apoCI	 and	 apoCII.	 Specifically,	 apoCII	 activates	 lipoprotein	 lipase	 -	 an	 enzyme	involved	 in	 triglyceride	 hydrolysis	 -	 thus	 yielding	 free	 fatty	 acids	 for	 use	 in	 energy	metabolism	 [19,	 244].	 Alongside	 this,	 apoCI	 induces	 lecithin	 cholesterol	acyltransferase	(LCAT)	activation,	resulting	 in	enhanced	cholesterol	ester	 formation	from	 free	cholesterol	 [242,	245].	As	a	 consequence,	VLDL	molecules	 transform	 into	LDL	molecules	via	transitional	ILDL	molecules.	The	smallest	of	all	 lipoproteins,	HDL	particles	measure	 from	120	-	70Å	in	diameter	[19].	Unlike	chylomicrons,	VLDL,	 IDL	and	LDL,	which	 transport	 triglycerides	and	cholesterol	 to	 tissues	 for	use	 in	 cellular	processes,	HDL	particles	remove	excess	cholesterol	from	tissues	for	excretion	in	the	bile	 [246].	Surface	embedded	apolipoproteins	are	 fundamental	 to	HDL	functions.	Of	particular	 importance	 to	 HDL,	 apoA1	 proteins	 facilitate	 a	 process	 termed	 reverse	cholesterol	 transport,	 in	which	 cholesterol	 is	 removed	 from	 peripheral	 tissues	 and	transported	to	the	liver	[246].						
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1.44.3 Apolipoprotein-E	–		Function	in	Health	and	Disease		ApoE	 has	 gained	 significant	 attention	 in	 modulating	 plasma	 lipid	 levels	 and	subsequent	plaque	formation	[247].	As	such,	this	section	will	discuss	the	role	of	apoE	in	modulating	disease	and	the	immune	response.		ApoE	 is	 an	 arginine	 rich	 apolipoprotein	 that	 forms	 an	 integral	 component	 of	many	plasma	 lipoproteins	 [248].	 Three	 apoE	 isoforms	 have	 been	 characterised,	 termed	apoE2	(E2),	apoE3	(E3),	and	apoE4	(E4)	[249],	all	with	varying	affinity	for	LDLRs	and	receptors	 located	 on	 chylomicron	 remnants.	 Interestingly,	 unlike	 other	apolipoproteins,	 apoE	 is	 produced	 widely	 throughout	 the	 body.	 Specific	 areas	 of	production	include,	the	brain,	spleen,	kidneys,	smooth	muscle	cells	and	ovaries	[250].	Due	to	its	affinity	for	LDLRs	in	the	liver,	apoE	plays	an	important	role	in	endocytosis-mediated	metabolism	of	LDL	and	chylomicron	remnants	in	the	liver	[251].		Due	 to	 its	 fundamental	 role	 in	 the	 lipid	 metabolism,	 apoE	 has	 been	 linked	 to	 the	progression	of	CVD	and	in	particular	atherosclerosis.	Individuals	with	the	hereditary	condition	 familial	 dysbetalipoproteinemia	 -	 in	which	 apoE2	 synthesis	 is	 defective	 -	display	defective	lipid	clearance	and	enhanced	atherosclerosis	formation	[252,	253].	Highlighting	the	role	of	apoE	in	lipid	regulation,	selective	knock-out	of	apoE	protein	in	 rodents	 has	 formed	 the	 basis	 of	 the	 apoE	 knock	 out	 mouse	 model	 of	atherosclerosis	 [254,	 255].	 ApoE-/-	mice	 display	 elevated	 plasma	 cholesterol	 levels	compared	 to	 wild	 type	 C57BL/6	mice	 [59].	 Due	 to	 the	 absence	 of	 functional	 apoE	proteins	 –	 and	 hence	 apoE	 mediated	 cholesterol	 clearance	 -	 cholesterol	 remnants	accumulate	 in	 the	 circulation	 of	 apoE-/-	 mice.	 As	 a	 result,	 apoE-/-	 mice	 develop	widespread	 atherosclerotic	 lesions,	with	many	 aspects	 of	 human	 disease,	 including	inflammatory	cell	 involvement	[256].	As	such,	 the	apoE-/-	mouse	model	has	become	the	gold	standard	animal	model	of	atherosclerosis.	In	particular,	and	relevant	to	this	thesis,	 apoE-/-	 mice	 have	 been	 used	 to	 characterise	 the	 pro-atherogenic	 role	 of	various	immune	cells,	including	T-cells,	B-cells,	and	dendritic	cells	[81,	120,	156,	257,	258].			
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Interestingly,	independent	of	its	role	in	atherosclerosis,	apoE	has	been	implicated	in	the	 development	 of	 neurological	 conditions,	 specifically	 Alzheimer’s	 disease	 (AD)	[259].	 Particularly,	 the	 E4	 isoform	 is	 a	 recognised	 major	 risk	 factor	 for	 the	development	of	AD	[260].	Recent	data	have	indicated	that	E4	functions	to	accelerate	the	 formation	 of	 pathological	 alpha-beta	 amyloid	 structures	 in	 the	 brain	 [261].	Intriguingly,	unlike	E4,	E2	and	E3	are	believed	to	convey	neuro-protective	functions	[261].	 Loss	 of	 E2	 receptors	 of	 very	 low	 density	 lipoprotein	 receptors	 (VLDLr)	 is	believed	 to	 impair	 the	 function	 of	 Reelin	 –	 a	 neuroprotective	 protein	 involved	 in	neuron	plasticity	[262].																										
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1.44.4 Apolipoprotein-E	(apoE)	–	Roles	in	Immunity	Independent	 of	 its	 role	 in	 lipid	 homeostasis	 and	 neurobiology,	 apoE	 has	 been	implicated	 as	 a	 modulator	 of	 peripheral	 inflammation.	 Interestingly,	 apoE-/-	mice	show	 increased	 susceptibility	 to	a	 range	of	bacterial	 infections	 that	 readily	develop	into	 sepsis	 [263-265].	 Underlining	 a	 role	 of	 apoE	 in	 inflammation,	 apoE	 has	 been	shown	to	bind	lipopolysaccharide	(LPS)	from	gram-negative	bacteria	and	re-direct	it	to	 the	 liver	 for	excretion	 in	bile	 [266].	Due	 to	 the	absence	of	 this	process	 in	apoE-/-	mice,	 systemic	 LPS	 levels	 increase,	 resulting	 in	 cellular	 activation	 and	 secretion	 of	pro-inflammatory	 cytokines.	Although	all	 lipoprotein	 classes	 are	 capable	of	 binding	endotoxin	products	[267-272],	an	approximate	8-fold	increase	in	VLDL	levels	in	apoE-/-	 mice	 is	 insufficient	 to	 protect	 against	 sepsis,	 thus	 reinforcing	 the	 importance	 of	apoE	in	LPS	removal.		Using	 in	 vitro	 approaches,	 early	 researchers	 identified	 apoE’s	 particular	 ability	 to	control	 lymphocyte	 expansion,	 cytolytic	 T-cell	 formation	 and	 neutrophil	 activation	[273-277].	 Reinforcing	 the	 role	 of	 apoE	 to	 these	 processes,	 other	 apolipoproteins	failed	to	modulate	lymphocyte	activity	[275].	In	context	of	T-cell	immunity,	apoE	has	been	 reported	 to	 inhibit	 CD4+	 and	 CD8+	 T-cell	 proliferation	 in	 vitro	 [274,	 275].	Providing	a	plausible	explanation	for	these	findings,	some	have	suggested	that	apoE	restricts	the	availability	of	bioactive	IL-2	and	IL-2R	[274,	275].	As	well	as	affecting	IL-2	mediated	pathways,	apoE	has	been	shown	to	significantly	inhibit	also	IL-4	induced	proliferation	 of	 lymphocytes	 [274].	 Suggesting	 the	 involvement	 of	 a	 non-specific	pathway,	 apoE	 has	 been	 shown	 to	 inhibit	 IL-2	 /	 IL-4	 induced	 proliferation	 by	preventing	G1	cell	cycle	processes	[274].		Taken	together,	 these	studies	highlight	the	pleotropic	actions	of	apoE.	As	such,	they	reinforce	 the	 notion	 that	 apoE	 is	 important	 in	 controlling	 several	 aspects	 of	peripheral	inflammation.		Interestingly,	 some	have	provided	 evidence	 indicating	 the	potential	 role	 of	 apoE	 in	regulating	T-cell	and	APC	interactions	[278].	Specifically,	 in	comparison	to	WT	cells,	macrophages	from	apoE-/-	mice	injected	i.p.	with	IFN-Υ	show	enhanced	ability	to	up-regulate	CD40,	 CD80	and	MHC-II	 [278].	 Important	 for	 the	 initial	 priming	of	T-cells,	
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these	 molecules	 provide	 co-stimulation	 and	 TCR	 stimulation	 of	 T-cells.	 Due	 to	 the	enhanced	 expression	 of	 such	markers	 in	 the	 absence	 of	 apoE,	 researchers	 indicate	that	apoE	may	function	to	regulate	initial	T-cell	–	APC	interactions	in	vivo	[278].		Macrophages	 represent	 a	 major	 cell	 type	 involved	 in	 apoE	 protein	 synthesis.	 Of	specific	 importance	 to	atherosclerosis,	 arterial	macrophages	and	 foam	cells	express	copious	amounts	of	apoE	[279].	Underlining	the	role	of	apoE	in	macrophage	function	and	 atherogenesis,	 loss	 of	 apoE	 expression	 in	 macrophages	 significantly	 enhances	lesion	 formation	 [279].	 Conversely,	 enhanced	 expression	 of	 macrophage	 apoE	reduces	many	aspects	of	the	pro-atherogenic	immune	response	[247].	Adding	further	to	 this,	 others	 have	 shown	 the	 ability	 of	 apoE	 to	 induce	 an	 anti-inflammatory	 M2	phenotype	over	an	M1	pro-inflammatory	phenotype	[280].	Translated	in	vivo,	apoE-/-	mice	 transplanted	 with	 apoE+/+	bone	 marrow	 display	 a	 significant	 increase	 in	 the	number	of	peritoneal	M2	macrophages	[280].	Underlining	the	protective	role	of	apoE	in	atherosclerosis,	 apoE	expression	 in	LDLR-/-	has	been	 linked	 to	enhanced	apoA1+	HDL	expression,	reduced	adhesion	molecule	expression	and	reduced	monocyte	lipid	content	[247].		Taken	together,	 the	studies	described	above	provide	strong	evidence	 for	 the	role	of	apoE	 in	 regulating	 various	 aspects	 of	 both	 adaptive	 and	 innate	 immunity.	 Of	relevance	to	this	thesis,	they	also	provide	evidence	that	modulation	of	such	processes	may	affect	disease	progression.			As	part	of	chapter	3,	we	used	the	apoE-/-	mouse	model	to	study	Tfh	cell,	GC	B-cell	and	antibody	kinetics	in	context	of	hyperlipidemia.	As	discussed	above,	loss	of	functional	apoE	 protein	 can	 affect	 immune	 cell	 function	 and	 subsequent	 pathological	involvement.	Therefore,	to	determine	whether	loss	of	apoE	protein	affected	adaptive	immunity,	we	assessed	cell	populations	in	C57BL/6	WT	and	apoE-/-	mice	immunized	sub	 cutaneous	 (s.c.)	 with	 OVA	 emulsified	 in	 CFA	 and	 flow	 cytometry	 of	 dLNs	conducted	9	days	later.				
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1.44.5 Aims	1. Determine	whether	immunized	C57BL/6	WT	and	apoE-/-	mice	displayed	variable	CD4+	T-cell	and	B220+	B-cell	populations;	2. Assess	whether	CD4+	T-cell	activation	(CD44)	varied	between	immunised	groups;	3. Study	if	apoE	deficiency	affected	CXCR5	expression	on	CD4+	and	CD4+	CD44hi	T-	cells;	4. Determine	whether	loss	of	apoE	affected	Tfh	cell	and	GC	B-cell	formation.																										
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 Results	
In	 chapter	 2	 we	 used	 the	 apoE-/-	 mouse	 model	 to	 study	 Tfh	 cell,	 GC	 B-cell	 and	antibody	kinetics	in	context	of	hyperlipidemia.	Using	this	approach,	we	found	that	Tfh	cell,	 GC	B-cell	 and	 antibody	 kinetics	 followed	 a	 pattern	 in	 line	with	 atherosclerosis	progression.	As	such,	we	attributed	a	potential	role	of	the	Tfh	cell	 :	GC	B-cell	axis	in	atherosclerosis.			Independent	of	its	role	in	atherosclerosis,	some	have	suggested	that	loss	of	apoE	may	significantly	affect	the	immune	response	[247,	249,	274,	275,	277,	278,	280,	281].	To	ensure	the	results	obtained	in	chapter	2	were	a	result	of	disease	progression,	and	not	a	consequence	of	apoE	deficiency,	we	characterised	T-cell	and	B-cell	populations	 in	C57BL/6	 WT	 and	 apoE-/-	 mice	 immunized	 with	 OVA	 in	 CFA.	 Used	 commonly	throughout	the	literature	as	a	means	of	inducing	a	thymus	dependent	T-cell	response,	OVA	 /	 CFA	 injection	 induces	 enhanced	 T-cell	 proliferation	 in	 an	 antigen	 specific	manner	 [235,	 237,	 282].	 As	 such,	 we	 were	 able	 to	 characterise	 the	 differences	 in	adaptive	immune	responses	between	C57BL/6	WT	and	apoE-/-	mice.			As	part	of	this	chapter,	we	phenotyped	various	cell	types	in	the	draining	lymph	nodes	of	immunized	C57BL/6	WT	and	apoE-/-	mice.	As	this	thesis	is	focused	on	the	Tfh	cell	:	GC	B-cell	axis,	particular	attention	was	given	to	the	phenotyping	Tfh	cells	and	GC	B-cells.	Table	2	below	summarises	the	populations	assessed	via	flow	cytometry.												
138		
								
Table	 2:	 Adaptive	 Immune	 Cells	 Characterised	 in	 C57BL/6	 WT	 and	 apoE-/-	
Immunized	s.c.	with	OVA	/	CFA	Using	 flow	 cytometry	 staining,	 adaptive	 immune	 cells	 were	 phenotyped	 in	 the	draining	 lymph	nodes	of	C57BL/6	WT	and	apoE-/-	mice	 immunized	s.c.	with	100	µg	OVA	emulsified	in	100	µl	CFA.																						
Cell$Population$Phenotyped$$ Marker$Combination$$
T"cells' CD4+$
B"cells' B220+$
Activated'T"cells' CD4+$CD44hi$
'
T/h'cells''
CD4+$CXCR5+$ICOS+$CD4+$CXCR5+$PDA1+$$CD4+$CXCR5+$BclA6+$$CD4+$CD44hi$CXCR5+$ICOS+$CD4+$CD44hi$CXCR5+$PDA1+$CD4+$CD44hi$CXCR5+$BclA6+$
GC'cells' B220+$PNA+$FAS+$
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 Effects	of	apoE	deficiency	on	Adaptive	Immune	Cells	
1.46.1 Apolipoprotein-E	 Deficiency	 does	 not	 Affect	 CD4+	 T-cell	
and	B220+	B-cell	Responses	in	vivo	As	 part	 chapter	 2,	 variations	 in	 the	 expression	 of	 Tfh	 cells	 and	GC	B-cells	 between	C57BL/6	WT	and	apoE-/-	mice	 fed	diet	 for	varying	 lengths	of	 time	was	assessed.	To	phenotype	these	cells,	Tfh	cells	were	first	gated	for	on	a	CD4+	pre-gate	and	GC	B-cells	were	gated	for	on	a	B220+	pre-gate.	To	determine	whether	loss	of	apoE	significantly	altered	the	expression	of	CD4+	and	B220+	cells,	flow	cytometry	was	used	to	stain	for	CD4+	T-cells	and	B220+	B-cells	in	the	draining	lymph	nodes	of	mice	immunized	with	OVA	/	CFA.			No	difference	 in	 the	percentage	of	B220+	B-cells	between	C57BL/6	WT	and	apoE-/-	mice	 (25.02	%	 -	 vs	 -	27.60	%)	 immunized	 s.c.	with	OVA	/	CFA	 (Fig	25)	was	 found.	Coupled	 with	 this,	 little	 variation	 in	 the	 percentage	 of	 CD4+	 T-cells	 between	immunized	C57BL/6	WT	and	apoE-/-	mice	(29.16	%	-	vs	–	26.28	%)	was	 found	(Fig	25).											 	 						
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Figure	25:	Flow	cytometry	analysis	of	B220+	B-cell	and	CD4+	T-cell	populations	
in	 the	draining	 lymph	nodes	of	C57BL/6	WT	and	apoE-/-	mice	 immunized	S.C.	
with	OVA	/	CFA	Two	groups	 of	mice	 [C57BL/6	WT	 (n	=	 6)	 and	 apoE-/-	(n	 =6)]	were	 immunized	 s.c.	with	100	µg	of	OVA	emulsified	in	100	µl	of	CFA.	Nine	days	after	immunization,	dLNs	(axillary	 and	 brachial)	 were	 dissected	 and	 prepared	 for	 surface	 flow	 cytometry	staining.	Lymphocytes	were	gated	for	on	the	basis	of	FSC	and	SSC.	Using	these	gates,	CD4+	 T-cell	 and	 B220+	 B-cell	 expression	 was	 assessed.	 Statistical	 analysis	 was	performed	using	GraphPad	Prism	and	an	unpaired	students	t-test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001.																								
141		
1.46.2 Apolipoprotein-E	 Deficiency	 Significantly	 Enhances	 CD4+	
CD44hi	T-cell	Responses	in	vivo	As	well	as	using	CD4	to	pre-gate	Tfh	cells,	a	CD4+	CD44hi	pre-gate	was	also	included	(gating	strategy	2)	(see	chapter	3).	Therefore,	as	part	of	chapter	4,	the	effect	of	apoE	deficiency	on	CD4+	CD44hi	T-cell	 expression	 in	C57BL/6	WT	and	apoE-/-	mice	was	also	 determined.	 In	 comparison	 to	 C57BL/6	 WT	 mice,	 apoE-/-	 mice	 displayed	 a	significant	increase	in	the	percentage	of	CD4+	CD44hi	cells	in	the	brachial	and	axillary	lymph	nodes	9	days	after	immunization	(16.13	%	-	vs	-	18.92%)	(Fig	26).																							
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Figure	 26:	 Flow	 cytometry	 analysis	 of	 CD4+	 CD44hi	 T-cell	 populations	 in	 the	
draining	lymph	nodes	of	C57BL/6	WT	and	apoE-/-	mice	immunized	s.c.	with	OVA	
/	CFA	Two	groups	 of	mice	 [C57BL/6	WT	 (n	=	 6)	 and	 apoE-/-	(n	 =6)]	were	 immunized	 s.c.	with	 100	 µg	 of	 OVA	 emulsified	 in	 100	 µl	 of	 CFA.	 9	 days	 after	 immunization,	 dLNs	(axillary	 and	 brachial)	 were	 dissected	 and	 prepared	 for	 surface	 flow	 cytometry	staining.	Lymphocytes	were	gated	for	on	the	basis	of	FSC	and	SSC	parameters.	Using	these	gates,	CD4+	T-cells	were	selected,	upon	which	CD44hi	expression	was	assessed.	Statistical	analysis	was	performed	using	GraphPad	Prism	and	an	unpaired	students	t-test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001.			
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1.46.3 Summary	of	 the	Effects	 of	Apolipoprotein-E	Deficiency	on	
CD4+	T-cell,	B220+	B-cell	and	CD4+	CD44hi	Populations	Taken	together,	our	data	indicates	that	apoE	deficiency	does	not	affect	the	percentage	of	 CD4+	 T-cells	 and	 B220+	 B-cells	 in	 vivo.	 In	 comparison	 to	 this,	 our	 data	 also	suggests	that	apoE	deficiency	results	in	the	enhanced	ability	to	up-regulate	CD44	on	CD4+	T-cells	while	supressing	GC	B-cell	expression.																					
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 Effects	of	apoE	Deficiency	on	Tfh	Cell	Populations	
1.47.1 Apolipoprotein-E	Deficiency	Does	not	Affect	CD4+	CXCR5+	
ICOS+,	 CD4+	 CXCR5+	 PD-1+	 or	 CD4+	 CXCR5+	 Bcl-6+	 Tfh	 Cell	
Populations	in	vivo	In	 chapter	 2,	 we	 studied	 Tfh	 cell	 kinetics	 in	 apoE-/-	 mice	 with	 varying	 degrees	 of	hyperlipidemia.	As	such,	we	determined	whether	Tfh	cell	kinetics	followed	a	pattern	in	 line	 with	 atherosclerosis	 progression.	 In	 this	 chapter,	 we	 aimed	 to	 determine	whether	loss	of	apoE	affected	Tfh	cell	populations	in	vivo	and	as	such	could	provide	a	plausible	explanation	of	the	findings	in	chapter	2.	To	do	this,	we	phenotyped	Tfh	cell	populations	in	the	dLNs	of	immunized	C57BL/6	WT	and	apoE-/-	mice.			We	phenotyped	Tfh	cells	as	follows:		 1. CD4+	CXCR5+	ICOS+	Cells	[206]	2. CD4+	CXCR5+	PD-1+	Cells	[214,	222,	237]	3. CD4+	CXCR5+	Bcl-6+	Cells	[214,	222]		As	 well	 as	 phenotyping	 Tfh	 cells	 using	 a	 CD4+	 pre-gate,	 we	 also	 included	 the	glycoprotein	CD44	in	our	analysis.	As	a	result	of	this,	we	were	able	to	profile	Tfh	cells	in	the	manner	in	which	they	were	phenotyped	in	chapter	2.		Phenotyping	Tfh	cells	in	this	manner,	we	determined	Tfh	cells	as,			 1. CD4+	CD44hi	CXCR5+	ICOS+	Cells		2. CD4+	CD44hi	CXCR5+	PD-1+	Cells	[222,	283]	3. CD4+	CD44hi	CXCR5+	Bcl-6+	Cells	[222,	237]		Using	this	approach,	no	difference	in	the	expression	of	CD4+	CXCR5+	ICOS+	(3.64	%	-	vs	-	4.65	%),	CD4+	CXCR5+	PD-1+	(2.19	%	-	vs	-	2.45	%)	or	CD4+	CXCR5+	Bcl-6+	(1.83	%	-	vs	-	2.43	%)	Tfh	cells	was	found	in	the	draining	lymph	nodes	of	C57BL/6	WT	vs	apoE-/-	mice	(Fig	27).	
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Mirroring	this,	no	difference	in	the	percentage	of	CD4+	CD44hi	CXCR5+	ICOS+	(15.25	%	 -	 vs	 -	 16.73	%),	 CD4+	 CD44hi	 CXCR5+	 PD-1+	 (6.30	%	 -	 vs	 –	 4.66	%)	 or	 CD4+	CD44hi	CXCR5+	Bcl-6+	(10.73	%	-	vs	–	10.42	%)	Tfh	cells	was	found	in	the	draining	lymph	nodes	of	C57BL/6	WT	vs	apoE-/-	mice	(Fig	28).		 	 						 					 						
Figure	27:	Flow	cytometry	analysis	of	CD4+	CXCR5+	ICOS+,	CD4+	CXCR5+	PD-1+	
and	CD4+	CXCR5+	Bcl-6+	Tfh	 cell	populations	 in	 the	draining	 lymph	nodes	of	
C57BL/6	WT	and	apoE-/-	mice	immunized	s.c.	with	OVA	/	CFA	Two	groups	 of	mice	 [C57BL/6	WT	 (n	=	 6)	 and	 apoE-/-	(n	 =6)]	were	 immunized	 s.c.	with	100	µg	of	OVA	emulsified	in	100	µl	of	CFA.	Nine	days	after	immunization,	dLNs	(axillary	 and	 brachial)	 were	 dissected	 and	 prepared	 for	 surface	 flow	 cytometry	staining.	Lymphocytes	were	gated	for	on	the	basis	of	FSC	and	SSC	parameters,	after	which	 single	 cells	were	 selected	 for.	Using	 these	 gates,	 CD4+	T-cells	were	 selected.	Using	 these	 parent	 gates,	 CXCR5+	 ICOS+,	 CXCR5+	 PD-1+	 and	 CXCR5+	 Bcl-6+	 cells	were	 gated.	 Statistical	 analysis	 was	 performed	 using	 GraphPad	 Prism	 and	 an	unpaired	students	t-test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001.		
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Figure	 28:	 Flow	 cytometry	 analysis	 of	 CD4+	 CD44hi	 CXCR5+	 ICOS+,	 CD4+	
CD44hi	CXCR5+	PD-1+	and	CD4+	CD44hi	CXCR5+	Bcl-6+	Tfh	cell	populations	in	
the	draining	lymph	nodes	of	C57BL/6	WT	and	apoE-/-	mice	immunized	s.c.	with	
OVA	/	CFA	Two	groups	 of	mice	 [C57BL/6	WT	 (n	=	 6)	 and	 apoE-/-	(n	 =6)]	were	 immunized	 s.c.	with	100	µg	of	OVA	emulsified	in	100	µl	of	CFA.	Nine	days	after	immunization,	dLNs	(axillary	 and	 brachial)	 were	 dissected	 and	 prepared	 for	 surface	 flow	 cytometry	staining.	Lymphocytes	were	gated	for	on	the	basis	of	FSC	and	SSC	parameters,	after	which	 single	 cells	were	 selected	 for.	Using	 these	 gates,	 CD4+	T-cells	were	 selected,	followed	 by	 a	 subsequent	 CD44hi	 gate.	 Using	 these	 parent	 gates,	 CXCR5+	 ICOS+,	CXCR5+	 PD-1+	 and	 CXCR5+	 Bcl-6+	 cells	 were	 gated.	 Statistical	 analysis	 was	performed	using	GraphPad	Prism	and	an	unpaired	students	t-test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001.				
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1.47.2 Apolipoprotein-E	Deficiency	 Significantly	Attenuates	PD-1	
and	Bcl-6	Mean	Fluorescence	Intensity		To	refine	the	experimental	approach,	the	mean	fluorescence	intensity	(MFI)	of	ICOS,	PD-1	and	Bcl-6	on	pre-gated	(CD4+	and	CD4+	CD44hi)	CXCR5+	ICOS,	CXCR5+	PD-1+	and	CXCR5+	Bcl-6+	Tfh	cells	was	assessed	respectively.			Used	throughout	 the	 literature,	MFI	 is	a	useful	 tool	 for	 the	study	of	relative	marker	expression	 on	 a	 selected	 cell	 population.	 As	 such,	 variations	 in	 MFI	 can	 help	determine	 whether	 selected	markers	 are	 lowly	 or	 highly	 expressed	 under	 varying	conditions.			Using	 this	 approach,	no	difference	 in	 the	MFI	of	 ICOS	on	both	CD4+	CXCR5+	 ICOS+	and	 CD4+	 CD44hi	 CXCR5+	 ICOS+	 Tfh	 cells	 was	 found	 (Fig	 29).	 Interestingly,	 in	comparison	 to	 C57BL/6	WT	mice,	 apoE-/-	mice	 displayed	 a	 significant	 reduction	 in	PD-1	MFI	 on	 both	 CD4+	 CXCR5+	 PD-1+	 and	 CD4+	 CD44hi	 CXCR5+	 PD-1+	 Tfh	 cells	(Fig	29).	Following	a	similar	pattern,	apoE-/-	mice	displayed	a	significant	reduction	in	Bcl-6	MFI	 on	 CD4+	 CXCR5+	Bcl-6+	 and	 CD4+	 CD44hi	 CXCR5+	Bcl-6+	 Tfh	 cells	 (Fig	29).	 							 			
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Figure	29:	MFI	of	ICOS,	PD-1	and	Bcl-6	on	CD4+	and	CD4+	CD44hi	pre-gated	Tfh	
cells	Two	groups	 of	mice	 [C57BL/6	WT	 (n	=	 6)	 and	 apoE-/-	(n	 =6)]	were	 immunized	 s.c.	with	100	µg	of	OVA	emulsified	in	100	µl	of	CFA.	Nine	days	after	immunization,	dLNs	(axillary	 and	 brachial)	 were	 dissected	 and	 prepared	 for	 surface	 flow	 cytometry	staining.	Lymphocytes	were	gated	for	on	the	basis	of	FSC	and	SSC	parameters.	Using	these	gates,	CD4+	and	CD4+	CD44hi	T-cell	were	gated.	Using	these	two	parent	gates,	CXCR5+	ICOS+,	CXCR5+	PD-1+	and	CXCR5+	Bcl-6	Tfh	cells	were	gated.	ICOS,	PD-1	and	Bcl-6	MFI	was	subsequently	measured	on	double	positive	CXCR5+	ICOS+	(A),	CXCR5+	PD-1+	 (B)	 and	 CXCR5+	 Bcl-6+	 (C)	 cells	 respectively.	 Statistical	 analysis	 was	performed	using	GraphPad	Prism	and	an	unpaired	students	t-test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001.																						
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1.47.3 Apolipoprotein-E	 Deficiency	 does	 not	 Affect	 CXCR5	
Expression	on	CD4+	and	CD4+	CD44hi	Cells		Membrane	bound	CXCR5	 is	 fundamental	 to	 the	migration	of	Tfh	 cells	 to	B-cell	 rich	areas	 in	secondary	lymphoid	organs.	As	such,	 its	expression	is	 important	to	Tfh	cell	function,	GC	B-cell	 differentiation	and	GC	productivity.	To	determine	whether	 apoE	deficiency	significantly	affected	CXCR5	expression	 in	apoE-/-	mice,	and	thus	affected	Tfh	cell	migration,	the	MFI	of	CXCR5	on	CD4+	and	CD4+	CD44hi	cells	was	determined.			No	 difference	 in	 the	MFI	 of	 CXCR5	 on	 CD4+	 T-cells	 from	 C57BL/6	WT	 and	 apoE-/-	mice	 was	 observed	 (Fig	 30).	 Mirroring	 this,	 no	 difference	 in	 the	MFI	 of	 CXCR5	 on	CD4+	CD44hi	T-cells	from	C57BL/6	WT	and	apoE-/-	mice	was	also	found	(Fig	30).		 									
Figure	30:	MFI	of	CXCR5	on	CD4+	and	CD4+	CD44hi	T	cells	Two	groups	 of	mice	 [C57BL/6	WT	 (n	=	 6)	 and	 apoE-/-	(n	 =6)]	were	 immunized	 s.c.	with	100	µg	of	OVA	emulsified	in	100	µl	of	CFA.	Nine	days	after	immunization,	dLNs	(axillary	 and	 brachial)	 were	 dissected	 and	 prepared	 for	 surface	 flow	 cytometry	staining.	Lymphocytes	were	gated	for	on	the	basis	of	FSC	and	SSC	parameters.	CD4+	
(A)	and	CD4+	CD44hi	T-cells	(B)	were	subsequently	gated.	Using	these	two	gates,	the	MFI	 of	 CXCR5	 was	 calculated	 (A	 &	 B).	 Statistical	 analysis	 was	 performed	 using	GraphPad	Prism	and	an	unpaired	students	t-test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001.		
60
70
80
90
100
CX
CR
5%
M
FI
0
100
200
300
400
CX
CR
5%
M
FI
C57BL/6( apoE-/-( C57BL/6( apoE-/-(
CD4+%Pre)gated% CD4+%CD44hi%Pre)gated%A B
150		
1.47.4 Summary	of	 the	Effects	 of	Apolipoprotein-E	Deficiency	on	
Tfh	Cell	Phenotype	in	vivo	Taken	together,	our	results	demonstrate	that	apoE	deficiency	does	not	affect	Tfh	cell	formation	 but	 indicate	 that	 apoE-/-	mice	 display	 reduced	 ability	 to	 express	 Tfh	 cell	associated	markers	(PD-1	and	Bcl-6).	Importantly,	our	data	also	indicates	that	CD4+	and	CD4+	CD44hi	T-cells	 from	apoE-/-	mice	up-regulate	CXCR5	 to	 the	 same	 level	 as	C57BL/6	WT	mice.	As	such,	suggesting	equivalent	ability	to	migrate	to	B-cell	follicles.																									
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 Effects	of	apoE	Deficiency	on	GC	B-cell	Populations	
1.48.1 Apolipoprotein-E	 Deficiency	 Significantly	 Attenuates	
Germinal	Centre	B-cell	Populations			To	study	the	effects	of	apoE	deficiency	on	GC	B-cell	phenotype,	GC	B-cell	expression	was	 assessed	 in	 the	 draining	 lymph	 nodes	 of	 C57BL/6	 WT	 and	 apoE-/-	 mice	immunized	s.c.	with	OVA	/	CFA.		Using	 this	 approach,	 apoE-/-	 mice	 displayed	 significantly	 reduced	 percentages	 of	B220+	FAS+	PNA+	GC	B-cells	compared	to	C57BL/6	WT	mice	immunized	in	the	same	manner	(4.23	%	-	vs	–	2.30	%)	(Fig	31).		
		
Figure	31:	Flow	cytometry	analysis	of	B220+	FAS+	PNA+	GC	B-cell	populations	
in	 the	 draining	 lymph	nodes	 of	 C57BL/6	WT	and	 apoE-/-	mice	 immunized	 s.c.	
with	OVA	/	CFA	Two	groups	 of	mice	 [C57BL/6	WT	 (n	=	 6)	 and	 apoE-/-	(n	 =6)]	were	 immunized	 s.c.	with	100	µg	of	OVA	emulsified	in	100	µl	of	CFA.	nine	days	after	immunization,	dLNs	(axillary	 and	 brachial)	 were	 dissected	 and	 prepared	 for	 surface	 flow	 cytometry	staining.	Lymphocytes	were	gated	for	on	the	basis	of	FSC	and	SSC	parameters,	after	which	single	cells	were	selected	for.	Using	these	gates,	B220+	cells	were	selected	for	on	the	basis	of	a	B220	/	CD4	exclusion	gate.	Doublet	expression	of	FAS	and	PNA	was	subsequently	assessed	on	single	BB20+	cells.	Statistical	analysis	was	performed	using	GraphPad	Prism	and	an	unpaired	students	t-test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001.			
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1.48.2 Summary	of	 the	Effects	 of	Apolipoprotein-E	Deficiency	on	
B220+	FAS+	PNA+	GC	B-cell	Populations		Taken	together,	our	data	suggests	that	apoE	deficiency	attenuates	the	expression	of	GC	 B-cell	 associated	 markers	 (FAS	 and	 PNA)	 on	 B220+	 cells.	 As	 such,	 our	 data	indicates	 that	 apoE-/-	mice	 display	 reduced	 ability	 to	 form	GC	B-cell	 populations	 in	
vivo.																									
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 Discussion		
1.49.1 Summary	of	Aims	and	Objectives		In	 this	 chapter,	 we	 studied	 the	 effects	 of	 apoE	 deficiency	 on	 the	 adaptive	 immune	response	 in	vivo.	To	do	this,	we	immunized	both	C57BL/6	WT	and	apoE-/-	mice	with	OVA	antigen	emulsified	in	complete	freund’s	adjuvant	CFA.	Nine	days	later,	we	used	surface	 flow	 cytometry	 to	 stain	 for	 a	 range	 of	 adaptive	 immune	 cells	 of	 particular	interest.	As	such,	we	quantified	the	percentage	of	immune	cells	in	the	draining	lymph	nodes	of	both	animals.	The	cellular	subsets	phenotyped	in	this	study	are	summarised	in	table	3	below.		
	
Table	3:	Tabular	documentation	of	cell	types	and	marker	combinations	used	to	
document	adaptive	immune	cells	Using	surface	flow	cytometry	a	range	of	adaptive	 immune	cells	were	phenotyped	in	the	 draining	 lymph	 nodes	 of	 C57BL/6	 WT	 and	 apoE-/-	 mice	 immunized	 s.c.	 with	OVA/CFA.										
Cellular'Subsets'Analysed'via'Flow'Cytometry''
Cell'Phenotype' Marker'Combination''B"cells' B220'
T"cells'' CD4'Activated'T"cells'' CD4+'CD44+'
T5h'cells' CD4+'CXCR5+'ICOS+'CD4+'CXCR5+'PD"1+'CD4+'CXCR5+'Bcl"6+'Activated'T5h'cells'' CD4+'CD44+'CXCR5+'ICOS+'CD4+'CD44+'CXCR5+'PD"1+'CD4+'CD44+'CXCR5+'Bcl"6+''
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1.49.2 Summary	of	Findings	In	 this	 chapter	 we	 found	 that	 C57BL/6	WT	 and	 apoE-/-	 mice	 displayed	 equivalent	percentages	of	B220+	B-cells	 and	CD4+	T-cells	 in	 the	draining	 lymph	nodes	9	days	post-immunization.	 In	 contrast	 to	 this,	 apoE-/-	 mice	 displayed	 significantly	 greater	percentages	of	CD4+	CD44+	T-cells	than	C57BL/6	WT	mice.			We	detected	no	difference	 in	 the	percentage	of	Tfh	cells	between	C57BL/6	WT	and	apoE-/-	mice.	Conversely,	we	found	that	apoE-/-	Tfh	cells	expressed	PD-1	and	Bcl-6	at	lower	 levels	 than	 C57BL/6	 WT	 Tfh	 cells.	 As	 well	 as	 this,	 loss	 of	 apoE	 protein	significantly	attenuated	GC	B-cell	formation.	Reassuringly,	loss	of	apoE	did	not	affect	the	ability	of	T-cells	to	translocate	to	B-cell	follicles	–	a	finding	evident	by	equivalent	CXCR5	expression	on	CD4	T-cells	from	C57BL/6	WT	and	apoE-/-	mice.			Taken	together,	our	results	confirm	that	apoE	deficiency	in	vivo	does	not	affect	CD4+	T-cell,	 B220+	 B-cell	 and	 Tfh	 cell	 percentages.	 Our	 data	 also	 indicates	 that	 apoE	deficiency	 may	 function	 to	 depress	 GC	 B-cell	 formation	 in	 vivo,	 as	 well	 as	 reduce	available	 co-stimulation	 on	 Tfh	 cells.	 As	 such,	 our	 results	 provide	 an	 interesting	insight	 into	 the	 potential	 modulation	 of	 adaptive	 immunity	 by	 apoE	 in	 vivo.	 The	implications	of	such	variations	on	disease	progression	must	 therefore	be	taken	 into	account	and	will	be	discussed	herein.									
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1.49.3 Apolipoprotein-E	 Deficiency	 Does	 Not	 affect	 the	
Percentage	 of	 B220+	 B-cell,	 CD4+	 T-cell	 and	 Tfh	 Cells	 in	
Draining	lymph	Nodes	of	Mice		Both	CD4	and	B220	are	important	markers	for	the	pre-gating	of	Tfh	cells	and	GC	B-cells.	As	such,	we	determined	whether	loss	of	apoE	affected	CD4+	T-cell	and	B220+	B-cell	populations.	We	found	no	difference	in	CD4+	T-cell	or	B220+	B-cell	populations	
in	vivo.		We	can,	therefore,	be	confident	that	CD4+	T-cell	and	B220+	B-cell	gates	used	in	 chapter	 2	 were	 not	 inadvertently	 affected	 by	 the	 loss	 of	 apoE	 expression.	 In	support	of	our	data,	others	have	shown	that	loss	of	apoE	does	not	affect	T-cell	or	B-cell	percentages	in	vivo	[249].		While	apoE	functions	to	 inhibit	 lymphocyte	expansion	 in	vitro	[274,	275],	 the	use	of	non-physiological	 antigen	 doses	 and	 cultured	 cell	 lines	 in	 studies	 complicates	extrapolation	of	in	vitro	data	to	an	in	vivo	setting.	In	support	of	the	notion	that	apoE	regulates	lymphocyte	proliferation	and	activation,	we	found	that	apoE-/-	mice	display	significantly	enhanced	expression	of	the	activation	marker	CD44	(CD4+	CD44hi	cells).			As	a	model,	apoE-/-	mice	express	enhanced	levels	of	T-cell	activation	[54,	137,	284].	It	is	likely	that	loss	of	apoE	and	the	developing	pro-atherogenic	immune	response	both	contribute	 to	 the	 presence	 of	 enhanced	 T-cell	 activation.	 However	 the	 individual	contribution	by	apoE	deficiency	to	T-cell	activation	in	vivo	is	unknown.							
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1.49.4 Apolipoprotein-E	 Deficiency	 Does	 not	 Affect	 the	
Percentage	 of	 Tfh	 Cells	 or	 CXCR5	 Expression	 but	 Attenuates	
PD-1	and	Bcl-6	Expression	In	 previous	 chapters	we	 phenotyped	 Tfh	 cells	 using	 a	 variety	 of	 published	marker	combinations.	 Using	 the	 same	marker	 combinations,	with	 the	 addition	 of	 Bcl-6,	we	characterised	the	difference	in	Tfh	cell	percentages	between	C57BL/6	WT	and	apoE-/-	mice	 immunized	s.c.	with	OVA	/	CFA.	We	found	no	difference	in	Tfh	cell	percentage	between	 both	 groups.	 As	 such,	 we	 propose	 that	 differences	 in	 Tfh	 cell	 kinetics	observed	in	chapter	2	were	as	a	result	of	diet-induced	atherosclerosis	and	not	due	to	the	effects	of	apoE	deficiency.	This	is	supported	by	the	finding	that,	in	comparison	to	chow	diet,	HFD	induced	the	largest	increase	in	Tfh	populations	(chapter	3).	To	date,	no	 published	 data	 exists	 studying	 the	 difference	 in	 Tfh	 cell	 populations	 between	C57BL/6	WT	and	apoE-/-	mice	and	the	role	of	apoE	in	such	processes.	Adding	to	this	area,	 we	 can	 confirm	 that	 apoE	 deficiency	 does	 not	 inadvertently	 affect	 Tfh	 cell	percentages	in	vivo,	in	context	of	hyperlipidemia.		Interestingly,	 we	 found	 that	 apoE-/-	 mice	 displayed	 significantly	 less	 GC	 B-cell	populations	 than	 C57BL/6	 WT	 mice.	 Strikingly,	 as	 with	 T-cells,	 little	 data	 exists	assessing	the	role	of	apoE	in	regulating	GC	B-cells.	Importantly,	our	finding	that	apoE-/-	mice	display	 reduced	GC	B-cell	 populations	 following	 immunization	 supports	our	hypothesis	 that	 atherosclerosis	 and	 hyperlipidemia	 and	 not	 apoE	 deficiency	 are	major	drivers	of	the	enhanced	GC	responses	observed	in	atherosclerotic	mice.		As	well	as	assessing	cell	percentages,	we	studied	the	expression	of	Tfh	cell	associated	molecules	(ICOS,	PD-1	and	Bcl-6).	Using	mean	MFI,	marker	expression	was	assessed	on	 CD4+	 and	 CD4+	 CD44hi	 Tfh	 cells.	 Interestingly,	 we	 found	 that	 Tfh	 cells	 from	immunized	apoE-/-	mice	expressed	 significantly	 less	PD-1	and	Bcl-6.	Both	PD-1	and	Bcl-6	are	important	Tfh	cell	markers	[237,	283,	285].	Specifically,	PD-1	is	involved	in	co-stimulation	 and	 interacts	with	 its	 ligand	 on	 GC	 B-cells	 and	 APC	 in	 the	 GC	 [286,	287].	 Moreover,	 Bcl-6	 is	 well	 characterised	 as	 the	 Tfh	 cell	 master	 regulator	 of	function	and	plays	an	important	role	in	the	up-regulation	of	Tfh	cell	associated	genes	[236,	 285].	 As	 such,	 our	 data	 suggest	 that	 apoE	 deficiency	 does	 not	 affect	 Tfh	 cell	percentages	 but	 significantly	 attenuates	 Tfh	 cell	 associated	 marker	 expression.	 To	
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determine	 the	 functional	 consequences	of	 such	a	 finding	 in	vivo,	 future	studies	may	determine	 switched	 antibody	 production	 and	 IL-21	 secretion	 in	 response	 to	mitogenic	stimuli.		Importantly,	 PD-1	 provides	 negative	 signals	 during	 T-cell	 :	 APC	 interactions	 [287],	thus	regulating	T-cell	activation.	As	such,	 it	 is	plausible	 that	 loss	of	PD-1	may	affect	the	ability	of	Tfh	cells	to	interact	with	APCs.	Adding	to	this,	loss	of	PD-1	or	its	ligands	(programmed	death	ligand-1/2	(PD-L1	and	PD-L2))	has	been	shown	to	significantly	enhance	 atherosclerosis	 formation	 in	vivo	 by	 affecting	 both	 CD4+	 and	 CD8+	 T-cell	activation	 [288-291].	 Moreover,	 Bcl-6	 has	 been	 implicated	 in	 the	 regulation	 of	macrophage	 activation	 in	 animal	models	 of	 atherosclerosis	 [292].	 In	 summary,	 we	can	conclude	that	the	Tfh	cell	and	GC	B-cell	kinetics	observed	in	chapter	2	were	the	result	 of	 atherogenic	 processes	 in	 apoE-/-	 HFD	 fed	 mice	 and	 not	 due	 to	 apoE	deficiency.																		
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1.49.5 Summary	of	Findings		
• C57BL/6	 WT	 and	 apoE-/-	 display	 equivalent	 percentages	 of	 CD4+	 T-cells	 and	B220+	B-cells	
• Loss	of	apoE	protein	significantly	enhances	expression	of	CD44	on	CD4+	T-cells	in	apoE-/-	mice		
• Loss	of	apoE	does	not	affect	Tfh	cell	percentages	in	vivo		
• Loss	of	apoE	does	not	affect	CXCR5	expression	on	CD4+	T-cells	
• Loss	of	apoE	significantly	attenuates	PD-1	and	Bcl-6	expression	on	Tfh	cells		
• Immunised	 apoE-/-	 mice	 display	 impaired	 expression	 of	 B220+	 PNA+	 FAS+	germinal	centre	B-cells			
1.49.6 Concluding	Remarks	Together,	 our	 findings	 indicate	 that	 apoE	 mice	 do	 not	 display	 impaired	 ability	 to	express	 CD4+,	 B220+	 or	 Tfh	 cell	 populations	 in	 vivo.	 As	 such,	 they	 support	 our	hypothesis	 that	 the	 data	 presented	 in	 chapter	 2	 are	 a	 result	 of	 atherosclerosis	progression.	We	have	also	demonstrated	 that	CD4+	T-cells	 from	apoE	mice	express	CXCR5	to	the	same	level	as	C57BL/6	WT	mice.	As	such,	we	are	confident	that	Tfh	cells	from	apoE-/-	mice	display	equivalent	ability	to	migrate	to	B-cell	follicles.			In	 contrast	 to	 this	 our	 data	 also	 indicates	 that	 apoE	 deficiency	 may	 alter	 the	expression	of	Tfh	cell	associated	markers	(PD-1	and	Bcl-6).	The	functional	effects	of	this	 deficiency	 should	 form	 the	 basis	 of	 a	 follow	 up	 study,	 assessing	 antibody	formation	and	Tfh	cell	helper	function.									 	
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Chapter	 5:	 Effects	 of	 IL-21R	 Deficiency	 on	 the	
Development	of	Atherosclerosis		
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 Introduction		
The	role	of	 IL-21	 in	 regulating	 the	adaptive	 immune	response	has	gained	extensive	attention	over	the	past	few	years.	In	particular,	its	importance	in	the	formation	of	Tfh	cells,	 GC	 B-cells	 and	 consequently	 GC	 reactions	 has	 been	 the	 topic	 of	 many	publications.	 With	 direct	 relevance	 to	 the	 area	 of	 infection	 and	 immunity,	 these	publications	 have	 provided	 insights	 into	 the	 potential	 benefits	 of	 IL-21R	 signal	modulation	in	optimising	vaccine	production	and	biological	immunity.	As	well	as	this,	IL-21	 has	 been	 implicated	 as	 an	 important	 molecule	 in	 the	 pathogenesis	 of	 many	autoimmune	 diseases.	 Interestingly,	 although	 closely	 related	 to	 RA	 and	 other	autoimmune	 conditions,	 the	 role	 of	 the	 IL-21	 in	 atherosclerosis	 remains	 to	 be	elucidated.			We	have	shown	 in	chapter	2	 that	Tfh	cell	and	GC	B-cell	kinetics	 follow	a	pattern	 in	line	 with	 atherosclerosis	 progression	 in	 vivo.	 As	 part	 of	 this	 chapter	 we	 aimed	 to	modulate	Tfh	cell	and	GC	B-cell	populations	–	 in	the	context	of	hyperlipidemia	-	via	IL-21R	 ablation	 on	haematopoietic	 stem	 cells.	Moving	 on	 from	 this,	we	 studied	 the	effects	of	IL-21R	ablation	on	atherosclerosis	formation	and	antibody	production.		As	part	of	 this	 introduction,	 IL-21	and	 its	receptor	structure	will	be	discussed,	with	focus	 on	 the	 intercellular	 signalling	 molecules	 involved.	 In	 addition	 to	 this,	 the	importance	of	 IL-21	to	both	Tfh	cells	and	GC	B-cells	will	be	discussed,	as	well	as	 its	role	 in	other	autoimmune	conditions.	Finally,	 the	scope	of	 the	current	study	will	be	introduced,	as	well	as	the	rationale	behind	our	approach.												
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1.50.1 IL-21	&	the	IL-21	Receptor		IL-21	belongs	to	the	IL-2	family	of	cytokines	that	includes	other	cytokines	such	as,	IL-4,	 IL-7,	 IL-9	and	IL-15	[293].	 In	combination	with	the	common	γ-receptor	subunit	–	shared	 with	 the	 aforementioned	 cytokines	 –	 IL-21	 signals	 via	 a	 heterodimeric	receptor	 comprising	an	 IL-21	specific	 subunit	 [294]	 (Figure	32).	First	 cloned	at	 the	start	of	the	21st	century,	the	IL-21R	[295]	is	expressed	by	a	variety	of	immune	cells,	including	NK	cells,	T-cells,	B-cells	and	DCs	[296-298].	In	contrast	to	its	receptor,	IL-21	secretion	is	mainly	conserved	to	activated	T-cells	[206,	299-301].	Functioning	in	both	autocrine	and	paracrine	manners,	IL-21	is	able	to	exert	its	effects	on	a	wide	range	of	cell	types.		More	recently,	the	importance	of	IL-21	in	immune	cell	expansion	has	been	studied	in	detail.	 IL-21	 is	pivotal	 to	 the	expansion	of	both	CD4+	and	CD8+	T-helper	cells,	with	over-expression	being	 linked	 to	CD8+	T-cell	memory	 [302].	 In	particular,	 IL-21	has	been	shown	to	influence	the	formation	of	activated	cytotoxic	lymphocytes	(CTLs),	via	up-regulation	of	t-bet	in	T-cells	[303,	304].	Adding	further	to	the	pleiotropic	effects	of	IL-21,	 IL-21	supports	B-cell	differentiation	 into	antibody	secreting	plasma	cells	and	memory	B-cell	formation	[204,	205,	305,	306].																
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Figure	32:	Structural	composition	of	the	functional	IL-21R	receptor	The	 IL-21R	 belongs	 to	 the	 family	 of	 receptors	 that	 share	 the	 common-γ	 (γC)	 chain	receptor.	The	γC	chain	receptor	forms	a	heterodimer	with	an	IL-21R	specific	subunit,	giving	form	to	a	functional	IL-21R	receptor.	In	the	absence	of	an	IL-21	signal,	both	the	γC	chain	 receptor	 and	 IL-21R	 specific	 subunit	 remain	 separate	 from	 one	 another.	When	in	the	presence	of	IL-21,	both	subunits	combine	to	form	a	functional	IL-21R.											
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1.50.2 IL-21R	Signal	Propagation	Binding	of	 IL-21	 to	 the	 IL-21R	 results	 in	 the	 activation	of	 the	 janus	 kinase	 /	 signal	transducer	and	activator	of	transcription	(JAK	/	STAT)	pathway	(Figure	33).	Using	in	
vitro	approaches,	both	JAK1	and	JAK3	have	been	shown	to	propagate	the	initial	IL-21	–	 IL-21R	signal	 [294,	307].	 Subsequent	phosphorylation	of	 STAT3	–	and	 to	a	 lesser	extent	 STAT1	 –	 results	 in	 nuclear	 transcription	 and	 Tfh	 cell	 /	 GC	 B-cell	 expansion	[308-311].		Independent	 of	 the	 JAK	 /	 STAT	pathway,	 common-γ	 chain	 receptor	 cytokines	 have	been	 reported	 to	 activate	 phosphatidylinositol-4,5-bisphosphate	 3-kinase	 /	 protein	kinase	 B	 (P13K/Akt)	 and	 RAS	 and	 mitogen	 activated	 protein	 kinase	 (RAS/MAPK)	[310].	 It	 is	 therefore	 plausible	 that	 IL-21	 may	 initiate	 other	 signalling	 pathways	independent	 of	 the	 JAK/STAT.	 True	 to	 this,	 IL-21	 has	 been	 shown	 to	 induce	phosphorylation	of	both	SRC	homology	2-domain	containing	(SHC)	and	Akt,	with	the	subsequent	 induction	 of	 T-cell	 proliferation	 [310].	 Reinforcing	 the	 potential	significance	of	SHC	and	Akt,	blockade	of	these	results	in	abolition	of	IL-21	induced	T-cell	proliferation	[310].		Taking	these	findings	into	account,	it	is	likely	that	messaging	systems	–	other	than	the	JAK	/	STAT	pathway	–	are	involved	in	IL-21R	signal	propagation.	The	importance	of	these	pathways	to	IL-21R	function	is,	however,	in	its	infancy	and	may	help	to	explain	the	range	of	effects	IL-21	exerts.													
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Figure	33:	Signalling	pathways	involved	in	IL-21R	signalling	Binding	of	 IL-21	 to	 the	 functional	 IL-21R	–	 composed	of	 an	 IL-21R	 specific	 subunit	and	the	common	-γ	receptor	chain	–	results	in	the	activation	of	various	intracellular	signalling	processes.	 IL-21	activates	the	 JAK/STAT	pathway,	particularly	 JAK1,	 JAK3	and	 STAT	 3,	 although	 STAT1	 and	 STAT5	 can	 also	 be	 activated	 to	 varying	 degrees.	Phosphorylation	 of	 STAT	 molecules	 results	 in	 dimer	 formation	 and	 subsequent	translocation	 to	 the	 nucleus,	 where	 gene	 transcription	 leads	 protein	 production.	Additional	pathways,	such	as	the	MAPK	and	PI	3-kinase	can	also	be	activated.								
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1.50.3 The	Role	of	IL-21	in	Modulating	T-Follicular	Helper	Cells		More	recently,	IL-21	has	been	characterised	as	the	signature	cytokine	of	the	Tfh	cell	subset	[312].	Characterised	by	the	expression	of	CXCR5,	ICOS,	PD-1,	Bcl-6	and	IL-21,	Tfh	cells	aid	GC	B-cells	in	the	production	of	high	affinity,	isotype	switched	antibodies	[313].	Adding	to	the	importance	of	IL-21	to	Tfh	cells,	IL-21	functions	to	enhance	Bcl-6	expression	and	Tfh	cell	associated	gene	expression	in	naïve	T-helper	cells	[235,	305].	Acting	 in	 an	 autocrine	 and	 paracrine	 manner,	 IL-21	 affects	 the	 activation	 and	differentiation	of	Tfh	cells,	as	well	as	other	cells	within	vicinity.		With	 developments	 in	 Tfh	 cell	 biology,	 researchers	 now	 understand	 the	 complex	interplay	 between	 various	 nuclear	 transcripts	 and	 Tfh	 cell	 formation.	 Although	originally	Bcl-6	was	perceived	as	being	the	master	regulator	of	transcription,	recent	studies	have	casted	doubt	upon	its	exclusive	role	in	Tfh	cell	formation.	More	recently,	the	transcription	factor	musculoaponeurotic	fibrosarcoma	oncogene	homolog	(c-maf)	has	been	shown	to	be	important	in	optimal	Tfh	cell	 formation	and	IL-21	production	[285].	 Working	 in	 cooperation	 with	 Bcl-6,	 c-maf	 is	 essential	 to	 optimal	 IL-21	production	 by	 Tfh	 cells	 in	 vivo.	 Highlighting	 the	 importance	 of	 c-maf	 to	 IL-21	production,	 c-maf	 deficient	 mice	 are	 void	 of	 IL-21	 production	 in	 vivo	 [314,	 315].	Interestingly,	 transcription	 factors	 –	 other	 than	 c-maf	 and	 Bcl-6	 -	 have	 been	implicated	 in	 the	 IL-21	 production	 and	 Tfh	 cell	 formation.	 Specifically,	 the	transcription	 factor	 –	 basic	 leucine	 zipper	 transcription	 factor	 (BATF)	 –	 has	 been	shown	to	enhance	IL-21	production,	as	well	as	Bcl-6	and	c-maf	expression	[316].			Intriguingly,	some	have	provided	evidence	that	IL-21	is	dispensable	in	the	formation	of	 Tfh	 cells,	 thus	 raising	 questions	 over	 the	 importance	 of	 this	 cytokine	 to	 Tfh	 cell	development	[205].	The	role	of	varying	signalling	pathways,	the	diverse	actions	of	IL-21	and	the	methods	used	in	such	studies	are	likely	to	explain	these	findings.	Raising	questions	with	regards	 to	subset	plasticity,	others	have	demonstrated	that	Tfh	cells	secrete	 large	 amounts	 of	 cytokines	 associated	 with	 other	 T-helper	 cell	 subsets,	including	IL-4	and	IFN-γ	[312,	317].			
166		
Recent	studies	have	pointed	to	a	novel	mechanism	of	action	for	IL-21.	Acting	via	Vav1	–	a	signalling	molecule	involved	in	TCR	signalling	–	IL-21	can	co-stimulate	alongside	the	TCR,	at	a	level	that	surpasses	conventional	co-stimulation	[206,	296].		Taken	together,	 the	studies	described	above	provide	strong	evidence	 for	 the	role	of	IL-21R	 signalling	 in	 the	 development	 of	 Tfh	 cells.	 They	 also	 reinforce	 the	 complex	nature	 in	 which	 IL-21	 secretion	 is	 regulated	 in	 Tfh	 cell	 transcripts,	 as	 well	 as	 the	range	of	cells	IL-21	can	target.			
1.50.4 The	Role	of	IL-21	in	Modulating	Germinal	Centre	B-cells		Independent	of	its	effects	on	Tfh	cells,	IL-21	has	been	shown	to	play	an	important	role	in	the	formation	and	function	of	GC	B-cells,	memory	B-cells	and	plasma	cells	 in	vivo	[170,	 204,	 205,	 305,	 306].	 In	 terms	 of	 GC	 reactions,	 the	 primary	 source	 of	 IL-21	 is	derived	from	activated	Tfh	cells	found	within	the	local	vicinity	[205],	thus	reinforcing	the	intimate	association	between	both	cell	types.			B-cells	 express	 IL-21R	 at	 varying	 degrees	 throughout	 their	 developmental	programme.	 Immature	 transitional	 (T1)	 B-cells	 and	 marginal	 zone	 (MZ)	 B-cells	express	 low	 levels	 of	 IL-21R	 [318].	 Subsequent	 progression	 to	 transitional	 2	 (T2)	stages	confers	enhanced	levels	of	expression,	similar	to	that	found	on	follicular	B-cells	[318].	 Of	most	 importance	 to	 the	 GC	 reaction,	 human	GC	 B-cells	 express	 IL-21R	 at	high	levels,	with	memory	B-cells	being	void	of	expression	[319].			Intriguingly,	 IL-21	exerts	a	multitude	of	effects,	depending	on	the	presence	of	other	secreted	factors	and	the	context	of	stimulation.	IL-21	induces	death	of	resting	B	cells	while	 it	 promotes	 differentiation	 of	 B	 cells	 into	 plasma	 cells	 depending	 on	 the	signalling	context.		In	 recent	 times,	 IL-21	 has	 been	 shown	 to	 act	 directly	 upon	 GC	 B-cells	 in	 vivo.	Specifically,	 IL-21	regulates	Bcl-6	expression	 in	GC	B-cells	[204],	as	well	as	working	alongside	 other	 cytokines	 to	 up-regulate	 AID	 -	 an	 important	 enzyme	 involved	 in	antibody	 isotype	switching	 [320,	321].	Further	highlighting	the	 importance	of	 IL-21	and	 its	 receptor	 to	 GC	 B-cell	 and	 GC	 formation,	 loss	 of	 IL-21	 or	 IL-21R	 results	 in	
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inefficient	GC	reaction	production,	 reduced	antibody	production	and	reduced	GC	B-cell	populations	[204,	205].			Taken	together,	the	studies	described	above	provide	evidence	for	the	role	of	IL-21R	signalling	in	the	formation	of	GC	B-cells.	They	also	enforce	the	requirement	of	IL-21	for	 the	 formation	 and	 sustainment	 of	 GC	 reactions,	 as	 well	 as	 isotype	 switched	antibody	production.	As	such,	 IL-21	 functions	 in	a	process	 that	 is	essential	 to	GC	B-cell	and	GC	reaction	formation	in	vivo.		
1.50.5 The	Role	of	IL-21	in	Autoimmunity	In	the	past	decade,	 the	role	of	 IL-21	 in	autoimmunity	has	gained	attention.	As	such,	various	 animal	 studies	 have	 demonstrated	 the	 therapeutic	 potential	 of	modulating	the	IL-21	–	IL-21R	axis	in	vivo.	In	testament	to	the	advances	made	in	context	of	IL-21	and	 autoimmunity,	 several	 phase-I	 and	 phase-II	 clinical	 trials	 are	 currently	underway.			Clues	to	the	role	of	IL-21	in	autoimmunity	were	first	demonstrated	by	the	finding	that	IL-21	 levels	correlated	with	disease	progression	and	antibody	production	 in	animal	models	of	disease.	Specifically,	using	the	BXSB.B6-Yaa+	mouse	model	–	a	model	of	SLE	–	 researchers	demonstrated	 that	 IL-21	 serum	 levels	 correlated	with	age	dependent	increase	in	pathology,	as	well	as	antibody	levels	[305].	Furthermore,	sanroque	mice	–	formed	 as	 a	 result	 of	 a	 mutation	 in	 the	 roquin	 gene	 -	 display	 enhanced	 Tfh	 cell	numbers	and	elevated	serum	IL-21	levels	[322].			In	 humans,	 serum	 IL-21	 levels	 have	 been	 shown	 to	 correlate	with	 criteria	 used	 to	diagnose	RA,	including	DAS28	scores	and	anti-cyclic	citrullinated	peptide	(anti-CCP)	antibodies	[323].	Moreover,	increased	numbers	of	IL-21	secreting	T-cells	are	evident	in	 patients	 suffering	 from	 SLE	 [324]	 -	 a	 finding	 attributed	 to	 elevated	 numbers	 of	Th17	cells	–	another	source	of	IL-21.			Collectively,	 these	 studies	 provide	 evidence	 that	 IL-21	 may	 be	 associated	 to	 the	development	of	autoimmunity	in	humans	and	in	animal	models	of	disease.	Although	
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suggesting	 an	 association,	 they	 do	 not	 provide	 evidence	 for	 direct	 role	 of	 IL-21	 in	autoimmunity.		With	the	development	of	techniques	to	specifically	block	IL-21R	or	IL-21,	researchers	have	 able	 to	 dissect	 the	 consequences	 of	 impaired	 IL-21	 signalling	 in	 disease	progression.	In	particular,	blockade	of	IL-21R	using	an	IL-21R-Fc	fusion	protein	in	an	animal	model	of	SLE	results	in	reduced	kidney	pathology,	as	well	as	reduced	IgG1	and	IgG2a	antibody	 production	 [325].	 Blockade	 of	 IL-21	 in	 two	models	 of	 inflammatory	arthritis	 reduces	 inflammation,	 antibody	 levels	 and	 pathological	 outcome	 [326].		Adding	 further	 to	 this,	 K/BxN	mice	 –	 a	model	 for	 autoantibody	 induced	 arthritis	 –	when	 crossed	with	 IL-21R	 deficient	mice	 do	 not	 develop	 arthritis	 or	 autoantibody	titres.	Moreover,	K/BxN	mice	treated	with	an	inflammatory	insult,	alongside	IL-21R-Fc	 fusion	 proteins,	 fail	 to	 develop	 severe	 forms	 of	 disease	 [327].	 	 Adding	 further	evidence	to	the	role	of	IL-21	in	the	immunoinflammatory	response,	IL-21R	blockade	reduces	gut	inflammation	in	an	animal	model	of	colitis	by	affecting	Th17	cells,	[328]	and	has	been	 shown	 to	be	 important	 in	 conferring	protection	 from	 type-1	diabetes	[329-332].		Taken	together,	these	studies	provide	evidence	for	the	role	of	the	IL-21	–	IL-21R	axis	in	 the	 development	 and	 progression	 of	 immune	 conditions.	 Highlighting	 the	pleiotropic	 actions	 of	 IL-21,	 these	 studies	 also	 stress	 the	 involvement	 of	 various	immune	 cell	 subsets	 involved	 in	 IL-21	 signalling	 and	 consequently	 disease	progression.	Conversely,	they	provide	strong	evidence	for	the	role	of	the	IL-21	–	IL-21R	axis	in	controlling	pathological	Tfh	cell	and	GC	B-cell	responses	in	autoimmunity	and	that	modulation	may	consequently	affect	Tfh	cell	and	GC	B-cell	processes	in	vivo.											
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1.50.6 Scope	of	Current	Study	&	Aims	Interestingly,	 atherosclerosis	 shares	 many	 common	 inflammatory	 hallmarks	 with	other	autoimmune	diseases,	including	RA	and	SLE.	Intriguingly,	the	role	of	IL-21	and	IL-21R	signalling	in	context	of	atherosclerosis	has	not	been	addressed.		
	We	have	shown	in	previous	chapters	that	Tfh	cell	and	GC	B-cell	kinetics	change	in	line	with	atherosclerosis	progression.	Importantly,	IL-21	has	been	shown	to	significantly	modulate	these	populations	in	vivo,	in	context	of	disease.	With	this	in	mind,	we	aimed	to	dissect	the	effects	of	IL-21R	modulation	in	context	of	atherosclerosis.			To	study	this	aim,	we:		 1. Determined	the	effects	of	IL-21R	ablation	on	Tfh	cell	and	GC	B-cell	populations	in	 the	 context	 of	 hyperlipidemia	 by	 generating	 IL-21R-/-	 	 :	 	 LDLR-/-	chimeric	mice.;	2. Assessed	whether	IL-21R	ablation	resulted	in	altered	serum	antibody	levels	to	modified	forms	of	low-density	lipoprotein	(LDL);	3. Determined	whether	ablation	of	IL-21R	modified	atherosclerosis	formation.																
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 Results	
 Optimisation	of	Chimeric	Model	
1.52.1 Optimisation	 of	 Radiation	 Dose	 Required	 to	 Ablate	 Host	
Lymphocytes	To	determine	the	optimum	radiation	dose	required	to	ablate	host	hematopoietic	stem	cells,	 a	 range	 of	 radiation	 doses	were	 tested.	 CD45.2	mice	were	 lethally	 irradiated	with	9,	9.5,	10.0	or	10.5	Grays	of	X-ray	radiation.	Mice	were	then	reconstituted	with	4	X	106	CD45.1	bone	marrow	derived	stem	cells.	8	weeks	later,	the	efficiency	of	CD4+	T-cell	and	B220+	B-cell	reconstitution	was	assessed	via	flow	cytometry.			B220+	B-cells	were	particularly	sensitive	 to	all	 radiation	doses,	with	approximately	90%	 of	 B220+	 cells	 being	 CD45.1	 positive	 at	 all	 doses	 (Fig	 34	 and	 Fig	 35).	 In	comparison	 to	 this,	 host	 CD4+	 T-cells	 were	 more	 resistant	 to	 radiation-induced	ablation.	 Maximal	 CD45.2	 CD4+	 T-cell	 reconstitution	 was	 only	 achieved	 at	 higher	doses	(10.5	Grays),	with	over	80%	of	CD4+	T-cells	being	CD45.2	positive	(Fig	34	and	Fig	35).		Under	 Home	 Office	 regulations	 of	 The	 United	 Kingdom,	 it	 is	 prohibited	 to	 expose	animals	to	radiation	levels	exceeding	10.5	Grays	in	a	single	dose.		As	a	result,	animals	were	 irradiated	 with	 a	 single	 dose	 of	 10.5	 Grays	 X-ray	 radiation.	 This	 allowed	 for	maximal	 CD4+	 T-cell	 and	 B220+	 B-cell	 reconstitution,	 thus	 allowing	 for	 the	assessment	of	both	Tfh	cell	and	GC	B-cell	compartments.										
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Figure	35:	Pie	charts	display	variation	in	the	percentage	of	CD45.1+	/	CD45.2+	
CD4+	T-cells	and	B220+	B-cells	under	each	condition.										
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1.52.2 Confirmation	of	Chimera	Status		To	confirm	the	successful	ablation	of	host	and	reconstitution	of	donor	bone	marrow,	C57BL/6NJ	:	LDLR-/-	and	IL-21R-/-	:	LDLR-/-	mice	were	assessed	for	LDLR	and	IL-21R	expression.	 Using	 surface	 flow	 cytometry,	 LDLR	 expression	 was	 determined	 on	peripheral	 blood	 monocytes	 8	 weeks	 after	 reconstitution.	 To	 confirm	 successful	reconstitution	 of	 secondary	 lymphoid	 organs,	 IL-21R	 expression	 was	 assessed	 on	B220+	B-cells	from	pLN,	spleen	and	pao-LN	compartments	on	the	day	of	cull.			
1.52.3 LDLR	 Expression	 on	 Circulating	 Peripheral	 Blood	
Monocytes		8	 weeks	 post-reconstitution,	 circulating	 peripheral	 blood	 monocytes	 were	characterised	 as	 LY6Chi	 CD115+	 cells.	 Using	 the	 gating	 style	 shown	 in	 Figure	 36A,	LDLR	expression	was	determined	on	LYC6Chi	CD115+	cells	from	C57BL/6NJ	:	LDLR-/-	and	IL-21R-/-	:	LDLR-/-	mice.			Mice	 from	 both	 C57BL/6NJ	 :	 LDLR-/-	 and	 IL-21R-/-	 :	 LDLR-/-	 groups	 displayed	equivalent	 LDLR	 expression	 on	 peripheral	 blood	 monocytes	 as	 C57BL/6	 positive	control	 groups	 (Fig	 36B).	 As	 well	 as	 this,	 a	 single	 positive	 population	 of	 LDLR	expressing	 cells	 was	 identified	 in	 both	 groups,	 thus	 indicating	 complete	 LDLR	 re-constitution	on	circulating	peripheral	blood	monocytes.	Taken	together,	these	results	suggest	our	approach	was	successful	 in	replacing	host	LDLR	deficient	bone	marrow	with	LDLR	sufficient	stem	cells	(Fig	36B).										
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Figure	36:	Confirmation	of	LDLR	reconstitution	on	peripheral	blood	monocytes	
from	chimeric	mice		Two	groups	of	8	week	old	LDLR-/-	mice	were	lethally	irradiated	with	10.5	Grays	X-ray	radiation.	Mice	were	subsequently	injected	i.v.	with	4	X	106	C57BL/6NJ	(n	=	10)	or	IL-21R-/-	(n	=	9)	bone	marrow.	After	8	weeks,	blood	was	collected	via	tail	venepuncture	and	 LDLR	 expression	 assessed	 on	 peripheral	 blood	monocytes	 via	 flow	 cytometry.	Myeloid	cells	were	gated	on	 the	basis	of	an	 initial	FSC	and	SSC	gate,	after	which	an	exclusion	gate	was	made	(CD4-	CD19-)	(A).	Subsequent	CD45+,	CD11B+	and	Ly6C+	gates	 were	 made.	 LDLR	 expression	 was	 subsequently	 assessed	 on	 such	 cells	 (A).	Representative	 histogram	 plot	 shows	 LDLR	 expression	 on	 circulating	 peripheral	blood	 monocytes	 from	 IL-21R-/-	 :	 LDLR-/-,	 C57BL/6	 positive	 control	 and	 LDLR-/-	negative	control	mice	(B).																								
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1.52.4 IL-21R	 Expression	 on	 Secondary	 Lymphoid	 Resident	
B220+	B-cells		As	well	as	confirming	LDLR	expression	on	circulating	blood	monocytes,	the	lack	of	IL-21R	expression	on	lymphoid	resident	B220+	B-cells	was	also	determined.	Unlike	Tfh	cells,	B-cells	express	IL-21R	at	basal	levels	throughout	their	differentiation	pathway.	As	 a	 result,	 the	 B220+	B-cell	 population	was	 selected	 to	 confirm	 IL-21R	 deficiency	upon.			To	 gain	 a	 comprehensive	 profile	 of	 IL-21R	 ablation	 in	 systemic	 tissues,	 IL-21R	expression	was	assessed	on	cells	from	pLNs,	spleen	and	pao-LNs.	Therefore	providing	an	 understanding	 of	 donor	 graft	 reconstitution	 in	 each	 organ	 of	 interest.	 Using	 the	gating	 style	 shown	 in	 Figure	 34A,	 IL-21R	 expression	 on	 B220+	 B-cells	 from	C57BL/6NJ	:	LDLR-/-	and	IL-21R-/-	:	LDLR-/-	mice	was	determined.			No	IL-21R	expression	was	detected	on	B220+	B-cells	from	IL-21R-/-	:	LDLR-/-	mice	in	all	 compartments	 (pLNs,	 spleen	 and	 pao-LNs)	 (Fig	 37B),	 with	 expression	 being	identical	to	that	of	isotype	controls.	In	contrast,	IL-21R	expression	could	be	detected	on	B220+	B-cells	from	C57BL/6NJ-/-	:	LDLR-/-	mice	in	all	compartments	(pLNs,	spleen	and	pao-LNs)	(Fig	37B).	Taken	together,	these	results	indicate	that	IL-21R-/-	:	LDLR-/-	mice	 were	 successfully	 reconstituted	 with	 IL-21R	 deficient	 bone	 marrow.	 Adding	further	 to	 this,	 the	 detection	 of	 a	 single	 peak	 (Fig	 37B)	 indicates	 the	 complete	reconstitution	 of	 the	 IL-21R-/-	 population,	 with	 no	 IL-21R	 positive	 peaks	 being	observed.											
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Figure	37:	Confirmation	of	IL-21R	deficiency	in	IL-21R-/-	:	LDLR-/-	mice		Two	groups	of	8	week	old	LDLR-/-	mice	were	lethally	irradiated	with	10.5	Grays	X-ray	radiation.	Mice	were	subsequently	injected	i.v.	with	4	X	106	C57BL/6NJ	(n	=	10)	or	IL-21R-/-	(n	=	9)		bone	marrow.	Following	recovery,	both	groups	were	placed	on	HFD	for	14	weeks.	Following	completion	of	the	dietary	period,	pLNs,	spleen	and	pao-LNs	were	harvested	 and	 IL-21R	 expression	 on	 B220+	 B-cells	 assessed	 via	 flow	 cytometry.	Lymphocytes	were	gated	for	on	the	basis	of	a	FSC	and	SSC	gate	(A),	with	subsequent	single	cell	and	B220+	gates	being	made	(A).	Using	these	parent	gates,	 IL-21R+	cells	were	selected	for.	Representative	histogram	plots	show	IL-21R	expression	on	B220+	B-cells	from	pLNs,	spleen	and	pao-LNs	of	IL-21R-/-	:	LDLR-/-	mice	(B).																							
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1.52.5 IL-21R	Deficiency		IL-21	is	attributed	as	the	signature	cytokine	of	Tfh	cells	-	and	its	relation	to	Tfh	cell	biology	 –	 has	 been	 the	basis	 of	 intense	 investigation	 [235,	 333].	Reported	 as	 being	important	in	the	induction	of	Bcl-6	in	Tfh	cells	[321],	IL-21	may	play	a	role	in	Tfh	cell	fate	commitment.			Of	 those	 studies	 conducted	 on	 IL-21	 and	 its	 receptor,	 IL-21R	 expression	 has	 been	linked	 to	 the	maintenance	 of	 Tfh	 cell	 populations	 in	vivo.	As	 a	 result,	 we	 aimed	 to	assess	Tfh	cell	development	 in	C57BL/6NJ	 :	LDLR-/-	and	 IL-21R-/-	 :	LDLR-/-	mice.	By	generating	an	IL-21R	deficient	mouse,	coupled	with	a	deficiency	in	the	LDLR,	we	were	able	 to	 assess	 the	 effects	 of	 impaired	 Tfh	 cell	 formation	 on	 atherosclerotic	progression.	To	induce	lesion	formation,	C57BL/6NJ	:	LDLR-/-	and	IL-21R-/-	 :	LDLR-/-	mice	were	placed	on	HFD	for	a	period	of	14	weeks.															
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 IL-21R	 Deficiency	 Impairs	 Tfh	 Cell	 Formation	 in	 IL-
21R-/-	:	LDLR-/-	Mice	
To	determine	whether	IL-21R	deficiency	impaired	Tfh	cell	formation	in	vivo,	Tfh	cell	marker	 expression	 was	 assessed	 in	 the	 pLNs,	 spleen	 and	 pao-LNs	 of	 C57BL/6NJ	 :	LDLR-/-	and	IL-21R-/-	:	LDLR-/-		mice	fed	HFD	for	14	weeks.			Using	 the	 same	 marker	 combination	 as	 discussed	 in	 chapter	 3,	 Tfh	 cells	 were	phenotyped	as	CD4+	CXCR5+	PD-1+	or	CD4+	CD44+	CXCR5+	PD-1+	cells.	In	addition	to	 this,	 ICOS	 expression	 on	 CD4+	 CXCR5+	 and	 CD4+	 CD44+	 CXCR5+	 Tfh	 cells	 was	determined.	 As	 a	 result,	 this	 provided	 a	 comprehensive	 profile	 of	 how	 IL-21R	deficiency	affected	Tfh	cell	formation.																						
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1.53.1 Peripheral	Lymph	Nodes	IL-21R-/-	:	LDLR-/-		mice	displayed	significantly	reduced	CD4+	CXCR5+	PD-1+	pLN	Tfh	cell	populations	than	those	observed	in	C57BL/6NJ	:	LDLR-/-	control	mice	(0.944	%	vs	0.38	 %)	 (Fig	 38).	 Following	 a	 similar	 pattern,	 IL-21R-/-	 :	 LDLR-/-	 	 mice	 displayed	significantly	reduced	CD4+	CD44+	CXCR5+	PD-1+	Tfh	cell	profiles	than	C57BL/6NJ	:	LDLR-/-	control	mice	(1.77	%	vs	0.71	%)(Fig	38).			
1.53.2 Spleen	Following	a	similar	pattern	to	that	observed	in	pLNs,	IL-21R	deficiency	resulted	in	a	significant	reduction	in	splenic	CD4+	CXCR5+	PD-1+	Tfh	cells	(3.74	%	vs	1.04	%)	(Fig	39).	 As	well	 as	 this,	 IL-21R-/-	 :	 LDLR-/-	mice	 displayed	 significantly	 reduced	 splenic	CD4+	CD44+	CXCR5+	PD-1+	Tfh	cell	profiles	than	C57BL/6NJ	 :	LDLR-/-	control	mice	6.01	%	vs	2.32	%	(Fig	39).		
1.53.3 Para-aortic	Lymph	Nodes	Para-aortic	 lymph	 nodes	 comprise	 an	 important	 site	 for	 the	 trafficking	 of	 immune	cells	to	and	from	luminal	plaques.	As	such,	the	effects	of	IL-21R	deficiency	on	local	Tfh	cell	 compartments	 was	 assessed.	 As	 observed	 in	 both	 peripheral	 lymph	 node	 and	splenic	compartments,	 IL-21R	deficiency	resulted	 in	a	significant	reduction	 in	CD4+	CXCR5+	PD-1+	Tfh	cell	expression	(2.46	%	vs	0.54	%)	(Fig	40).	In	addition	to	this,	IL-21R-/-	:	LDLR-/-	mice	displayed	significantly	reduced	CD4+	CD44+	CXCR5+	PD-1+	Tfh	cell	profiles	(5.81	%	vs	1.30	%)	(Fig	40).							
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Figure	38:	Percentage	of	CXCR5+	PD-1+	Tfh	cells	in	pLNs	of	C57BL/6NJ	:	LDLR-/-	
and	IL-21R-/-	:	LDLR-/-	mice	Two	groups	of	8	week	old	LDLR-/-	mice	were	lethally	irradiated	with	10.5	Grays	X-ray	radiation.	Mice	were	subsequently	injected	i.v.	with	4	X	106	C57BL/6NJ	(n	=	10)	or	IL-21R-/-	(n	=	9)	bone	marrow	derived	stem	cells.	Following	recovery,	both	groups	were	placed	on	HFD	for	14	weeks.	Following	completion	of	the	dietary	period,	pLNs	were	harvested	 and	 Tfh	 cell	 populations	 assessed	 via	 surface	 flow	 cytometry	 staining.	Lymphocytes	 were	 gated	 for	 on	 the	 basis	 of	 an	 initial	 FSC	 and	 SSC	 gate	 and	subsequent	 CD4+	 and	 CD4+	 CD44hi	 gates	 made.	 Using	 these	 two	 parent	 gates,	CXCR5+	PD-1+	Tfh	cells	were	gated.	An	exclusion	gate	using	B220+	cells	was	used	at	the	 CD4+	 gating	 point.	 Open	 bars	 represent	 C57BL/6NJ	 :	 LDLR-/-	mice	 and	 shaded	black	bars	represent	IL-21R-/-	:	LDLR-/-	mice.	Representative	plots	are	taken	from	end	point	 analysis	 for	 each	 organ	 analysed.	 Statistical	 analysis	 was	 performed	 using	GraphPad	Prism	and	by	conducting	an	unpaired	students	t-test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001,	****	P	<	0.0001.	
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Figure	39:	Percentage	of	CXCR5+	PD-1+	Tfh	cells	in	spleen	of	C57BL/6NJ	:	LDLR-
/-	and	IL-21R-/-	:	LDLR-/-	mice	Two	groups	of	8	week	old	LDLR-/-	mice	were	lethally	irradiated	with	10.5	Grays	X-ray	radiation.	Mice	were	subsequently	injected	i.v.	with	4	X	106	C57BL/6NJ	(n	=	10)	or	IL-21R-/-	(n	=	9)	bone	marrow	derived	stem	cells.	Following	recovery,	both	groups	were	placed	 on	 HFD	 for	 14	 weeks.	 Following	 completion	 of	 the	 dietary	 period,	 spleens	were	harvested	and	Tfh	cell	populations	assessed	via	surface	flow	cytometry	staining.	Lymphocytes	 were	 gated	 for	 on	 the	 basis	 of	 an	 initial	 FSC	 and	 SSC	 gate	 and	subsequent	 CD4+	 and	 CD4+	 CD44hi	 gates	 made.	 Using	 these	 two	 parent	 gates,	CXCR5+	PD-1+	Tfh	cells	were	gated.	An	exclusion	gate	using	B220+	cells	was	used	at	the	 CD4+	 gating	 point.	 Open	 bars	 represent	 C57BL/6NJ	 :	 LDLR-/-	mice	 and	 shaded	black	bars	represent	IL-21R-/-	:	LDLR-/-	mice.	Representative	plots	are	taken	from	end	point	 analysis	 for	 each	 organ	 analysed.	 Statistical	 analysis	 was	 performed	 using	GraphPad	Prism	and	by	conducting	an	unpaired	students	t-test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001,	****	P	<	0.0001.			
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Figure	 40:	 Percentage	 of	 CXCR5+	 PD-1+	 Tfh	 cells	 in	 pao-LNs	 of	 C57BL/6NJ	 :	
LDLR-/-	and	IL-21R-/-	:	LDLR-/-	mice	Two	groups	of	8	week	old	LDLR-/-	mice	were	lethally	irradiated	with	10.5	Grays	X-ray	radiation.	Mice	were	subsequently	injected	i.v.	with	4	X	106	C57BL/6NJ	(n	=	10)	or	IL-21R-/-	(n	=	9)	bone	marrow	derived	stem	cells.	Following	recovery,	both	groups	were	placed	 on	 HFD	 for	 14	weeks.	 Following	 completion	 of	 the	 dietary	 period,	 pao-LNs	were	harvested	and	Tfh	cell	populations	assessed	via	surface	flow	cytometry	staining.	Lymphocytes	 were	 gated	 for	 on	 the	 basis	 of	 an	 initial	 FSC	 and	 SSC	 gate	 and	subsequent	 CD4+	 and	 CD4+	 CD44hi	 gates	 made.	 Using	 these	 two	 parent	 gates,	CXCR5+	PD-1+	Tfh	cells	were	gated.	An	exclusion	gate	using	B220+	cells	was	used	at	the	 CD4+	 gating	 point.	 Open	 bars	 represent	 C57BL/6NJ	 :	 LDLR-/-	mice	 and	 shaded	black	bars	represent	IL-21R-/-	:	LDLR-/-	mice.	Representative	plots	are	taken	from	end	point	 analysis	 for	 each	 organ	 analysed.	 Statistical	 analysis	 was	 performed	 using	GraphPad	Prism	and	by	conducting	an	unpaired	students	t-test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001,	****	P	<	0.0001.	
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 IL-21R	deficiency	Attenuates	ICOS	MFI	on	Tfh	cells	
	Interaction	of	membrane	bound	ICOS	with	ICOSL	is	essential	to	the	initiation	of	early	Tfh	cell	development	[207,	214,	334].	Involved	in	the	initiation	of	Tfh	cell	associated	nuclear	 transcripts,	 ICOS	 blockade	 has	 been	 shown	 to	 impair	 Tfh	 cell	 formation	 in	
vivo	[207].	 As	 a	 result,	 ICOS	 expression	 can	 provide	 an	 interesting	 insight	 into	 the	potential	of	activated	CD4+	T-cells	to	develop	down	a	Tfh	cell	pathway.			With	this	 in	mind,	we	assessed	the	MFI	of	ICOS	on	the	surface	of	CD4+	CXCR5+	and	CD4+	CD44+	CXCR5+	T-cells.	These	cells	were	phenotyped	in	pLN,	spleen	and	pao-LN	compartments,	 thus	 providing	 an	 insight	 into	 the	 likelihood	 of	 CXCR5+	 T-cells	 to	adopt	a	Tfh	cell	phenotype.			
1.54.1 ICOS	Expression	on	CD4+	CXCR5+	CD4+	CD44+	CXCR5+	T-
cells		IL-21R	deficiency	resulted	in	a	significant	reduction	in	ICOS	expression	on	both	pLN	CD4+	 CXCR5+	 and	 CD4+	 CD44+	 CXCR5+	 T-cells	 (Fig	 41).	Mirroring	 this,	 IL-21R-/-	 :	LDLR-/-	mice	 displayed	 significantly	 less	 ICOS	on	 the	 surface	 of	 splenic	 and	pao-LN	CD4+	CXCR5+	and	CD4+	CD44+	CXCR5+	T-cells	(Fig	41).		Taken	together,	 these	results	 indicate	that	CD4+	T-cells	 from	IL-21R-/-	:	LDLR-/-	mice	are	 less	 likely	 to	 express	membrane	bound	 ICOS	–	 a	molecule	 required	 for	Tfh	 cell	formation	 in	 vivo.	 Notably,	 although	 IL-21R	 deficiency	 reduced	 ICOS	 expression,	 a	sizable	population	remained	ICOS+	(Fig	41).				
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Figure	 41:	 ICOS	 MFI	 on	 CD4+	 CXCR5+	 and	 CD4+	 CD44+	 CXCR5+	 T-cells	 from	
C57BL/6NJ	:	LDLR-/-	and	IL-21R-/-	:	LDLR-/-	Two	groups	of	8	week	old	LDLR-/-	mice	were	lethally	irradited	with	10.5	Grays	X-ray	radiation.	Mice	were	subsequently	 injected	with	4	X	106	C57BL/6NJ	(n	=	10)	or	 IL-21R-/-	 (n	 =	 9)	 bone	 marrow	 derrived	 stem	 cells.	 Following	 recovery,	 both	 groups	were	placed	on	HFD	for	14	weeks.	Following	completion	of	the	dietary	period,	pLNs,	spleen	 and	 pao-LNs	 were	 harvested.	 CD4+	 CXCR5+	 and	 CD4+	 CD44+	 CXCR5+	populations	were	 assessed	 via	 surface	 flow	 cytometry	 staining.	 Lymphocytes	were	gated	for	on	the	basis	of	an	initia	FSC	and	SSC	gate	and	subsequent	CD4+	CXCR5+	and	CD4+	 CD44+	 CXCR5+	 parent	 gates	 made.	 Using	 these	 gates,	 MFI	 of	 ICOS	 was	determined.	 Open	 bars	 represent	 C57BL/6NJ	 :	 LDLR-/-	mice	 and	 shaded	 black	 bars	represent	IL-21R-/-	:	LDLR-/-	mice.	Statistical	analysis	was	performed	using	GraphPad	Prism	and	by	conducting	an	unpaired	students	t-test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001,	****	P	<	0.0001.	
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1.54.2 Summary	of	Findings		Taken	 together,	 our	 results	 provide	 strong	 evidence	 that	 IL-21R	 deficiency	significantly	 attenuates	 Tfh	 cell	 formation	 in	 vivo.	 In	 addition	 to	 this,	 our	 results	indicate	 that	 IL-21R	 deficiency	 significantly	 affects	 ICOS	 expression	 on	 Tfh	 cells	 in	
vivo	–	an	important	co-stimulatory	molecule	required	for	Tfh	function.																								
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 IL-21R	 Deficiency	 Impairs	 GC	 B-cell	 Formation	 in	 IL-
21R-/-	:	LDLR-/-	Mice	
As	 well	 as	 Tfh	 cells,	 GC	 B-cell	 comprise	 a	 crucial	 component	 of	 the	 GC	 reaction.	Interacting	 with	 Tfh	 cells,	 GC	 B-cells	 form	 the	 pre-cursors	 for	 antibody	 secreting,	long-lived	plasma	cells	and	B-cell	memory.	Central	to	this	developmental	pathway,	is	the	IL-21-IL-21R	pathway,	which	induces	GC	B-cell	proliferation	and	differentiation.	As	a	result,	we	aimed	to	assess	whether	IL-21R	deficiency	would	result	 in	 impaired	GC	B-cell	formation	in	vivo.		Using	flow	cytometry,	GC	B-cell	 formation	was	assessed	in	C57BL/6NJ	 :	LDLR-/-	and	IL-21R-/-	:	LDLR-/-	mice	fed	HFD	for	14	weeks.	To	gain	an	understanding	of	how	GC	B-cell	 expression	 varied	 depending	 on	 location,	 GC	 B-cells	 were	 phenotyped	 in	 pLN,	spleen	and	pao-LN	compartments.			
1.55.1 B220+	PNA+	FAS+	GC	B-cells		In	 comparison	 to	 C57BL/6NJ	 :	 LDLR-/-	 mice,	 IL-21R-/-	 :	 LDLR-/-	 mice	 displayed	 a	significant	 reduction	 in	 the	 percentage	 of	 pLN	 B220+	 PNA+	 FAS+	 GC	 B-cell	populations	 (1.39	 %	 vs	 0.36	 %)	 (Fig	 42).	 Following	 a	 similar	 pattern,	 IL-21R	deficiency	 resulted	 in	 the	 complete	 ablation	of	 splenic	B220+	PNA+	FAS+	GC	B-cell	populations	(1.99	%	vs	0.08	%)	(Fig	43).	This	pattern	was	mirrored	in	the	pao-LNs	of	mice,	with	IL-21R-/-	:	LDLR-/-	mice	displaying	near	complete	ablation	of	pao-LN	B220+	PNA+	FAS+	GC	B-cell	profiles	(3.49	%	vs	0.38	%)	(Fig	44).		Collectively,	these	results	provide	strong	evidence	that	IL-21R	expression	is	required	for	the	formation	and	maintenance	of	GC	B-cells,	irrespective	of	anatomical	location.							
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Figure	42:	Percentage	of	B220+	FAS+	PNA+	GC	B-cells	 in	pLNs	of	C57BL/6NJ	 :	
LDLR-/-	and	IL-21R-/-	:	LDLR-/-	mice		Two	groups	of	8	week	old	LDLR-/-	mice	were	lethally	irradiated	with	10.5	Grays	X-ray	radiation.	Mice	were	subsequently	injected	i.v.	with	4	X	106	C57BL/6NJ	(n	=	10)	or	IL-21R-/-	(n	=	9)	bone	marrow	derived	stem	cells.	Following	recovery,	both	groups	were	placed	on	HFD	for	14	weeks.	Following	completion	of	the	dietary	period,	pLNs	were	harvested	 and	 GC	 B-cell	 populations	 assessed	 via	 surface	 flow	 cytometry	 staining.	Lymphocytes	 were	 gated	 for	 on	 the	 basis	 of	 an	 initial	 FSC	 and	 SSC	 gate	 and	 a	subsequent	 B220+	 gate.	 Using	 this	 parent	 gate	 FAS+	 PNA+	 cells	 were	 gated.	 Open	bars	represent	C57BL/6NJ	:	LDLR-/-	mice	and	shaded	black	bars	represent	IL-21R-/-	:	LDLR-/-	mice.	Representative	plots	are	taken	from	end	point	analysis	for	each	organ	analysed.	Statistical	analysis	was	performed	using	GraphPad	Prism	and	by	conducting	an	unpaired	students	t-test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001,	****	P	<	0.0001.											
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Figure	43:	Percentage	of	B220+	FAS+	PNA+	GC	B-cells	in	spleen	of	C57BL/6NJ	:	
LDLR-/-	and	IL-21R-/-	:	LDLR-/-	mice	Two	groups	of	8	week	old	LDLR-/-	mice	were	lethally	irradiated	with	10.5	Grays	X-ray	radiation.	Mice	were	subsequently	injected	i.v.	with	4	X	106	C57BL/6NJ	(n	=	10)	or	IL-21R-/-	(n	=	9)	bone	marrow	derived	stem	cells.	Following	recovery,	both	groups	were	placed	 on	 HFD	 for	 14	 weeks.	 Following	 completion	 of	 the	 dietary	 period,	 spleens	were	 harvested	 and	 GC	 B-cell	 populations	 assessed	 via	 surface	 flow	 cytometry	staining.	Lymphocytes	were	gated	for	on	the	basis	of	an	initial	FSC	and	SSC	gate	and	a	subsequent	 B220+	 gate.	 Using	 this	 parent	 gate	 FAS+	 PNA+	 cells	 were	 gated.	 Open	bars	represent	C57BL/6NJ	:	LDLR-/-	mice	and	shaded	black	bars	represent	IL-21R-/-	:	LDLR-/-	mice.	Representative	plots	are	taken	from	end	point	analysis	for	each	organ	analysed.	Statistical	analysis	was	performed	using	GraphPad	Prism	and	by	conducting	an	unpaired	students	t-test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001,	****	P	<	0.0001.									
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Figure	44:	Percentage	of	B220+	FAS+	PNA+	GC	B-cells	in	pao-LNs	of	C57BL/6NJ	:	
LDLR-/-	and	IL-21R-/-	:	LDLR-/-	mice		Two	groups	of	8	week	old	LDLR-/-	mice	were	lethally	irradiated	with	10.5	Grays	X-ray	radiation.	Mice	were	subsequently	injected	i.v.	with	4	X	106	C57BL/6NJ	(n	=	10)	or	IL-21R-/-	(n	=	9)	bone	marrow	derived	stem	cells.	Following	recovery,	both	groups	were	placed	 on	 HFD	 for	 14	weeks.	 Following	 completion	 of	 the	 dietary	 period,	 pao-LNs	were	 harvested	 and	 GC	 B-cell	 populations	 assessed	 via	 surface	 flow	 cytometry	staining.	Lymphocytes	were	gated	for	on	the	basis	of	an	initial	FSC	and	SSC	gate	and	a	subsequent	 B220+	 gate.	 Using	 this	 parent	 gate	 FAS+	 PNA+	 cells	 were	 gated.	 Open	bars	represent	C57BL/6NJ	:	LDLR-/-	mice	and	shaded	black	bars	represent	IL-21R-/-	:	LDLR-/-	mice.	Representative	plots	are	taken	from	end	point	analysis	for	each	organ	analysed.	Statistical	analysis	was	performed	using	GraphPad	Prism	and	by	conducting	an	unpaired	students	t-test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001,	****	P	<	0.0001.											
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1.55.2 Summary	of	Findings		In	 combination,	 our	 results	 indicate	 that	 IL-21R	 deficiency	 is	 important	 for	 the	formation	 of	 B220+	 FAS+	 PNA+	 GC	 B-cells	 in	vivo.	This	 is	 evident	 by	 the	 complete	ablation	of	 FAShi	PNAhi	 expressing	B220+	B-cells.	As	with	Tfh	 cell	 populations,	 IL-21R	deficiency	results	in	ablation	of	GC	B-cells	in	all	organs	assessed.		As	a	result,	we	were	confident	that	our	chimeric	approach	provided	a	reliable	model	for	dual	Tfh	cell	and	GC	B-cell	deficiency	in	vivo.																							
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1.55.3 IL-21R	Ablation	Attenuates	Total	IgM	and	IgG	Titres	While	
Exacerbating	Total	IgE	Responses		Both	Tfh	cells	and	GC	B-cells	are	intimately	involved	in	the	production	of	high	affinity	antibodies	 via	 GC	 reactions.	 Therefore,	 to	 study	 whether	 IL-21R	 ablation	 affected	antibody	production	in	vivo	we	measured	serum	antibody	levels	in	both	C57BL/6NJ	:	LDLR-/-	 and	 IL-21R-/-	 :	 LDLR-/-	mice.	 Specifically,	 we	 studied	 total	 IgM,	 IgG	 and	 IgE	titres,	as	well	as	MDA-Ox-LDL	specific	IgM,	IgG2C,	IgG1	and	IgG3.	As	such,	we	gained	an	insight	 into	 the	 variation	 of	 total	 and	 antigen	 specific	 antibody	 kinetics	 in	 our	chimeric	mice.			IL-21R	 ablation	 resulted	 in	 an	 approximate	 two	 and	 a	 half-fold	 reduction	 in	 total	serum	 IgM	 titres	 (Fig	 45).	 Mirroring	 this,	 loss	 of	 IL-21R	 resulted	 in	 a	 significant	reduction	in	total	serum	IgG	(Fig	45).	Interestingly,	and	in	comparison	to	IgM	and	IgG	titres,	IL-21R-/-	:	LDLR-/-	mice	displayed	approximately	4	times	more	total	serum	IgE	than	C57BL/6NJ-/-	:	LDLR-/-	control	mice	(Fig	45).				 		 												
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Figure	45:	Total	IgM,	IgG	and	IgE	serum	antibody	kinetics	in	C57BL/6NJ	:	LDLR-
/-	and	IL-21R-/-	:	LDLR-/-	mice	Serum	 from	 C57BL/6NJ	 :	 LDLR-/-	 and	 IL-21R-/-	 :	 LDLR-/-	 mice	 was	 tested	 for	 the	presence	of	 total	 IgM,	 IgG	 and	 IgE	 antibodies.	 Plots	display	 titration	of	 serum	 from	both	groups,	 from	concentrated	 to	most	dilute.	Results	are	displayed	as	normalised	mean	OD	values	for	each	dilution.	Normalised	values	were	calculated	by	dividing	OD	values	with	OD	values	of	a	constant	dilution	of	C57BL/6NJ	serum	on	each	ELISA	plate.	Statistical	 analysis	was	performed	using	GraphPad	Prism	and	by	 conducting	a	 two-way-ANOVA	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001,	****	P	<	0.0001.																									
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1.55.4 IL-21R	 Deficiency	 Significantly	 Attenuates	 MDA-Ox-LDL	
IgM	and	IgG2c	Responses		As	 well	 as	 determining	 total	 antibody	 titres,	 we	 studied	 antibody	 titres	 to	 the	pathological	Ox-LDL.	Described	as	the	 implicated	antigen	in	atherosclerosis,	Ox-LDL	is	 important	 to	 the	 formation	 of	 intra-arterial	 plaques.	 Specifically,	 we	 determined	anti-MDA-Ox-LDL-IgM,	IgG2c,	IgG1,	IgG3	and	IgE	serum	antibody	titres.			In	 comparison	 to	 C57BL/6NJ	 :	 LDLR-/-	 mice,	 IL-21R-/-	 :	 LDLR-/-	mice	 displayed	 a	significant	 reduction	 in	 anti-MDA-Ox-LDL-IgM	 and	 anti-MDA-Ox-LDL-IgG2c	 serum	levels	 (Fig	 46).	 In	 contrast,	 no	 difference	 in	 anti-MDA-Ox-LDL	 IgG1	titres	 between	both	groups	was	 found	(Fig	46).	Although	displaying	a	 trend	 towards	reduction,	no	significant	difference	 in	anti-MDA-Ox-LDL	 IgG3	serum	antibody	 levels	between	both	groups	was	 detected	 (Fig	 46).	 Anti-MDA-Ox-LDL-IgE	 titres	were	 below	 the	 limit	 of	detection	in	both	C57BL/6NJ	:	LDLR-/-	and	IL-21R-/-	:	LDLR-/-	mice	(data	no	shown).			 								 									
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Figure	46:	Anti-MDA-Ox-LDL-IgM,	IgG2c,	IgG1	and	IgG3	serum	antibody	levels	in	
C57BL/6NJ	:	LDLR-/-	and	IL-21R-/-	:	LDLR-/-	mice	Serum	 from	 C57BL/6NJ	 :	 LDLR-/-	 and	 IL-21R-/-	 :	 LDLR-/-	 mice	 was	 tested	 for	 the	presence	of	total	anti-MDA-Ox-LDL-IgM,	IgG2c,	IgG1	and	IgG3	antibodies.	Plots	display	titration	 of	 serum	 from	both	 groups,	 from	 concentrated	 to	most	 dilute.	 Results	 are	displayed	as	normalised	mean	OD	values	 for	each	dilution.	Normalised	values	were	calculated	by	dividing	OD	values	with	OD	values	of	a	constant	dilution	of	C57BL/6NJ	serum	on	each	ELISA	plate.	Statistical	analysis	was	performed	using	GraphPad	Prism	and	by	conducting	a	two-way-ANOVA	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001,	****	P	<	0.0001.																				
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1.55.5 IL-21R	Deficiency	 Enhances	 Atherosclerosis	 Formation	 in	
the	 Aortic	 Sinus	 but	 does	 not	 Affect	 Plaque	 Burden	 in	 the	
Aortic	Tree		Our	results	provide	strong	evidence	as	 to	 the	 important	role	of	 IL-21R	signalling	 in	the	 maintenance	 of	 Tfh	 cell	 and	 GC	 B-cell	 populations	 in	vivo.	 As	 well	 as	 this,	 our	results	 show	 that	 loss	 of	 such	 populations	 coincides	 with	 significantly	 attenuated	antibody	 responses.	 Taking	 this	 further,	 we	 wished	 to	 determine	 whether	 IL-21R	ablation	affected	plaque	formation	in	vivo.			To	study	this,	we	used	various	histological	approaches	to	quantify	plaque	burden	and	phenotype	 in	 areas	 predisposed	 to	 lesion	 formation.	 As	 such,	 we	 were	 able	 to	determine	whether	IL-21R	deficiency	affected	lesion	formation	in	IL-21R-/-	 :	LDLR-/-	mice.		To	 obtain	 a	 comprehensive	 assessment	 of	 the	 effects	 IL-21R	 deficiency	 had	 on	atherosclerosis	formation,	the	following	histological	parameters	were	assessed.			 										
Table	 4:	 Stains	 used	 for	 histological	 assessment	 of	 atherosclerotic	 plaque	
formation	and	lesion	composition	in	C57BL/6NJ	:	LDLR-/-	and	IL-21R-/-	:	LDLR-/-	
mice.		
Stain&& Organ&
Assessed&&
Aim&of&Histological&Procedure&& Question&Addressed&&
Oil&Red&O&
(ORO)&
Aortic'Sinus' To'quantify'plaque'burden'in'an'area'susceptible'to'lesion'formation.''' Does'IL;21R'de?iciency'result'in'modi?ied'plaque'burden?'
Oil&Red&O&
(ORO)&
&
Whole'Aorta'' To'determine'whole'aorta'plaque'burden.' Does'IL;21R'de?iciency'result'in'whole'aorta'modi?ied'plaque'burden?'
Picro&Sirius&
Red&&
Aortic'Sinus'' To'quantify'collagen'?iber'content'in'an'area'susceptible'to'lesion'formation.''' Does'IL;21R'de?iciency'result'in'a'more'stable'or'unstable'plaque'phenotype?'
CD68&& Aortic'Sinus'' To'quantify'macrophage'burden'in'an'area'susceptible'to'lesion'formation.'' Does'IL;21R'de?iciency'result'in'enhanced'macrophage'in?iltration'to'a'site'susceptible'to'plaque'formation?''
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 Histological	Assessment	of	Atherosclerosis	in	IL-21R-/-	
:	LDLR-/-	Mice	
1.56.1 IL-21R	 Deficiency	 Does	 Not	 Affect	 Plaque	 Burden	 in	 the	
Aortic	Tree			To	quantify	whole	aorta	 lesion	composition,	whole	mount	aortas	were	stained	with	the	 lipid	 stain	 -	 ORO.	 By	 measuring	 total	 plaque	 area	 and	 total	 aorta	 area,	 the	percentage	of	whole	aorta	comprising	plaque	was	calculated.		IL-21R	deficiency	did	not	affect	lesion	formation	throughout	the	aortic	tree	(Fig	47).											
Figure	47:	Whole	aorta	En	Face	Oil	Red	O	staining	Aortas	 from	C57BL/6NJ	 :	LDLR-/-	 (n	=	10)	and	IL-21R-/-	 :	LDLR-/-	 (n	=	9)	mice	were	dissected	 as	 previously	 described.	 Following	 excision	 of	 visceral	 fat,	 samples	 were	stained	with	ORO	and	 cut	 longitudinally	 through	 their	 luminal	 opening	 and	pinned	out	using	fine	dissection	needles.	En	face	images	were	acquired	using	an	8-megapixel	camera.	 Using	 imagej	 quantification	 software,	 total	 aorta	 area	 was	 measured	alongside	ORO	positive	plaque	area.	Percentage	of	aorta	plaque	area	was	calculated.	Bar	 =	 100	 μm	 Statistical	 analysis	 was	 performed	 using	 GraphPad	 Prism	 and	 by	conducting	an	unpaired	students	t-test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001,	****	P	<	0.0001.				
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1.56.2 IL-21R	 Deficiency	 Results	 in	 Enhanced	 Sinus	 Plaque	
Content		Using	ORO	stain,	total	plaque	content	of	aortic	sinuses	from	C57BL/6NJ	:	LDLR-/-	and	IL-21R-/-	 :	 LDLR-/-	 mice	 was	 assessed.	 To	 gain	 an	 appreciation	 of	 plaque	 content	throughout	 the	 aortic	 sinus,	 11	 sequential	 sections	 from	 each	 animal	were	 stained	with	ORO	 and	plaque	 area	 plotted	 against	 sinus	 thickness.	 Sections	 stained	 started	from	0	μm	and	ended	at	660	μm.		In	 comparison	 to	 C57BL/6NJ	 :	 LDLR-/-	 mice,	 IL-21R-/-	 :	 LDLR-/-	 mice	 displayed	 an	approximate	 a	 two	 fold	 increase	 in	 sinus	 plaque	 area	 (Fig	 48).	 This	 variation	 was	consistent	throughout	the	entire	aortic	sinus	of	IL-21	deficient	mice.			 																				
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Figure	48:	Aortic	sinus	–	sequential	Oil	Red	O	staining	Aortic	sinuses	from	C57BL/6NJ	:	LDLR-/-	(n	=	10)	and	IL-21R-/-	:	LDLR-/-	(n	=	9)	mice	were	 dissected	 as	 previously	 described.	 8	 micron	 thick	 sections	 were	 cut,	 with	sections	being	stained	in	60	micron	increments.	Sections	were	cut	until	a	total	length	of	 660	microns	was	 reached,	 thus	 allowing	 for	 the	 depiction	 of	 lesion	 progression	throughout	 the	 aortic	 sinus.	 Sections	 were	 stained	 with	 ORO	 and	 haematoxylin	counterstain	 was	 applied.	 Sections	 were	 mounted	 in	 ProlongGold	 mountant	 and	imaged	using	a	light	microscope	(EVOS	cell	imaging	station,	life	Technologies).	Bar	=	100	μm.	Statistical	analysis	was	performed	using	GraphPad	Prism	and	by	conducting	an	unpaired	students	t-test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001,	****	P	<	0.0001.																						
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1.56.3 IL-21R	 Ablation	 Does	 not	 Affect	 Aortic	 Sinus	 Collagen	
Content		Using	polarised	light	and	conventional	light	microscopy,	collagen	content	in	the	aortic	sinus	 of	 C57BL/6NJ	 :	 LDLR-/-	 and	 IL-21R-/-	 :	 LDLR-/-	mice	 was	 determined.	 Using	Picrosirius	 Red	 staining,	 collagen	 content	 was	 assessed	 on	 sequentially	 cut	 sinus	sections	(determined	every	60	μm).	Sections	were	cut	and	stained	to	a	completion	of	660	μm.		IL-21R	 deficiency	 did	 not	 alter	 sinus	 plaque	 content,	 with	 the	 percentage	 of	 sinus	collagen	 being	 equivalent	 in	 C57BL/6NJ	 :	 LDLR-/-	 and	 IL-21R-/-	 :	 LDLR-/-		mice	 (Fig	49).	 As	 such,	 these	 findings	 suggest	 that	 IL-21R	 deficiency	 does	 not	 affect	 plaque	collagen	content.		 																
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Figure	49:	Aortic	sinus	Picro	Sirius	red	staining	Aortic	sinuses	from	C57BL/6NJ	:	LDLR-/-	and	IL-21R-/-	 :	LDLR-/-	mice	were	dissected	as	 previously	described.	 Sections	were	 stained	with	Picro	 Sirius	Red	 Samples	were	subsequently	 mounted	 using	 DPX	 mounting	 media	 and	 visualised	 under	 polarised	light	using	an	epifluorescent	microscope	at	X5	magnification.	Statistical	analysis	was	performed	using	GraphPad	Prism	and	by	conducting	an	unpaired	students	t-test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001,	****	P	<	0.0001.																								
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1.56.4 IL-21R	 Ablation	 Results	 in	 Reduced	 Sinus	 CD68	
Macrophage	Infiltration	Macrophages	 represent	 one	 of	 the	 most	 readily	 recognised	 hallmarks	 of	 early	atherogenesis	and	their	plaque	content	influence	lesion	stability.	As	such,	the	effects	of	IL-21R	ablation	on	sinus	macrophage	content	were	studied.			Using	 fluorescent	 microscopy,	 we	 stained	 for	 CD68	 expressing	 macrophages	 in	sequential	sinus	sections	from	C57BL/6NJ	:	LDLR-/-	and	IL-21R-/-	:	LDLR-/-	mice.	When	compared	to	control	mice,	we	found	that	IL-21R	deficient	mice	displayed	significantly	enhanced	 sinus	 CD68+	 macrophage	 infiltration.	 Therefore	 indicating	 that	 IL-21R	deficiency	 results	 in	 enhanced	 macrophage	 accumulation	 and	 increased	 plaque	inflammation	and	instability	(Fig	50).												
Figure	50:	Aortic	sinus	–	sequential	CD68	macrophage	staining	Aortic	sinuses	 from	C57BL/6NJ	 :	LDLR-/-	and	IL-21R-/-	 :	LDLR-/-	mice	were	dissected	as	 previously	 described.	 Sections	 were	 incubated	 in	 rat-anti-mouse	 CD68	 and	subsequently	donkey-anti-rat-IgG	conjugated	to	CY3.	Sections	were	then	mounted	in	ProlongGold	 mountant	 containing	 DAPI.	 Sections	 were	 analysed	 using	 an	epifluorescent	microscope	 at	 X40	magnification.	 Statistical	 analysis	was	 performed	using	GraphPad	Prism	and	by	conducting	a	students	t-test.	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001,	****	P	<	0.0001.			
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1.56.5 Summary	of	Findings	Our	en	face	studies	suggest	that	IL-21R	deficiency	does	not	affect	lesion	formation	in	the	whole	 aorta.	 This	was	 evident	 by	 the	 finding	 that	 en	 face	 lesion	 formation	was	indifferent	 between	C57BL/6NJ	 :	 LDLR-/-	 and	 IL-21R-/-	:	 LDLR-/-	mice.	 In	 contrast	 to	this,	 our	 sinus	 studies	 suggest	 that	 IL-21R	 deficiency	 functions	 to	 enhance	 lesion	formation	 and	 an	 unstable/proinflammatory	 plaque	 phenotype	 (as	 indicated	 by	enhanced	CD68+	macrophage	content).	This	was	evident	by	 the	 finding	 that	 IL-21R	deficient	mice	displayed	enhanced	sinus	lesion	size	and	macrophage	content.																											
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 Discussion	
In	 this	 chapter,	 we	 studied	 the	 effects	 of	 IL-21R	 deficiency	 in	 the	 context	 of	atherosclerosis.	To	do	this,	we	generated	IL-21R-/-	:	LDLR-/-	and	C57BL/6NJ	:	LDLR-/-	chimeric	 mice;	 in	 which	 hematopoietic	 stem	 cells	 were	 void	 of	 IL-21R	 expression.	Using	surface	flow	cytometry	staining,	IF	and	ELISAs;	we	determined	the	effects	of	IL-21R	deficiency	on	Tfh	cell	and	GC	B-cell	formation,	antibody	production	and	disease	progression.				
1.57.1 Summary	of	Findings		In	 this	 chapter,	 we	 demonstrated	 that	 IL-21R	 deficiency	 –	 in	 context	 of	hyperlipidemia	–	significantly	attenuates	Tfh	cell	and	GC	B-cell	formation	in	vivo.	This	reduction	 was	 associated	 with	 a	 significant	 increase	 in	 sinus	 plaque	 content	 and	macrophage	 infiltration,	 with	 no	 difference	 in	 sinus	 collagen	 content	 and	 plaque	formation	throughout	the	aortic	tree.	Linking	Tfh	cell	and	GC	B-cell	kinetics,	IL-21R-/-		:	 LDLR-/-	mice	 displayed	 significantly	 attenuated	 total	 IgM	 and	 IgG	 serum	 antibody	titres.	 This	was	 coupled	with	 a	 significant	 reduction	 in	MDA-Ox-LDL	 specific	 IgG2C,	while	 MDA-Ox-LDL	 IgG1	 and	 IgG3	 titres	 remained	 unchanged.	 IL-21R	 ablation	 also	resulted	in	enhanced	total	IgE	titres.			Together,	our	results	 indicate	that	IL-21R	signalling	is	athero-protective	 in	vivo,	and	may	exert	its	effects	via	modulation	of	the	Tfh	cell	/	GC	B-cell	axis.	Our	findings	add	to	the	area	of	adaptive	immunity	in	atherosclerosis,	with	few	studies	addressing	the	role	of	 the	 Tfh	 cell	 /	 GC	 B-cell	 axis	 in	 plaque	 formation.	 Our	 results	 also	 provide	 an	interesting	insight	into	the	therapeutic	advantage	of	Tfh	cell	/	GC	B-cell	modulation	in	atherosclerosis.							
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1.57.2 Tfh	 cell	 and	 GC	 B-cell	 Development	 in	 IL-21R-/-	 :	 LDLR-/-		
Mice	 is	 Significantly	 Reduced	 in	 Comparison	 to	 C57BL/6NJ	 :	
LDLR-/-	Mice	Using	flow	cytometry,	we	stained	for	Tfh	cells	and	GC	B-cells	in	the	pLNs,	spleen	and	pao-LNs	of	chimeric	mice	fed	HFD	for	14	weeks.	This	allowed	us	to	study	the	effects	of	 IL-21R	 deficiency	 on	 Tfh	 cell	 and	 GC	 B-cell	 formation	 in	 systemic	 and	 local	environments;	where	auto-reactive	immune	cells	circulate	and	drain	affected	arteries	respectively.			We	found	that	Tfh	cell	and	GC	B-cell	expression	was	significantly	reduced	in	IL-21R-/-	:	 LDLR-/-	 mice.	 We	 propose	 this	 is	 due	 to	 the	 lack	 of	 IL-21R	 signalling,	 providing	important	 proliferation	 and	 differentiation	 signals	 to	 both	 Tfh	 cells	 and	 GC	B-cells.	Indeed,	 IL-21R	 signalling	 is	 important	 for	 the	 induction	 of	 the	 Tfh	 cell	 associated	transcription	factors,	including	Bcl-6	and	c-maf	[285,	335].	As	well	as	this,	IL-21	acts	directly	on	GC	B-cells	 to	 induce	proliferation,	 isotype	switching,	expression	of	Bcl-6	and	survival	of	antigen	specific	memory	B-cells	[170,	204,	205,	305,	306].	It	is	likely	these	processes	were	deficient	 in	our	model	and,	as	a	result,	mice	 failed	 to	develop	bonafide	Tfh	cell	and	GC	B-cell	populations.	As	a	consequence,	IL-21R	deficient	mice	failed	to	develop	functional	GC	reactions	with	impaired	B-cell	switching	and	antibody	production.			Interestingly,	 some	 have	 suggested	 that	 Tfh	 cells	 can	 form	 independent	 of	conventional	 IL-21R	signalling	[205,	283].	Raising	questions	over	the	 importance	of	IL-21,	 these	 studies	 suggest	 the	 involvement	 of	 additional	 pathways	 in	 Tfh	 cell	formation.	 Indeed	 some	 have	 provided	 evidence	 to	 suggest	 that	 IL-21	 can	 co-stimulate	with	the	TCR	of	T-cells	[206,	296].	Adding	to	this,	others	have	indicated	the	IL-21s	ability	to	induce	signalling	molecules,	other	that	JAK	and	STAT	proteins	[310].	It	 is	 therefore	 plausible	 that	 the	 role	 of	 additional	 pathways	 involved	 in	 Tfh	 cell	development	may	explain	the	presence	of	Tfh	cells	in	such	studies.	In	support	of	the	notion	 that	 additional	 mechanisms	 drive	 Tfh	 cell	 development,	 adjuvant	administration	has	been	shown	to	enhance	T-cell	survival	via	up-regulation	of	Bcl-3	
in	vivo	[336].	
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Irrespective	 of	 the	 studies	 above,	 we	 have	 shown	 unequivocally	 that	 IL-21R	deficiency	 significantly	 attenuates	 Tfh	 cell	 and	GC	B-cell	 formation	 in	 experimental	atherosclerosis.			
1.57.3 Deficient	Tfh	cell	and	GC	B-cell	Responses	Have	an	Impact	
on	Atherosclerosis	Formation		Moving	 from	 studying	 the	 role	 of	 IL-21R	 deficiency	 on	 Tfh	 cell	 and	 GC	 B-cell	development,	 we	 assessed	 whether	 IL-21R	 ablation	 affected	 atherosclerosis	progression.	 Using	 histochemical	 approaches,	 we	 found	 that	 IL-21R	 deficiency	significantly	attenuated	plaque	formation	and	macrophage	infiltration	into	the	aortic	sinus	of	mice.	Sinus	collagen	content	remained	unchanged,	as	did	total	aorta	plaque	content.			Supporting	our	 findings,	 others	have	 shown	 the	pro-inflammatory	effects	of	 IL-21R	deficiency	 in	 models	 of	 experimental	 autoimmune	 encephalomyelitis	 (EAE)	 [337],	SLE	 [338]	 and	 chronic	 arthritis	 [339].	 Linking	 both	 Tfh	 cells	 and	 GC	 B-cells	 to	pathological	progression,	we	suggest	that	enhanced	atherosclerosis	in	our	model	is	a	result	 of	 defective	 Tfh	 cell	 and	 GC	 B-cell	 responses,	 induced	 by	 insufficient	 IL-21R	signalling.			In	contrast	to	our	findings,	genome	wide	association	studies	(GWAS)	have	identified	risk	variants	in	the	IL-21	gene	locus	for	autoimmune	conditions,	including	SLE	[340],	RA	 [341]	 and	 diabetes	 [342].	 This	 is	 complimented	 by	 the	 finding	 that	 IL-21R	deficiency	ameliorates	disease	severity	in	several	models	of	autoimmunity	[326,	332,	343,	344].			Although,	these	studies	contradict	our	findings,	some	other	studies	have	provided	an	interesting	explanation	for	this	apparent	discrepancy.	Pointing	to	the	diverse	range	of	effects	 IL-21	can	exert,	 others	have	 reported	 that	 IL-21	can	 function	as	both	a	pro-inflammatory	 and	 anti-inflammatory	 cytokine.	 Specifically,	 in	 the	 BXSB-yaa	 mouse	model	of	SLE,	neutralisation	of	 IL-21R	signalling	by	IL-21R-Fc	antibody	exacerbates	disease	 in	 early	 stages	 and	 reduces	 disease	 at	 later	 stages.	 The	 reason	 for	 this	
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differential	regulation	is	unknown,	however	is	most	likely	to	be	linked	to	the	dynamic	induction	 of	 regulatory	 compartments	 later	 on	 in	 the	 BXSB-yaa	 model.	 Mirroring	these	findings,	IL-21R	deficiency	in	two	models	of	inflammatory	arthritis	functions	to	be	protective	at	one	phase	and	detrimental	at	another	[339].		Interestingly,	 IL-21R-/-	 mice	 induced	 to	 develop	 inflammatory	 arthritis	 display	impaired	 regulation	 of	 suppressor	 of	 cytokine	 signalling	 (SOCS)	 proteins	 [339].	 As	well	 as	 inhibiting	 JAK	 /	 STAT	 signalling	 [345,	 346],	 SOCS	 proteins	 also	 inhibit	 TLR	signalling	 [347].	 As	 such,	 impaired	 regulation	 of	 TLR	 signalling	 –	 as	 a	 result	 of	deficient	SOCS	expression	–	may	explain	enhanced	pathology	observed	in	our	study.	In	recent	years,	the	role	of	TLR	signalling	in	atherosclerosis	has	been	studied	in	detail.	Deficiency	of	myeloid	differentiation	primary	response	gene	88	(MyD88)	–	one	of	the	major	 TLR	 signalling	 molecules	 –	 has	 been	 reported	 to	 both	 promote	 and	 inhibit	atherosclerosis	 formation	 [348-350].	 These	 findings	 are	 most	 likely	 due	 to	 the	expression	of	TLRs	on	various	immune	cell	subsets,	with	each	subset	playing	distinct	roles	 in	 atherosclerosis.	 Suggesting	 a	 pro-atherogenic	 role	 of	 TLR2	 and	 TLR4	signalling	 in	atherosclerosis,	 specific	deletion	of	 these	 receptors	 conveys	protection	from	lesion	development	[351,	352].	It	is	therefore	plausible	that	impaired	regulation	of	TLRs	by	SOCS	proteins	in	our	mice	may	have	resulted	in	increased	TLR	activation	and	 enhanced	 pathology.	 To	 say	 with	 certainty	 that	 TLR	 mediated	 processes	contribute	 significantly	 to	 disease	 progression	 in	 our	 model,	 assessment	 of	 TLR	expression	in	IL-21R-/-	:	LDLR-/-	mice	would	be	necessary.			In	combination,	 these	 findings	suggest	 that	 IL-21	may	not	simply	 function	as	a	pro-inflammatory	 or	 anti-inflammatory	 cytokine;	 rather	 play	 distinct	 roles	 in	 different	stages	of	 the	 immune	response.	To	determine	whether	 IL-21R	deficiency	exerts	 the	same	dual	effects	in	our	model,	it	would	be	advantageous	to	quantify	atherosclerosis	formation	in	IL-21R-/-	:	LDLR-/-	mice	at	early	and	late	stage	atherosclerosis.		
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1.57.4 IL-21R	 Deficiency	 Alters	 the	 Pro-atherogenic	 /	 Athero-
protective	Antibody	Response	in	vivo.		In	this	study,	we	demonstrated	that	loss	of	IL-21R	signalling	significantly	attenuated	GC	 B-cell	 and	 Tfh	 cell	 populations	 in	 vivo.	 Moreover,	 loss	 of	 these	 populations	significantly	altered	antibody	production.	As	such,	our	data	demonstrates	the	central	role	of	IL-21R	signalling	in	Tfh	cell	and	GC	B-cell	formation	and	function.		The	 role	 of	 antibodies	 in	 atherosclerosis	 has	 been	 the	 subject	 of	 much	 debate	 for	years.	 Generally,	 IgM	 antibodies	 are	 perceived	 to	 confer	 athero-protective	 effects	[353],	while	their	switched	counterparts	–	specifically	IgG2C	–	are	believed	to	be	pro-atherogenic.	Preventing	Ox-LDL	uptake	into	macrophages,	IgM	antibodies	prevent	the	formation	 of	 pathological	 foam	 cells	 as	 well	 as	 forming	 immune	 complexes	 that	prevent	 Ox-LDL	 accumulation	 [354].	 Moreover,	 increased	 IgM	 titres	 are	 linked	 to	reduced	atherosclerosis	 formation	 in	humans	as	well	as	 reduced	cell	death	and	cell	debris	 formation	 [355].	 In	 contrast	 to	 this,	 IgG	 antibodies	 have	 been	 shown	 to	potentiate	 scavenger	 receptor	 (SR)	mediated	uptake	of	Ox-LDL	 into	artery	 resident	macrophages,	thus	enhancing	atherosclerosis	formation.		Considering	 the	 intimate	 link	 between	 the	 Tfh	 cell	 :	 GC	 B-cell	 axis	 and	 antibody	production,	 we	 propose	 that	 variations	 in	 antibody	 kinetics	 are	 to	 explain	 for	 the	enhanced	 pathology	 is	 IL-21R	 deficient	 mice.	 As	 such,	 we	 propose	 herein,	 a	mechanism	by	which	loss	of	IL-21R	alters	GC	processes	and	subsequent	pathology.	To	summarise,	IL-21R	deficiency	significantly	alters	serum	antibody	titres	as	follows,		
• Attenuated	total	IgM	and	IgG	titres		
• Reduced	MDA-Ox-LDL	specific	IgG2C	titres	
• Enhanced	total	IgE	titres			Due	to	the	loss	of	athero-protective	MDA-Ox-LDL	IgM	antibodies,	we	propose	that	IL-21R-/-	:	LDLR-/-	mice	would	be	deficient	in	their	ability	to	control	pathogenic	Ox-LDL	levels.	As	 such,	 it	 is	plausible	 to	 assume	 that	 IL-21R-/-	 :	 LDLR-/-	mice	would	display	enhanced	macrophage	and	foam	cell	formation.	This	phenomenon	was	confirmed	in	
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our	 histochemical	 studies	 of	 the	 sinus,	 where	 IL-21R	 deficient	 mice	 displayed	significantly	enhanced	CD68+	macrophage	infiltration.			IL-21R	ablation	also	enhanced	serum	IgE	expression,	while	no	MDA-Ox-LDL	IgE	titres	could	be	detected	in	both	groups.	This	finding	is	supported	by	the	negative	role	of	IL-21R	signalling	 in	murine	 IgE	B-cell	 switching	 [356].	Due	 to	 the	 loss	of	 this	axis,	we	propose	that	IgE	specific	B-cells	fail	to	receive	suppressive	signals.	As	such,	negative	regulation	 of	 IgE	 specific	 germ	 line	 transcription	 factors	 is	 prevented,	 leading	 to	enhanced	 IgE	 specific	 B-cell	 proliferation	 and	 IgE	 production.	 It	 is	 likely	 that	 this	process	 explains	 the	 enhanced	 total	 IgE	 titres	 found	 in	 IL-21R-/-	 :	 LDLR-/-	 mice.	Further	supporting	our	data,	others	have	demonstrated	the	potent	effects	of	 IL-21R	deficiency	on	enhancing	the	IgE	subtype	in	vivo	[205,	226,	306].	Of	importance	to	our	study,	 IgE	 has	 been	 linked	 to	 increased	 atherosclerosis	 in	 both	 humans	 and	 mice	[174].	 Specifically,	 IgE	 has	 been	 shown	 to	 increase	macrophage	 activation,	 cellular	apoptosis	and	necrotic	core	formation	[174].	Moreover,	IgE	also	functions	to	enhance	number	 of	 lesional	 T	 cells,	 mast	 cells	 and	 MHC-II	 expression	 [174].	 Taking	 these	findings	 into	 account,	 we	 propose	 that	 a	 culmination	 of	 impaired	 protection	 from	reduced	 IgM	 and	 enhanced	 susceptibility	 from	 increased	 IgE	 explains	 increased	disease	 in	IL-21R	deficient	mice.	To	confirm	the	 involvement	of	 IgE	 in	our	model,	 it	would	be	 logical	 to	use	histochemical	approaches	 to	determine	 IgE	and	 its	receptor	expression	 in	 lesions	 from	C57BL/6	 :	 LDLR-/-	 and	 IL-21R-/-	 :	 LDLR-/-		mice.	As	 such,	this	would	comprise	a	plausible	follow	up	study.			As	discussed	before,	IgG2C	has	been	linked	to	increased	lesion	formation.	Importantly,	IL-21R	ablation	significantly	reduced	circulation	IgG2C.	As	such,	it	would	be	logical	to	assume	 that	 loss	of	 IgG2C	 antibodies	would	 convey	athero-protection.	Although	 this	may	 be	 true,	 it	 is	 likely	 that	 the	 pro-atherogenic	 effect	 of	 increased	 IgE	 and	diminished	athero-protection	from	reduced	IgM	masked	IgG2C’s	effects.			Taken	 together,	 we	 propose	 a	mechanism	 by	which	 IL-21R	 deficiency	 significantly	enhances	 atherosclerosis	 formation.	 We	 propose	 that	 IL-21R	 deficiency	 induced	ablation	of	Tfh	cell	and	GC	B-cell	populations	significantly	alters	the	pro-atherogenic	/	athero-protective	antibody	response	in	atherosclerosis.	As	a	result,	pro-atherogenic	antibody	 responses	 predominate,	 while	 athero-protective	 responses	 are	 hindered,	
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thus	leading	to	lesion	formation.	Figure	51	summarises	the	proposed	mechanism	by	which	IL-21R	ablation	may	enhance	atherosclerosis	formation	in	vivo.																																	
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Figure	 51:	 Mechanism	 by	 which	 IL-21R	 ablation	 enhances	 atherosclerosis	
formation		Following	 reconstitution	 of	 donor	 bone	marrow,	 IL-21R-/-	 :	 LDLR-/-	mice	 displayed	significantly	reduced	Tfh	cell	and	GC	B-cell	populations	in	all	organs	assessed	(pLNs,	spleen	and	pao-LNs).	This	was	coupled	with	a	concomitant	increase	in	lesion	burden	and	instability.	Comprising	a	functional	component	of	these	changes,	IL-21R-/-	:	LDLR-/-	mice	displayed	significant	reductions	in	total	IgM	and	IgG	and	MDA-Ox-LDL	IgM	and	IgG2C.	Consistent	with	the	negative	effects	of	IL-21R	signalling	on	IgE	production,	IL-21R	ablation	significantly	enhanced	total	serum	IgE	titres.	As	such,	we	propose	that	the	 pro-atherogenic	 antibody	 response	 is	 dominant	 in	 IL-21R-/-	 :	 LDLR-/-	 	 mice	(increased	IgE	and	reduced	IgM),	leading	to	reduced	protection	from	atherosclerosis	and	enhanced	lesion	formation.																							
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1.57.5 IL-21R	Deficiency’s	May	Regulate	Other	Pro-inflammatory	
Cell	Types	As	 discussed	 earlier	 in	 this	 chapter,	 IL-21	 exerts	 a	 range	 of	 pleotropic	 effects	 on	different	cellular	subtypes.	It	 is,	therefore,	 important	to	consider	the	possibility	that	IL-21R	ablation	may	have	affected	the	function	and/or	proliferation	of	these	subsets.	The	effect	that	this	may	have	had	on	disease	progression	must	therefore	be	discussed.			Enhanced	 disease	 severity	 in	 BXSB-Yaa	 mice	 treated	 with	 IL-21-Fc	 has	 been	attributed	to	defective	CD8+	T-reg	populations	in	vivo	[344].		Indeed,	IL-21	functions	to	enhance	the	proliferation	of	CD8+	T-regs	and	promote	their	survival.	Functioning	as	 a	 checkpoint	 for	 aberrant	 T-cell	 responses,	 CD8+	 T-regs	 help	 maintain	 self-tolerance.	 It	 is	 plausible,	 that	 in	 our	model,	 IL-21R	 deficiency	 resulted	 in	 defective	CD8+	T-reg	expansion,	resulting	in	aberrant	T-effector	cell	expansion	and	function.	It	would	 therefore,	 be	 advantageous	 to	 assess	 the	 expression	 of	 other	 T-helper	 cell	subtypes	–	name	Th1	cells	-	in	our	model.	Of	great	importance	to	our	study,	CD8+	T-regs	have	been	shown	to	limit	atherosclerosis	progression	by	modulating	the	Tfh	cell	/	 GC	 B-cell	 axis	 in	 vivo	 [142].	 It	 is,	 therefore,	 possible	 that	 loss	 of	 CD8+	 T-reg	populations	 in	our	mice	would	result	 in	defective	T-cell	 regulation	and	may	explain	our	 findings.	 Subsequent	 follow-up	 studies,	 profiling	 CD8+	T-reg	 populations	 in	 IL-21R-/-	 :	 LDLR-/-	 and	C57BL/6NJ	 :	 LDLR-/-	mice	would	provide	 an	 interesting	 insight	into	whether	CD8+	T-reg	compartments	are	deficient	in	our	model.		As	well	as	affecting	regulatory	processes,	 IL-21	inhibits	DC	function	and	induces	DC	apoptosis.	 Particularly,	 IL-21	 reduces	major	 histocompatibility	 complex-II	 (MHC-II)	expression	 on	 the	 surface	 of	 DCs	 [297].	 As	 a	 result,	 IL-21	 can	 function	 to	 inhibit	antigen	presentation	and	subsequent	T-cell	activation	[298].	It	is	therefore	plausible	that,	 in	 comparison	 to	 C57BL/6NJ	 :	 LDLR-/-	 control	 mice,	 IL-21R-/-	 :	 LDLR-/-	 mice	displayed	enhanced	antigen	presenting	capacity,	 thus	 influencing	 increased	effector	T-cell	responses.	Indeed	DC	function	is	important	to	lesion	formation	and	variations	in	antigen	presenting	capacity	may	impact	on	pathology	greatly.	As	such,	Assessment	of	MHC-II	expression	on	DC	subsets	from	control	and	IL-21R-/-	 :	LDLR-/-	mice	would	help	to	determine	whether	IL-21R-/-	deficiency	results	in	enhanced	DC	activity.		
215		
Intriguingly	 loss	of	PD-1	expression	 in	atherosclerosis	has	been	 linked	 to	enhanced	CD4+	and	CD8+	T-cell	activation	[291].	Although	inducing	increased	T-reg	responses,	PD-1	deficiency	has	been	 reported	 to	 enhance	 IFN-γ	 secreting	Th1	 cell	 populations	[291].	 Adding	 to	 the	 pro-atherogenic	 effects	 of	 PD-1	 signalling,	 PD-1	 and	 PD-L1	expression	is	significantly	reduced	in	patients	with	coronary	artery	disease	(CAD),	a	finding	 linked	 to	enhanced	T-effector	cell	 responses	 [357].	As	part	of	our	study,	we	demonstrated	that	IL-21R	deficiency	significantly	reduces	PD-1	expression	in	vivo.	It	is	 therefore	possible	 that	 lack	of	PD-1	expression	enhanced	Th1	 cell	mediated	pro-atherogenic	immune	response	in	our	mice.	As	suggested	before,	to	address	this	issue	it	would	 be	 advantageous	 to	 profile	 different	T-helper	 subsets	 in	 IL-21R-/-	:	 LDLR-/-	mice.		
1.57.6 Conditional	Tfh	cell	knock	out	models	Although	we	 can	 be	 confident	 that	 IL-21R	 deficiency	 affects	 Tfh	 cell	 and	 GC	 B-cell	development	 in	 our	model,	 the	 expression	of	 IL-21R	by	other	 cell	 types,	means	we	cannot	affirm	that	deficient	Tfh	cell	and	GC	B-cell	development	is	the	only	cause	for	our	 findings.	 To	 address	 this	 issue,	 subsequent	 studies,	 using	 conditional	 Tfh	 cell	knock	out	mice	would	be	required.	To	date,	several	models	have	been	developed	that	allow	for	the	conditional	knock	out	of	Tfh	cells	 in	vivo.	Using	a	chimeric	approach	or	cross	 breeding,	 we	 could	 develop	 a	 conditional	 T	 cell	 knock	 out	 in	 context	 of	atherosclerosis.		Since	 the	 development	 of	 this	 project,	 various	 studies	 have	 provided	 insights	 into	how	this	would	be	possible.	Recently,	several	molecules	have	been	identified	-	that	-	independent	 of	 Bcl-6	 -	 regulate	 Tfh	 cell	 transcripts.	 Specifically,	 the	 transcription	factor	achaete-scute	homologue	2	 (Ascl-2)	 [237]	and	 the	ubiquitin	 ligase	 Itch	 [222]	has	been	shown	to	be	important	in	Tfh	cell	formation.	Adding	to	this,	deficiency	of	the	transcription	 factor	 BATF	 –	 in	 context	 of	 atherosclerosis	 –	 would	 result	 in	 the	selective	deficiency	of	both	Tfh	cell	and	GC	B-cells	[316],	thus	reconfirming	our	data.		Crossing	hyperlipidemic	mice	with	the	conditional	KO	described	above	or	generating	a	chimera	(as	in	this	study)	would	allow	for	the	selective	deficiency	of	Tfh	cells	and	or	GC	 B-cells	 in	 context	 of	 atherosclerosis.	 As	 such,	 follow	 up	 studies	 are	 required	 to	
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fully	confirm	our	data	and	support	a	pro-atherogenic	role	of	the	Tfh	cell	/	GC	B-cell	axis	in	atherosclerosis.		
1.57.7 Summary	of	Findings	
• IL-21R	deficiency	 significantly	 attenuated	Tfh	 cell	 and	GC	B-cell	development	 in	context	of	atherosclerosis	
• IL-21R	deficiency	significantly	alters	total	and	MDA-Ox-LDL	antibody	titres	
o Decreased	total	IgM	and	IgG	
o Increased	total	IgE	
o Decreased	MDA-Ox-LDL	IgG2C	
• IL-21R	ablation	significantly	enhanced	atherosclerosis	formation.		
1.57.8 Concluding	Remarks	Together,	our	findings	 indicate	the	importance	of	 IL-21R	signalling	 in	the	formation	of	Tfh	cells	and	GC	B-cells	in	context	of	hyperlipidemia.	Lack	of	Tfh	cell	and	GC	B-cell	populations	 in	 IL-21R-/-	 :	 LDLR-/-		mice	was	 linked	 to	 significant	 changes	 in	 athero-protective	 and	 pro-atherogenic	 antibody	 titres.	We,	 therefore,	 propose	 that	 IL-21R	deficiency	 alters	 Tfh	 cell	 and	 GC	 B-cell	 populations,	 leading	 to	 a	 skewed	 pro-atherogenic	 antibody	 response.	 Importantly,	 our	 study	has	provided	extensive	data	warranting	the	further	study	of	IL-21R	signalling	in	atherosclerosis.													
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Chapter	 6:	 Summary	 of	 Findings	 and	 Future	
Direction	
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 Chapter	3	-	Summary	of	Key	Findings		
As	part	of	chapter	2,	Tfh	cell	and	GC	B-cell	populations	were	characterised	in	context	of	hyperlipidemia.	To	do	this,	C57BL/6	WT	mice	were	fed	chow	diet	and	two	groups	of	 apoE-/-	 mice	 fed	 chow	 or	 HFD	 for	 1,	 2,	 4,	 8	 and	 12	 weeks.	 These	 time	 points	coincided	 with	 early	 stage	 atherosclerosis,	 as	 well	 as	 late	 stage	 progression.	 As	 a	result,	it	was	determined	whether	Tfh	cell	and	GC	B-cell	kinetics	changed	in	line	with	hyperlipidemia	and	atherosclerosis	progression.		pLN,	splenic	and	pao-LN	Tfh	cell	populations	increased	in	line	with	age	in	both	apoE-/-	chow	and	apoE-/-	HFD	fed	mice,	peaking	at	12	weeks	post-diet.	Interestingly,	GC	B-cell	populations	peaked	in	the	pLNs	and	pao-LNs	of	apoE-/-	chow	and	HFD	fed	mice	at	4	weeks	post	diet.		ApoE-/-	 chow	 and	HFD	 fed	mice	 displayed	 an	 increasing	 trend	 in	 anti-MDA-Ox-LDL	IgG2c	antibodies	while	concomitantly	displaying	a	decreasing	 trend	 in	anti-MDA-Ox-LDL	IgG1	antibodies.		Spleen	 sections	 from	 atherosclerotic	 mice	 displayed	 evidence	 of	 CD4+	 T-cell	translocation	to	B-cell	follicles.	Moreover,	CD4+	T-cells	from	apoE-/-	mice	fed	HFD	for	12	weeks	comprised	the	sole	group	expressing	the	Tfh	cell	transcription	factor	–	Bcl-6	–	while	being	aptly	positioned	in	B-cell	follicles.	Interestingly,	apoE-/-	mice	fed	HFD	for	 4	weeks	 (peak	 of	 GC	 response)	 displayed	 significantly	 larger	 GC	 reactions	 than	respective	C57BL/6	WT	controls.	
	In	 summary,	 our	 results	 indicate	 that	 hyperlipidemia	may	 be	 an	 important	 driving	force	in	the	development	of	Tfh	cells	in	vivo.	As	such,	they	suggest	that	Tfh	cells	may	comprise	a	significant	cell	 type	 involved	 in	atherosclerosis	development.	 In	support	of	 this,	 others	 have	 demonstrated	 the	 involvement	 of	 Tfh	 cells	 in	 the	 regulation	 of	tertiary	lymphoid	organ	formation	(TLOs)	in	human	aortic	aneurism	[142].		The	 finding	 that	 GC	 B-cell	 kinetics	 peak	 in	 apoE	mice	 (chow	 and	HFD)	 at	 4	weeks	post-diet,	 alongside	 changes	 in	 antibody	 kinetics,	 suggests	 that	 GC	 B-cell	mediated	processes	may	be	of	significance	in	atherosclerosis.	Our	data	suggests	the	presence	of	
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an	 early	 Tfh	 cell	 response	 potentially	 being	 able	 to	 induce	 GC	 B-cell	 responses.	Although	some	may	indicate	that	B-cells	can	differentiate	in	extra-follicular	locations	and	 produce	 low-affinity	 antibodies	 [358],	 we	 demonstrated	 via	 IF	 that	 GC	 results	reported	at	4	weeks	were	follicular	in	nature.		Importantly,	our	 IF	also	demonstrated	 the	exclusive	expression	of	Bcl-6	 in	Tfh	cells	from	apoE-/-	mice	fed	HFD	for	12	weeks.	Bcl-6	expression	is	essential	to	Tfh	cell	and	GC	B-cell	function,	as	well	as	GC	integrity	[236,	359,	360].	The	exclusive	expression	in	Tfh	cells	from	apoE-/-	mice	fed	HFD	for	12	weeks	indicates	that	severe	hyperlipidemia	is	important	in	the	expression	of	bonafide	Tfh	cell	markers.		In	 conclusion,	 chapter	2	provided	a	 crucial	 insight	 into	 the	potential	 significance	of	Tfh	 cells	 and	 GC	 B-cells	 in	 experimental	 atherosclerosis	 and	 indicated	 a	 potential	mechanism	 by	 which	 antibodies	 from	 the	 Tfh	 cell	 :	 GC	 B-cell	 axis	 may	 modulate	disease	formation	and	progression.	
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 Chapter	4	-	Summary	of	Key	Findings		
In	 the	 third	 chapter	of	 this	 thesis,	 the	 effect	 of	 apoE	deficiency	on	T-cell	 and	B-cell	responses	 following	 immunization	 was	 assessed.	 To	 study	 this,	 C57BL/6	 WT	 and	apoE-/-	 mice	 were	 immunised	 s.c.	 with	 OVA	 emulsified	 in	 CFA.	 Nine	 days	 later,	immune	cell	populations	were	characterised	via	flow	cytometry.			Loss	of	apoE	did	not	affect	CD4+	T-cell	or	B220+	B-cell	formation,	while	expression	of	CD44	 on	 CD4+	 T-cells	 was	 significantly	 expanded	 in	 apoE-/-	 mice.	 Expression	 of	CXCR5	 was	 indifferent	 between	 both	 groups,	 as	 was	 Tfh	 cell	 expression,	 as	characterised	by	6	published	marker	combinations	(see	chapter	3).	Interestingly,	Bcl-6	and	PD-1	expression	was	 significantly	 reduced	on	CD4+	CXCR5+	gated	and	CD4+	CD44hi	gated	Tfh	cells,	while	B220+	PNA+	FAS+	GC	B-cell	populations	were	deficient	in	apoE-/-	mice.	
	Our	results	demonstrate	that	apoE	deficiency	does	not	affect	CD4+	T-cell	and	B220+	B-cell	 formation.	As	 a	 result,	 they	 reaffirm	 that	 the	Tfh	 cell	 and	GC	B-cell	 pre-gates	used	 in	 chapter	 2	 were	 not	 inadvertently	 affected	 by	 loss	 of	 apoE	 in	 apoE-/-	 mice.	Although	 CD44	 expression	was	 elevated	 on	 CD4+	 T-cells	 from	 apoE-/-	mice,	 this	 is	most	 likely	 due	 to	 enhanced	 inflammatory	 profiles	 in	 apoE-/-	 mice	 and	 the	significance	of	CD44	in	lesion	formation	[361].			As	discussed	previously,	CXCR5	is	important	for	translocation	of	Tfh	cells	to	the	B-cell	follicle	 [362].	Our	data	 indicates	 that	Tfh	 cells	 from	apoE-/-	mice	display	equivalent	expression	 of	 CXCR5,	 therefore	 indicating	 no	 regulatory	 role	 of	 apoE	 in	 CXCR5	expression.	As	 such,	 it	 is	plausible	 to	assume	 that	CD4+	T-cells	 from	both	C57BL/6	WT	and	apoE-/-	mice	exhibit	equivalent	ability	to	migrate	to	B-cell	follicles	and	form	Tfh	cells.	Moreover,	this	finding	confirms	that	the	results	obtained	in	chapter	2	were	not	affected	by	differential	CXCR5	expression.			Interestingly,	GC	B-cell	expression	was	reduced	in	apoE-/-	mice,	suggesting	that	apoE	mice	are	deficient	in	the	formation	of	GC	B-cell	populations.	Moreover,	expression	of	Bcl-6	and	PD-1	was	reduced	on	Tfh	cells,	 indicating	that	Tfh	cell	marker	expression	may	be	reduced	in	apoE-/-	mice.	
221		
	In	 summary,	 our	 data	 supports	 our	 hypothesis	 that	 atherosclerosis	 and	hyperlipidemia,	and	not	apoE	deficiency,	are	 the	major	drivers	of	 the	enhanced	Tfh	cell	and	GC	responses	observed	in	atherosclerotic	mice.		
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 Chapter	5	-	Summary	of	Key	Findings		
In	 chapter	 4,	 the	 effects	 of	 IL-21R	 deficiency	 on	 atherosclerosis	 formation	 were	assessed.	Involved	in	Tfh	cell	formation	and	GC	B-cell	differentiation,	IL-21	is	central	to	 the	 Tfh	 cell	 :	 GC	 B-cell	 axis,	 and	 thus	 significant	 in	 diseases	where	 aberrant	 GC	reactions	form	[204-206].	To	study	this,	a	chimeric,	hyperlipidemic,	IL-21R	deficient	mouse	was	developed	(IL-21R-/-	:	LDLR-/-),	in	which	all	hematopoietic	stem	cells	were	devoid	of	IL-21R	expression.		IL-21R	deficiency	significantly	reduced	Tfh	cell	formation.	Mirroring	these	results,	IL-21R-/-	 :	 LDLR-/-	mice	were	 devoid	 of	 B220+	 PNA+	 FAS+	 GC	 B-cell	 expression	 in	 all	organs	assessed.		IL-21R	 deficiency	 significantly	 attenuated	 total	 IgM	 and	 IgG	 antibody	 titres,	 while	exacerbating	total	IgE	titres.	Lastly,	loss	of	IL-21R	significantly	enhanced	aortic	sinus	lesion	 content,	 increased	 CD68+	 macrophage	 infiltration	 but	 did	 not	 affect	 sinus	collagen	content.	
	We	 have	 identified	 an	 essential	 role	 of	 IL-21R	 signalling	 in	 Tfh	 cell	 and	 GC	 B-cell	development	in	experimental	atherosclerosis.	We	propose	that	loss	of	Tfh	cell	and	GC	B-cell	populations	in	IL-21R-/-	:	LDLR-/-	mice	enhances	atherosclerosis	by	affecting	the	balance	 between	 athero-protective	 and	 pro-atherogenic	 antibodies.	 As	 such,	 we	conclude	 that	 IL-21	and	 the	Tfh	cell	 :	GC	B-cell	axis	 is	protective	 in	atherosclerosis.	More	 recently	 others	 have	 demonstrated	 that	 control	 of	 the	 T	 follicular	 helper-germinal	 centre	 B-cell	 axis	 by	 CD8⁺	 regulatory	 T	 cells	 limits	 atherosclerosis	 and	tertiary	lymphoid	organ	development	[142].	Unfortunately,	our	study	did	not	extend	to	 phenotyping	 regulatory	 cells.	 As	 such,	 the	 effect(s)	 of	 IL-21R	 deficiency	 on	regulatory	compartments	in	our	hands	is	unknown.	The	effects	this	may	have	on	Tfh	cell	 populations	 and	 subsequent	 GC	 processes	 must	 therefore	 be	 addressed	 in	subsequent	studies.		It	is	also	important	to	note	that	IL-21R	signalling	is	important	in	the	development	and	function	of	other	immune	cells,	in	particular	Th17	cells	[363].	As	part	of	our	study,	we	did	 not	 assess	 the	 effects	 of	 IL-21R	 ablation	 of	 these	 populations	 and	 the	 resulting	
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effects	on	pathology.	As	such,	we	cannot	be	confident	that	other	cells	(and	processes)	are	 not	 affected	 by	 loss	 of	 IL-21R	 in	 IL-21R-/-	 :	 LDLR-/-	mice.	 To	 address	 this,	 and	attribute	a	definitive	role	of	Tfh	cells	in	atherosclerosis,	a	refined	model	in	which	Tfh	cells	 are	 selectively	ablated	 is	 required.	Throughout	 the	development	of	 this	 thesis,	several	studies	have	 indicated	as	 to	how	this	may	be	possible.	 In	particular,	several	molecules	 required	 for	 Tfh	 cell	 differentiation	 have	 been	 identified,	 including	 the	transcription	factors,	ascl-2	[237],	BATF	[316],	Bcl-6	[236],	and	the	messenger	C-maf	[285].	Using	the	cre/lox	system	it	would	be	advantageous	to	develop	a	mouse	model	in	 which	 one	 or	 more	 of	 the	 above	 is	 devoid	 in	 CD4+	 T-cells.	 In	 context	 of	hyperlipidemia,	 this	system	would	allow	for	the	definitive	discrimination	of	Tfh	cell	function	in	atherosclerosis.		In	conclusion,	this	thesis	has	provided	an	interesting	insight	 into	the	role	of	the	Tfh	cell	:	GC	B-cell	axis	in	atherosclerosis.	Using	the	approaches	described	throughout,	we	have	demonstrated	the	significance	of	Tfh	cell,	GC	B-cell	and	antibody	kinetics	in	the	apoE-/-	mouse	model.	 Furthermore,	we	have	 provided	 evidence	 indicating	 a	 role	 of	hyperlipidemia	in	driving	Tfh	cell	marker	expression.	Importantly,	our	data	provides	evidence	for	the	regulatory	role	of	IL-21	and	Tfh	cells	in	experimental	atherosclerosis	and	thus	warrants	further	investigation.																
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 Final	Comments	and	Future	Perspective		
To	date,	atherosclerosis	research	has	 focused	primarily	on	studying	 the	 importance	of	 Th-1	 cells	 –	 and	 their	 associated	 cytokines	 -	 in	 lesion	 formation.	 Therefore,	researchers	have	gained	valuable	information	as	to	the	processes	that	lead	to	lesion	formation	 and	 destabilisation.	 Importantly,	 however,	 the	 complex	 –	 and	 terminal	 -	interplay	 between	 T-cells,	 B-cells	 and	 antibody	 production	 is	 only	 just	 being	addressed.	Recognising	this,	this	thesis	explored	the	idea	that	Tfh	cells,	GC	B-cells	and	associated	antibody	kinetics	may	be	of	potential	significance	in	atherosclerosis.		The	first	question	posed	related	to	whether	or	not	Tfh	cells,	GC	B-cells	and	antibody	kinetics,	 1)	 followed	 a	 pattern	 in	 line	 with	 lesion	 formation	 in	 the	 apoE-/-	 mouse	model	 and	 2)	 whether	 T-cells	 from	 apoE-/-	 mice	 expressed	 markers	 of	 Tfh	 cell	phenotype	 and	 anatomical	 location.	 It	was	 found	 that	 severe	 hypercholesterolemia	was	important	in	modulating	Tfh	cell,	GC	B-cell	and	pathological	antibody	kinetics	in	apoE-/-	 mice.	 Moreover,	 expression	 of	 the	 Tfh	 cell	 master	 regulator	 –	 Bcl-6	 -	 was	linked	 to	 hypercholesterolemia,	with	 apoE-/-	mice	 fed	HFD	 for	 12	weeks	displaying	exclusive	 expression	 and	 follicular	 location.	 The	 results	 presented	 demonstrate	 the	first	 reports	 of	 a	 possible	 Tfh	 cell	 component	 to	 the	 adaptive	 immune	 response	 in	hypercholesterolemia	To	confirm	that	hypercholesterolemia	–	and	therefore	disease	severity	–	drive	Tfh	cell	populations	in	atherosclerosis,	future	studies	may	use	in	vitro	approaches	to	stimulate	cultured	naive	T-cells	from	HFD	fed	apoE-/-	mice	and	assess	Tfh	cell	markers,	Bcl-6	expression,	B-cell	helper	capacity	and	antibody	production.	The	second	question	posed	related	to	whether	modulation	of	the	key	Tfh	cell	cytokine	receptor	–	IL-21R	-	would	affect	atherosclerosis	formation	in	vivo.	Using	the	approach	described	in	chapter	5,	loss	of	IL-21R	expression	increased	plaque	burden,	conferred	an	unstable	plaque	phenotype	and	favoured	pro-atherogenic	antibody	production.	As	such,	IL-21R	signalling	is	protective	in	atherosclerosis.	Importantly,	IL-21R	signalling	also	mediates	mitogenesis	 of	 other	 cell	 subsets,	 including	NK	 cells,	 Th-17	 cells	 and	mast	 cells.	 Crucially,	 these	 subsets	 have	 been	 shown	 to	 be	 of	 importance	 in	atherogenic	processes	[113,	117,	364,	365].	Therefore,	the	pathological	effects	of	IL-21R	ablation	on	these	subsets	must	be	addressed,	including	CD8+	T-regs,	Tf-regs,	Th-17	 cells	 and	 conventional	 Th-1	 cells.	 To	 attribute	 a	 definitive	 role	 of	 Tfh	 cells,	 and	associated	 processes	 in	 atherosclerosis,	 future	 studies	 could	 focus	 on	 developing	 a	method	 in	 which	 Tfh	 cells	 are	 exclusively	 deficient	 in	 context	 of	
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hypercholesterolemia,	while	maintaining	integrity	of	other	subsets.	As	this	thesis	has	evolved,	several	studies	have	emerged	that	describe	methods	in	which	selective	Tfh	cell	 impairment	may	be	 conferred	 in	vivo.	 In	particular,	 several	key	molecules	have	been	 identified	 that	 preferentially	 regulate	 Tfh	 cell	 fate	 [222,	 237,	 316,	 335,	 366].	Using	 bone	 marrow	 chimera	 technology	 or	 the	 cre/lox	 system,	 lack	 of	 these	molecules	–	and	thus	Tfh	cells	–	in	context	of	atherosclerosis,	will	provide	a	definitive	answer	 to	 the	role	of	Tfh	cells	 in	atherosclerosis.	 Irrespective	of	 this,	 chapter	5	has	demonstrated	the	strong	protective	effects	of	the	Tfh	cell	cytokine	receptor	–	IL-21R	–	in	 atherosclerosis.	 To	 substantiate	 our	 hypothesis	 that,	 Tfh	 cells	 are	 athero-protective,	serum	transfer	studies	from	IL-21R-/-	:	LDLR-/-	into	hypercholesterolemic	LDLR-/-	 mice	 may	 confirm	 the	 protective	 roles	 of	 IL-21R	 signalling.	 Used	 in	 other	models,	 this	 method	 has	 proved	 valuable	 in	 conferring	 disease	 states	 in	 rodent	models	of	RA	[367]	and	as	such	may	prove	helpful	in	advancing	the	role	of	IL-21R	in	atherosclerosis.			The	aorta	comprises	the	site	at	which	atherosclerotic	lesions	form	and	progress,	and	as	 such	 represents	 a	 significant	 tissue	 of	 interest.	 Moreover,	 lesions	 house	 dense	populations	 of	 immune	 cells	 that	 contribute	 to	 the	 pro-inflammatory	 response.	Importantly,	 recent	 studies	 have	 indicated	 the	 presence	 of	 Tfh	 cells	 and	 associated	molecules	in	advanced	disease,	in	ATLOs	[45,	219].	In	this	context,	however,	the	Tfh	cell	 content	 of	 lesions	 in	 unknown,	 and	 in	 relation	 to	 this	 thesis	 -	 the	 subsequent	effects	of	IL-21R	ablation	on	such	populations.	As	described	in	chapter	3,	this	was	due	to	the	technical	limitation	of	absent	CXCR5	expression	post-digestion	in	the	aorta.	To	address	 this,	 future	studies	may	determine,	via	 IF,	 the	expression	of	plaque	Tfh	cell	markers,	 including	ICOS,	PD-1	and	Bcl-6.	Moreover,	 IF	staining	 for	 isotype	switched	antibodies	may	 indicate	a	 local	 response	 that	 eventually	develops	 into	a	 structured	ATLO	in	advanced	disease.			Taken	 together,	 the	 results	 presented	 throughout	 this	 thesis	 have	 provided	 an	interesting	 insight	 into	 the	 potential	 significance	 of	 the	 Tfh	 cell	 :	 GC	 B-cell	 axis	 in	atherosclerosis.	In	particular,	they	indicate	that	Tfh	cells	increase	in	line	with	lesion	development,	 hypercholesterolemia	 favours	 Bcl-6	 expression	 and	 loss	 of	 IL-21R	expression	significantly	aggravates	disease	states.			
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Appendix	1	–	Composition	of	High	Fat	Diet		
Diet	Name	 Western	RD	
Company		 Special	Diet	Services	(Essex,	United	Kingdom)	
Diet	Code		 829100	
Additional	Information		 Contains	0.15%	supplementary	cholesterol,	resulting	in	approximately	0.2%	total	cholesterol	content			
Diet	 829100	–	Western	RD	
Ingredient	 g%	(w/w)	Sucrose	 33.94	Milk	Fat	Anhydrous	 20.00	Casein	 19.50	Maltodextrin	 10.00	Corn	Starch	 5.00	Cellulose	 5.00	Corn	Oil	 1.00	Calcium	Carbonate	 0.40	L-Cystine	 0.30	Choline	Bitartrate	 0.20	Cholesterol	 0.15	Antioxidant	 0.01	AIN	–	76A	–	MX	 3.50	AIN	–	76A	–	VX	 1.00	
Total	 100				
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Appendix	2	–	Antibodies	for	Detection	of	Cells	via	Flow	Cytometry		 																																
T"Follicular+Helper+Cell+Antibodies++
Antibody+ Fluorochrome+ Company+ Concentration+ Clone+ Dilution+
Rat$Anti(Mouse$CXCR5$ Biotin$ BD$Bioscience$ 0.5$mg/ml$ 2G8$ 1$:$50$
Anti(Human/Mouse$CD4$ Alexa(Fluor$780$ Ebioscience$ 0.2$mg/ml$ IM7$ 1$:$400$
Anti(Human/Mouse$CD44$ PercP$Cy$5.5$ Ebioscience$ 0.2$mg/ml$ IM7$ 1$:$400$
Anti(Mouse$PD(1$ Pe$Cy$7$$ Ebioscience$ 0.2$mg/ml$ J43$ 1$:$500$
Anti(Human/Mouse/Rat$ICOS$ Alexa(Fluor$488$ Biolegend$$ 0.5$mg/ml$ C398.4A$ 1$:$100$Streptavidin$$ Brilliant$Violet$421$$ BD$Bioscience$$ 0.5$mg/ml$$ N/A$ 1$:$400$Rat$IgG2a$ Biotin$$ BD$Bioscience$ 0.5$mg$/ml$$ N/A$ 1$:$50$Armenian$Hamster$IgG$ 488$ Biolegend$ 0.5$mg/ml$ HTK888$ 1$:$100$
Mouse$IgG1$ Pe$Cy$7$$ Ebioscience$ 0.2$mg/ml$ P3.6.2.8.1$ 1$:$500$
Germinal)Centre)B-cell)Antibodies))
Antibody) Fluorochrome) Company) Concentration) Clone) Dilution)
Rat$Anti(Mouse$BB20$$ APC$$ BD$Bioscience$ 0.2$mg/ml$ RA3(6B2$ 1$:$100$Peanut$Agglutinin$(PNA)$ Biotin$ Vector$Labs$ 5$mg/ml$$ N/A$ 1$:$600$$
Human$Anti(Mouse$CD95$ PE$ BD$Bioscience$ 0.2$mg/ml$ DX2$ 1$:$400$Streptavidin$$ FITC$ BD$Bioscience$$ 0.5$mg/ml$ N/A$ 1$:$400$$
Mouse$IgG1$ PE$$ BD$Bioscience$ 0.2$mg/ml$ N/A$ 1$:$400$
Antibodies*for*the*Detection*of*Adaptive*Immune*Cells*
Antibody*
*
Fluorochrome* Company* Concentration* Clone* Dilution*
Anti%Human/Mouse/CD4/ Alexa%Fluor/780/ Ebioscience/ 0.2/mg/ml/ IM7/ 1/:/400/Anti%Human/Mouse/B220// APC// Ebioscience/ 0.2/mg/ml// RA3%6B2// 1/:/400/Anti%Human/Mouse/CD44/ PercP/Cy/5.5/ Ebioscience/ 0.2/mg/ml/ IM7/ 1/:/400/
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Appendix	 3	 –	 Antibodies	 for	 Detection	 of	 Antibody	 Isotypes	 via	
ELISA			
																									
Secondary*ELISA*Antibodies*
Antibody* Conjugate** Company* Clone* Dilution*
Goat%Anti)Mouse%IgG1% HRP% Southern%Biotech% N/A% 1%:%4000%Goat%Anti)Mouse%IgG2C%% HRP% Southern%Biotech% N/A% 1%:%4000%Goat%Anti)Mouse%IgG%% HRP% Southern%Biotech% N/A% 1%:%4000%Rat%Anti)Mouse%IgM% HRP% BD%Biosciences% II/41% 1%:%1000%
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Appendix	 4	 –	 Antibodies	 for	 Detection	 of	 Antibody	 Isotypes	 via	
ELISA		 															 															
Antibodies*for*Total*Serum*ELISAs*
(IgM,*IgG,*IgG2C*and*IgG1)*
Capture*Antibodies*
Antibody* Conjugate** Company* Clone* Dilution*
Af#iniPure*Goat*Anti/Mouse*IgG,*Fcγ*Subclass*2c*Speci#ic*** Puri#ied* Jackson*ImmunoResearch* N/A* 1*:*60*Af#iniPure*Goat*Anti/Mouse*IgG,*Fcγ*Subclass*1*Speci#ic** Puri#ied* Jackson*ImmunoResearch* N/A* 1*:*60*Af#iniPure*Goat*Anti/Mouse*IgG*+*IgM*(H+L)* Puri#ied* Jackson*ImmunoResearch* N/A* 1*:*60*
Detection*Antibodies*
Antibody* Conjugate** Company* Clone* Dilution*Goat*Anti/Mouse*IgG1* HRP* Southern*Biotech* N/A* 1*:*4000*Goat*Anti/Mouse*IgG2C* HRP* Southern*Biotech* N/A* 1*:*4000*Goat*Anti/Mouse*IgG* HRP* Southern*Biotech* N/A* 1*:*4000*Rat*Anti/Mouse*IgM* HRP* BD*Biosciences* II/41* 1*:*1000*
Secondary*Antibodies*for*MDA3Ox3LDL*Speci8ic*ELISAs*
Antibody* Conjugate** Company* Clone* Dilution*
Goat%Anti)Mouse%IgG1% HRP% Southern%Biotech% N/A% 1%:%4000%Goat%Anti)Mouse%IgG2C%% HRP% Southern%Biotech% N/A% 1%:%4000%Goat%Anti)Mouse%IgG%% HRP% Southern%Biotech% N/A% 1%:%4000%Rat%Anti)Mouse%IgM% HRP% BD%Biosciences% II/41% 1%:%1000%
Antibodies*for*Total*Serum*ELISAs*(IgE)*
Capture*Antibody*From*Mouse>IgE>Ready>SET>Go!*Kit*
Antibody* Conjugate** Company* Clone* Dilution*
Anti%Mouse+IgE+ Puri1ied+ Ebioscience+ N/A+ 1+:+250+
Detection*Antibody*From*Mouse>IgE>Ready>SET>Go!*Kit*+
Antibody* Conjugate** Company* Clone* Dilution*Anti%Mouse+IgE+ Biotinylated+ Ebioscience+ N/A+ 1+:+250+
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Appendix	5	–	Antibodies	for	Detection	of	Tfh	cells	and	GC	B-cells	via	
IF		
	
			
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
Germinal)Centre)B-cell)Antibodies)
Antibody) Fluorochrome) Company) Concentration) Clone) Dilution)Peanut'Agglutinin'' Biotinylated' Vector'Labs'' 5'mg'' N/A' 1':'400'Anti>Human/Mouse'B220' PE' Ebioscience' 0.2'mg/ml' RA3>6B2' 1':100'Anti>Mouse'CD4' Alexa'Fluor'647' BD'Bioscience' 0.1'mg/ml' RM4>5' 1':'100'Streptavidin' FITC' BD'Bioscience'' 0.5'mg/ml' N/A' 1':'400''
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Appendix	6	–	Antibodies	for	the	Detection	of	CD68	Macrophages	via	
IF			 																		
	
CD68%Immunohistochemistry%Antibodies%
Antibody% Conjugate%% Company% Clone% Dilution%
Rat$Anti(Mouse$CD68$ Puri4ied$ AbD$Serotec$ FA(11$ 1$:$500$Rat$Anti(Mouse$IgG2a$$ Puri4ied$ AbD$Serotec$ N/A$ 1$:$500$Donkey$Anti(Rat$IgG$$ Texas$Red$ Jackson$ImmunoResearch$ N/A$ 1$:$200$
